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1 Introduction 
1.1 Definition of cancer 
The National Cancer Institute (NCI) defines cancer as “a term used for diseases in 
which abnormal cells divide without control and are able to invade other tissues. Cancer 
cells can spread to other parts of the body through the blood and lymph systems” (NCI 
17.6.2011). The medical term for cancer is malignant neoplasm. According to the NCI 
cancer can be grouped into five broad categories: 
• carcinomas, which originate form epithelial cells 
• sarcomas, which originate form mesoderm or supporting tissue (like bones, 
cartilage, fat, muscle, blood vessels, etc.) 
• leukemia, which originates from blood forming tissue (bone marrow) and affects 
the blood cells 
• lymphoma and myeloma, which originate from cells of the immune system 
• central and nervous system cancers, which arise from cells of the central and 
peripheral nervous system  
Tumors are divided into benign and malignant tumors. Benign tumors are not cancerous 
and do not invade or metastasize to other parts of the body. Therefore, they can be 
removed surgically and mostly do not return. Malignant tumors are defined as cancer 
and can invade nearby tissues and metastasize.  
 
1.2 Epidemiology 
1.2.1 Epidemiology of cancer worldwide 
Cancer is the second of the leading causes of death (following heart diseases) in 
economically developed countries and the third leading cause of death in developing 
countries (following heart diseases and diarrheal diseases) (Garcia et al. 2007). 2008 the 
World Health Organization (WHO) reported 12,7 million new cancer cases. In 2008 7,6 
million people died of cancer which are around 13% of all deaths. 70% of all cancer 
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deaths occur in low- and middle-income countries (WHO 11.6.2011). The highest 
incidences of cancer are mainly seen in developed regions like Australia, New Zealand, 
Northern America and Europe. The lowest incidence rates are observed in Africa 
(except South Africa) and South-Central Asia. Although cancer incidence rates in 
developed countries are higher than in developing countries, mortality rates are almost 
the same (Globoscan 11.6.2011). The incidence rate of cancer in developing countries is 
increasing due to reduced childhood mortality and reduced deaths of infectious diseases 
leading to higher age. But also adopting western lifestyle behavior like smoking, high 
saturated fat and calorie dense diet connected with reduced physical activity raises the 
rates of cancer in these regions (Garcia et al. 2007).  
 
 
 
 
Figure 1: Cancer incidence and mortality worldwide in 2008 
(Globoscan 11.6.2011) 
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Apart from genetic factors cancer can be induced by physical carcinogens, chemical 
carcinogens and biological carcinogens (see chapter 1.3.1.1). Avoiding these external 
carcinogens and risk factors like alcohol abuse, smoking, overweight, poor diet and 
physical inactivity can prevent a considerable percentage of cancer deaths (WHO 
11.6.2011). About 15% of all cancers worldwide are caused by infection. In developing 
countries this percentage is three times higher (26%) than in developed countries (8%), 
caused by reduced availability and use of medical practices like cancer screening and 
treatment. Stomach cancer is the most infection-related cancer followed by liver and 
cervix cancer (Garcia et al. 2007).  
Worldwide the most frequent cancer types in men are lung cancer, prostate cancer, 
colorectal cancer, stomach cancer and liver cancer whereas lung cancer presents the 
most lethal cancer for men. The most common cancer for women is breast cancer which 
has also the highest mortality among all cancer types for women (Globoscan 
11.6.2011). 
 
men women
 
 
 
Figure 2: Worldwide incidence and mortality of most common cancer types 
(Globoscan 11.6.2011) 
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1.2.2 Epidemiology of colorectal cancer worldwide 
Colorectal cancer (CRC) is the third common (9-10%) cancer in both sexes and the 
fourth most common cause of death from cancer (8%) worldwide. 60% of CRC cases 
occur in developed countries like Australia, New Zealand, Europe and Northern 
America. The lowest incidence rates for CRC are estimated in Africa (excluding South 
Africa), Central America and South Central Asia. Also in countries in which the risk for 
CRC was historically low like Japan or Puerto Rico, the incidence rate is increasing. 
The greatest increase of CRC incidence is reported for Asia (Japan, Hong Kong, 
Singapore) and Eastern Europe (Hungary and Poland) as well as Israel and Puerto Rico. 
Changes in dietary patterns and increased obesity in these regions are quoted as reasons. 
The decrease of CRC rate which was observed in Northern America results from an 
increase of cancer detection and removal of precancerous lesions (Garcia et al. 2007).  
 
Figure 3: Worldwide incidence rate of colorectal cancer among men and women 
(Garcia et al. 2007) 
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Although screening for CRC increases survival rates and reduces mortality, only few 
countries have implemented organized national or regional screening programs. The 
five-year survival rate can reach 90% when CRC is detected at an early and localized 
stage. During 1982-1992 the survival rate for men in five developing countries (China, 
Cuba, India, the Philippines, and Thailand) was only 28%-42%. Today, for instance in 
the United States, the five-year survival rate for CRC is 64%. (Garcia et al. 2007).  
 
1.2.3 Epidemiology of cancer in Austria 
In 2010 77.199 people died in Austria. Among these, 43% died of cardiovascular 
diseases which were the major cause of death in Austria followed by cancer. Although 
cardiovascular diseases demonstrate the largest part of deaths, the percentage is 
declining compared to 1970. According to Statistik Austria approximately 25% of all 
events of death in 2010 were attributed to cancer. In contrast to cardiovascular diseases 
the percentage of cancer related deaths is increasing compared to 1970, caused by an 
increase of the life expectancy. People aged between 65 and 74 display the statistically 
highest risk for developing cancer. Other causes of death are respiratory diseases, 
injuries and intoxications as well as diseases of the gastro intestinal tract (GIT) 
(StatistikAustria 15.6.2011).  
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Since 1994 prostate cancer is the most frequent cancer type in Austrian men. Before 
1994 lung cancer was the predominant cancer type in men. In women breast cancer is 
the most frequent cancer type. In the last decade the incidence for prostate and breast 
cancer in Austria increased about 14% partly because of extended screening programs. 
In contrast, the incidence for gastric cancer in Austria has sharply dropped since 1987 
and also the incidence and mortality of cervical carcinoma in women decreased. The 
risk and mortality rate for lung cancer was increasing for women and decreasing for 
men during the last decade (Zielonke 2010). 
Breast cancer still presents the highest mortality rate of all cancer types in women. For 
men lung cancer displays the highest mortality followed by CRC. The mortality rate for 
CRC in women is at the third place behind lung cancer (Zielonke 2010). 
 
 
Figure 4: Causes of death in Austria 1970 and 2010 
(StatistikAustria 15.6.2011) 
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From 2005-2007 84% of all malignant tumors were carcinomas. Among these 45% 
were adenocarcinomas (cancer of the epithelia originated from glandular tissue) and 
Figure 5: Incidence and mortality of various cancer types in Austrian men and women 2007 
In the upper panel cancer incidence is presented by the blue bars for men, in the lower panel by the red bars for 
women. The grey bars present cancer mortality (Zielonke 2010). 
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10% squamous cell carcinoma. 1% of all malignant neoplastic diseases were sarcomas 
and 8% were leukemia (Zielonke 2010).  
 
1.2.4 Epidemiology of colorectal cancer in Austria 
Each year between 4.400 and 5.000 malignant colorectal tumors are diagnosed in 
Austria. This presents about 13% of all newly diagnosed malignant diseases. About 
2.200 people each year die from CRC in Austria. The risk to suffer from CRC is higher 
for men than for women. Nevertheless the age standardized incidence rate for CRC 
dropped about 24% and also the mortality rate decreased about 28% over the last 
decade. 60% of women and 53% of men with diagnosed CRC display a survival rate of 
more than 5 years in Austria (Zielonke 2010).  
 
 
Figure 6: Colorectal cancer incidence and mortality rate from 1990 to 2007 in Austria  
The left panel shows incidence rate, the right panel shows mortality. Blue lines represent 
men, red lines women (Zielonke 2010). 
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1.3 Cancerogenesis 
Cancerogenesis is the process of a normal cell developing into a malignant tumor. This 
transformation is a complex process which involves changes on cellular and genetic 
levels to reprogram cells and acquire malignant characteristics. During a process 
resembling Darwinian evolution, these characteristics are acquired by genetic 
modifications followed by the natural selection of cells capable to proliferate and 
survive more effectively than their neighbors (Stratton et al. 2009). 
 
 
Figure 7: Cancerogenesis and Darwinian selection 
(Weinberg 2008) 
  
Using a mouse model for skin cancer, the mechanism of carcinogenesis was described 
for the first time in 1941 by Berenblum. Treatment of the mouse skin with either 
polycyclic aromatic hydrocarbons (PAH) or inflammation inducing croton-oil alone 
could not cause cancer. But together a unique treatment by PAH followed by 
continuous treatment with croton-oil was sufficient to support cancer development. The 
sequence of treatment in this experiment was crucial leading to the assumption that 
carcinogenesis follows a defined order which was described in a three-stage model: 
initiation, promotion and progression. The theory of carcinogenesis as a multi-step 
process also in humans is nowadays confirmed. The intermediate stages do not always 
automatically lead into advanced tumor growth but could also represent a dead end (see 
Figure 7). Alternatively, it has been proposed for a variety of epithelial cancer to skip 
the intermediate states and to enter highly malignant growth right after early 
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hyperplastic growth. In many tissues these intermediate stages reach from hyperplastic, 
dysplastic to adenomatous growth. All of them are benign precursors of carcinomas. In 
CRC the multi-stage tumorigenesis is best described (see chapter 1.5.4) (Weinberg 
2007). 
 
 
Figure 8: Multi-step tumorigenesis in determined cancer types 
(Weinberg 2007) 
 
1.3.1 The three-stage model: Initiation – Promotion – Progression 
1.3.1.1  Tumor initiation 
Initiation is the first step of cancerogenesis and occurs relatively infrequent and only in 
proliferating cells. It is a spontaneous process and induces an advantage for growth and 
survival in the affected cells. Actively proliferating cells are genetically altered which 
can be triggered by exogenous carcinogens or endogenous replication errors. Exogenous 
carcinogens initiating tumor development are:  
o chemicals: e.g. aflatoxin, 3-methylcholanthrene in tobacco smoke, polycyclic 
aromatic hydrocarbons, asbestos, arsenic etc.  
o physical impacts: e.g. UV-lights and X-rays  
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o biological components: e.g. hepatitis B and C viruses, Helicobacter pylori, 
human papilloma virus, etc.  
DNA damage caused by carcinogens occurs quite often but is removed by DNA damage 
repair systems very efficiently (only 1 error per 109 nucleotides manifests in normal 
dividing cells). Genetic errors which are not eliminated by DNA-repair processes or 
apoptosis do manifest and mutations are transmitted to descendent cells. Initiation is an 
irreversible process. Genes which are affected by initiating mutation processes are often 
involved in cell cycle control, apoptosis or cell differentiation. In context with 
tumorigenesis these genes are also called oncogenes or tumor suppressor genes. So far 
more than 100 oncogenes and 30 tumor suppressor genes have been identified. In 
manifest tumors many of them are found to be mutated. Famous oncogenes are genes 
belonging to the Ras-family (see chapter 1.5.4.3) or myc. p53 is one of the best 
described tumor suppressor genes and mutated in 50% of human tumors. p53 plays a 
major role in proliferation control, cell cycle arrest and DNA-repair and induces 
apoptosis if the DNA cannot be repaired (see chapter 1.5.4.4) (Schulte-Hermann R. 
2004). Another example for a tumor suppressor gene is APC, which, because of its 
important role in CRC, will be gone deeper into in chapter 1.5.4.2. 
 
1.3.1.2  Tumor promotion 
Promotion occurs over a long period (months or years) and in contrast to initiation and 
progression it is a reversible process. During promotion initiated cells are proliferating 
preferentially as compared to not initiated cells. The homeostasis between cell 
replication and apoptosis rate is shifted towards a higher proliferation rate. This can be 
caused by stimulation of cell growth or decrease in apoptosis compared to normal cells. 
Initiated cells are more sensitive to growth stimulatory effects. Therefore, in initiated 
cells the replication rate is induced more by tumor promoters than in normal cells. 
(Schulte-Hermann et al. 1992). Pre-neoplastic or malignant cells can be also quite 
sensitive to growth inhibiting conditions. In this case promoted cell growth is 
regressing, which is called “anti-promotion”. Reducing tumor promoting factors like 
hormones, tobacco or diet result in a higher apoptosis rate and shrinkage of pre-stage 
tumors (Bursch et al. 1991; Grasl-Kraupp et al. 1994; Mao et al. 1997). 
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Tumor promoting factors are from different exogenous or endogenous origins. 
Endogenous tumor promoting factors are for instance signal proteins reacting with 
growth receptors, kinases and transcription factors. Examples for such signal proteins 
are hormones like estrogens and androgens and growth factors like Transforming 
Growth Factor α (TGF-α) which promotes its own expression by an autocrine loop. 
Other promoting factors are prostaglandins. They are produced by cyclooxygenase 
(COX-1, COX-2) which are over-expressed in many human tumors. Apart from 
endogenous factors also nutrition and inflammation which results in a release of 
mitogenic signals are attributed to tumor promotion (Schulte-Hermann R. 2004).  
 
1.3.1.3  Tumor progression 
During tumor progression cellular signaling pathways are impaired by multiple 
mutations in various oncogenes and tumor suppressor genes. But how many different 
sequential changes are required to transform cells and tissues in human cancer? 
Mutations of oncogenes and tumor suppressor genes were found to by synergistic in 
many cases. For example cotransfection of mutated Ras and myc leads to the malignant 
phenotype in murine cells (Land et al. 1983). In human cells more than two oncogenic 
mutations are essential to transform cells into a malignant phenotype. To accumulate 
mutations genetic instability is required. In normal cells DNA-repair processes avoid 
accumulation of mutations. Therefore, in many tumors these repair genes are affected 
and inactivated. Consequently, mutations occur in a higher frequency than usual, not 
least because of the increased proliferation capacity discussed earlier. Due to the various 
mutations, cell signaling is dramatically changed which finally affects hundreds or 
thousands of different genes (Schulte-Hermann R. 2004). But also epigenetic changes 
like hyper- or hypomethylation of promotor regions lead to alterations in gene 
expression in tumor cells (Esteller et al. 2000). All these changes result in the 
manifestation of a malignant phenotype of cancer which has been defined in “The 
hallmarks of cancer” by Hanahan and Weinberg as described below. 
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1.4 The hallmarks of cancer  
In 2000 Hanahan and Weinberg characterized six classical hallmarks of cancer: self-
sufficiency in growth signals, insensitivity to anti-growth signals, limitless replication, 
evasion of apoptosis, sustained angiogenesis and tissue invasion and metastasis. 
These six capabilities are shared in common in most human tumors (Hanahan and 
Weinberg 2000).  
 
 
 
 
1.4.1 Self-sufficiency in growth signals 
There are two key signal-transducing kinase pathways which can be activated by 
binding of growth signals to receptor tyrosine kinases (RTKs): the ERK-pathway (via 
Ras-Raf-MAPK) and the PI3K-pathway. Both of them activate mTOR which leads to a 
stimulation of cell proliferation. mTOR activity is also controlled by the availability of 
nutrients (glucose, amino acid and oxygen). In most cancers master regulators of these 
two pathways like K-Ras, H-Ras, N-Ras, B-Raf, the p110 (a PI3K subunit), and RTKs 
as well as their downstream effectors like Akt or PDK1 are mutated. Furthermore 
negative regulators can be affected by inactivating mutations (Shaw and Cantley 2006). 
But also the autonomous generation of growth signals by the tumor itself reduces its 
Figure 9: The hallmarks of cancer  
(Hanahan and Weinberg 2000) 
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dependence from the normal tissue microenvironment and alters homeostatic 
mechanisms (Hanahan and Weinberg 2000). 
 
 
Figure 10: Two key signaling pathways to achieve self-sufficiency in growth signaling 
(Shaw and Cantley 2006) 
 
1.4.2 Insensitivity to anti-growth signals 
Anti-proliferative signals play an important role in cellular quiescence and tissue 
homeostasis. Like growth signals they act via a transmembrane cell surface receptor and 
start a signaling cascade. They block proliferation by forcing the cell into a quiescent 
state (G0) or entering a postmitotic state usually associated with differentiation. 
Retinoblastoma protein (pRb) for instance blocks proliferation and its signaling 
pathway, also governed by Transforming Growth Factor β (TGF-β). pRb is disrupted in 
a variety of ways in many cancer types (Hanahan and Weinberg 2000).  
 
1.4.3 Evading apoptosis 
Apoptosis is a process which is also called the programmed cell death. Intracellular 
apoptotic signals result in loss of cell membrane symmetry, cell attachment, cell 
shrinkage, nuclear fragmentation, chromatin condensation and chromosomal DNA 
fragmentation which finally lead to the death of the cell. Evading apoptosis is therefore 
a crucial step for cancer development but also for chemotherapy resistance. 
Consequently, cancer cells often manifest resistance against mitochondrial membrane 
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permeabilization which is an important step of apoptosis (Kroemer and Pouyssegur 
2008). 
 
1.4.4 Limitless replicative potential 
As observed in cell culture, normal human cells have the capacity for 60-70 doublings. 
Limitless replication requires growth signal autonomy, insensitivity to antigrowth 
signals and resistance to apoptosis. One of the most important regulators of apoptosis is 
p53. p53 reacts on DNA-damage, oxidative stress, and osmotic shock and initiates cell 
cycle arrest, DNA repair, and apoptosis. To achieve limitless replicative potential, p53 
is mutated or lost in more than 50% of the human tumors. But also the induction of 
telomerase which prevents the chromosomal ends from shortening during replication 
results in an unlimited replicative potential of the cell (Hanahan and Weinberg 2000). 
 
1.4.5 Sustained angiogenesis 
Angiogenesis is important to supply required nutrients to the tumor. It also serves to 
transform the tumor into a malignant state and metastasize, where single cells break 
away from the tumor, enter the blood vessels and are carried to another part of the body 
via blood stream where they can implant and grow to a secondary tumor. Stimulators of 
angiogenesis like VEGF and FGF are often up-regulated in tumors (Hanahan and 
Weinberg 2000). 
 
1.4.6 Tissue invasion and metastasis 
E-cadherin plays an essential role in the maintenance of intercellular contacts within 
epithelia. Loss or inactivated E-cadherin goes in common with epithelial mesenchymal 
transition (EMT), a process which leads to metastasis. Development of metastasis 
causes 90% of human cancer deaths (Weinberg 2007). 
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1.4.7 Additional hallmarks 
There are other common features of malignant cells like an induced anabolic 
metabolism, avoidance of immune response and several stress phenotypes (Kroemer 
and Pouyssegur 2008). Kroemer and Pouyssegur added 2008 the “Evasion of immune 
surveillance” as a seventh hallmark of cancer. 2009 the hallmarks of Hanahan and 
Weinberg were expanded by Lou et. al. by five additional hallmarks, the stress 
phenotypes of cancer: DNA damage/replication stress, proteotoxic stress, mitotic 
stress, metabolic stress and oxidative stress. 
 
 
Figure 11: The new hallmarks of cancer  
(Luo et al. 2009) 
 
1.4.7.1  Evasion of Immunosurveillance 
Cytotoxic T-lymphocytes and natural killer cells act in an anti-tumor response and are 
frequently inhibited by the microenvironment of tumor cells. Furthermore, tumor cells 
attract inflammatory cells which participate in tumor progression (Kroemer and 
Pouyssegur 2008). 
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1.4.7.2 DNA damage and DNA replication stress 
Usually, the genome of cancer cells is altered by the accumulation of point mutations, 
deletions, complex chromosomal rearrangements, and aneuploidy. In normal cells DNA 
damage leads to a proliferation stop and induces DNA damage stress response pathways 
and DNA repair programs or apoptosis. Cancer cells have overcome these anti-
proliferative effects of DNA damage and continue to replicate in the presence of DNA 
damage (Luo et al. 2009). 
 
1.4.7.3  Proteotoxic stress 
Aneuploidy and gene copy-number changes result in an increase and decrease of 
transcript levels of certain genes. This leads in consequence to a stoichiometric 
imbalance of protein complex subunits which increases an amount of toxic unfold 
protein aggregates in the cell. Thus, protein folding and degradation machineries are 
stressed to overcome this imbalance which results in a proteotoxic stress for the cell. 
Heat shock response pathway which promotes the proper folding or/and degradation of 
proteins are therefore frequently activated in tumor cells (Luo et al. 2009). 
 
1.4.7.4  Mitotic stress 
During mitosis in many tumors the chromosomes are not segregated properly which 
leads to a certain kind of chromosome instability phenotype. This phenotype results 
from defective pathways, from defective mitotic proteins which are responsible for 
chromosome segregation and from defects in the spindle assembly checkpoint which 
coordinates the alignment of the chromosomes to the spindle. But also double strand 
breaks and chromosomal instability lead to mitotic stress (Luo et al. 2009). 
 
1.4.7.5  Metabolic stress 
Normal cells receive their energy from mitochondrial oxidative phosphorylation. Tumor 
cells instead predominantly produce energy glycolysis which is less efficient and leads 
to the excretion of large amount of lactic acid (Warburg 1956). This has been referred to 
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as the Warburg effect which helps the tumor to adapt to low oxygen environment. The 
excretion of lactic acid leads to an acidification of the surrounding environment which 
helps the tumor to invade and to suppress the immune surveillance. (Kroemer and 
Pouyssegur 2008; Luo et al. 2009). 
 
1.4.7.6 Oxidative Stress 
Oxidative stress is induced by reactive oxygen species (ROS) which due to their high 
reactivity contribute to DNA damage. In cancer cells ROS are typically generated more 
than in normal cells. ROS can also promote the activity of the transcription factor HIF-1 
(Hypoxia-Inducible Factor) by hypoxia which leads to glycolytic switch and 
angiogenesis in the tumor (Luo et al. 2009). 
 
1.4.7.7  Inflammatory microenvironment 
2009 Colotta and his group defined another hallmark: the inflammatory 
microenvironment. There is a relation between inflammation and cancer. As studies 
have revealed, chronic inflammation advantages the development of different cancer 
types. But there can also be found an inflammatory environment to most neoplastic 
tissues with no relation to obvious inflammatory processes. The cancer-related 
inflammation is linked to infiltration of white blood cells like tumor-associated 
macrophages, but also with polypeptide messengers of inflammation like cytokines such 
as tumor necrosis factor (TNF), interleukin (IL-)1 and IL-6, chemokines such as CCL2 
and CXCL8 as well as tissue remodeling and angiogenesis.  
There are two pathways linking cancer and inflammation: intrinsic and extrinsic. The 
intrinsic pathway shows expression of inflammation-related program due to genetic 
events in the course of cancer development which leads to an inflammatory 
microenvironment. In contrast the extrinsic pathway describes that cancer development 
is facilitated by inflammation via infection (e.g. Helicobacter pylori for gastric cancer, 
papilloma virus and hepatitis virus for cervical and liver carcinoma), autoimmune 
disease (e.g. inflammatory bowel disease for colon cancer), and inflammatory 
conditions of uncertain origin (e.g. prostatitis for prostate cancer) (Colotta et al. 2009). 
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1.5 Colorectal Cancer (CRC) 
1.5.1 Anatomy of the colon 
The lower gastrointestinal tract is divided into two parts: the small intestine and the 
large intestine. The large intestine consists of the cecum, colon, rectum, and anal canal. 
The human large intestine measures about 1,5m. In contrast to the small intestine the 
large intestine does not play a major role in absorbing food but is important for 
absorption of water, potassium and some fat soluble vitamins from the solid wastes 
before elimination from the body. The colon also harbors a bacterial flora which 
ferments unabsorbed material.  
The human colon consists of four different sections called the ascending colon, the 
transverse colon, the descending colon and the sigmoid colon. The 25cm long ascending 
colon is located at the right side of the abdomen behind the peritoneum (retroperitoneal) 
and connects the cecum with the transverse colon at the hepatic flexure. The transverse 
colon is encased in the peritoneum and consequently mobile and leads to the splenic 
flexure into the descending colon. In the descending colon food is stored until it is 
emptied into the rectum. The sigmoid colon is located between the descending colon 
and the rectum and is named after its S-shaped morphology. The colon is further 
characterized by multiple haustra which are small pouches caused by sacculation and 
gives the colon a segmented appearance. 
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1.5.2 Histology of the colon tissue 
The intestine is structured in five layers. The first layer which faces the interior cavity 
(lumen) of the gastrointestinal tract is the mucosa, a one-cell epithelial layer which 
absorbs nutrients, fat and proteins. The second layer underlying these epithelia is a 
basement membrane which is called muscularis mucosa. It forms part of the 
extracellular matrix and anchors the epithelial cells. Furthermore, it presents a barrier 
between the mucosa and the submucosa, the third layer. The submucosa consists of 
mesenchymal cells which are large fibroblasts and is also rich in vessels and immune 
cells. The forth layer is a thick layer of smooth muscle and called the muscularis propria 
Figure 12: Anatomy of the colon 
(Picture form website: http://media.web.britannica.com/eb-media/19/74319-004-68DBB5D6.jpg; 
30.6.11) 
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which is responsible for moving the content of the colonic lumen. The fifth and 
outermost layer is the serosa. 
 
 
 
The epithelium of the gut is a rapidly self-renewing tissue which is ordered into 
numerous villis and crypts. Stem cells are sitting near the bottom of the crypts. In the 
crypts the cells are proliferating resulting in precursor cells whereas at the villis cells are 
differentiated. Transient amplifying cells arrest their cell cycle and differentiate once 
they reach the crypt-villus-junction. As soon as they reach the tip of the villis the 
differentiated cells undergo apoptosis. This results in a contiguous sheet of cells which 
is perpetually moving upwards. In the large intestine there are abundant goblet cells 
which secret mucins that together with water form mucus. A loss of the proliferation 
control in the crypt is the cause for colorectal cancer.  
 
Figure 13: The five layers of the intestine 
(Picture from website: http://www.hopkinscoloncancercenter.org/CMS/CMS_Page.aspx?SS=& 
CurrentUDV=59&CMS_Page_ID=0B34E9BE-5DE6-4CB4-B387-4158CC924084; 18.6.11) 
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1.5.3 Development of colorectal cancer 
Most pathological changes which lead to colon carcinomas occur in the epithelium. 
Colon carcinoma develops during a multi-step tumorigenesis beginning with 
hyperplastic, dysplastic crypts and adenomatous growth leading to cancerous growth. 
Cells growing hyperplastically exhibit almost normal histology and appearance. 
Hyperplastic areas however display an unusual high cell division rate which leads to a 
thicker-than-normal epithelium. The well-ordered epithelial cell layer is now altered and 
also the morphology of the individual cells changes subtly and later progressively, 
which is called dysplasia. Larger areas of dysplastic cells growing more deviant are 
called polyp or adenoma. Polyps can be directly attached to the colonic wall or can be 
tethered by a stalk and share the morphology of a mushroom. As long as they do not 
break through the basement membrane, polyps are referred to as benign and can be 
easily removed by colonoscopy. Usually, CRC begins with the formation of a benign 
polyp. With increasing size of the adenomatous polyp the risk for development into 
 
Figure 14: Histology of colon tissue 
The left panel shows a schematic picture of a colonic crypt (Picture from website: 
http://img.medscape.com/fullsize/migrated/532/504/gastro532504.fig1.gif; 30.6.11).  
The right panel shows a histological staining of a colonic crypt (picture from website: 
http://classes.midlandstech.com/carterp/Courses/bio211/chap23/Slide44.JPG; 30.6.11) 
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cancer is elevated. Malignant adenomas are called adenocarcinomas and begin to break 
through the basement membrane and invade all colonic tissue layers. In advanced stages 
cancerous cells detach and metastasize into the circulatory system, invading other 
organs of the body like liver and lungs. 95% of colorectal cancer grows directly out 
form adenomatous polyps (Weinberg 2007). 
 
 
 
 
 
 
 
 
 
 
 
Abnormal cell growth and inflammation can cause dysplasia which presents another 
pre-cancerous condition for CRC. Chronic inflammation of the colon, as it occurs in 
patients suffering from Morbus Crohn, exposes them to a higher risk for developing 
CRC. 
 
Figure 15: Development of colorectal cancer 
Different stages of colorectal cancer development 
are presented in histological sections (Weinberg 
2007). 
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1.5.4 Molecular biology of colorectal cancer 
1.5.4.1  Vogelstein-model 
1988 Vogelstein et. al. presented a new model which explained the molecular 
mechanism behind the CRC development. Searching for genetic alterations they found a 
loss of heterozygosity (LOH) in the long arm of chromosome 5 in many early 
adenomas. LOH is the loss of the normal function of one allele (in context of 
cancerogenesis of a tumor suppressor gene) by e.g. deletion or point mutation in which 
the other allele has already been inactivated. The region on chromosome 5 affected by 
LOH is carrying the gene Adenomatous Polyposis Coli (APC) which is an important 
tumor suppressor. In slightly larger adenomas about 50% additionally display a mutated 
K-ras oncogene. A high rate of LOH on the long arm of chromosome 18 was found in 
even larger adenomas. Half of the carcinomas showed in addition a LOH on the short 
arm of chromosome 17 which harbors p53. These observations led to the assumption 
that genetic changes, which were acquired by an epithelial cell during the process of 
cancerogenesis, involved the activation of one proto-oncogen and the inactivation of at 
least three tumor suppressor genes. However, alterations of the APC-β-catenin pathway 
usually come first whereas the other genetic changes do not have to happen in a 
determined order (Vogelstein et al. 1988; Weinberg 2007).  
 
 
Figure 16: Carcinogenesis of colorectal cancer: Vogelstein-model  
(Weinberg 2007) 
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1.5.4.2  APC and the Wnt-pathway 
1.5.4.2.1  The canonical Wnt/β-catenin cascade  
The discovery of Wnt is traced back to a wingless Drosophila mutant and a related gene 
termed int-1 which was found up-regulated by mouse mammary tumor virus in mouse 
(Nusse et al. 1991). The human Wnt-family consists of 19 secreted glycoproteins that 
are involved in regulation of cell proliferation, cell morphology, cell motility and cell 
fate (Dale 1998; Katoh 2006a). Wnt proteins are tethered tightly to the extracellular 
matrix and bind the extracellular domain of transmembrane frizzled receptor. In 
addition to frizzled, Wnt also binds to a co-receptor protein, the LDL-receptor-related 
protein (LRP) (Alberts 2002).  
β-catenin is associated with the transmembrane adhesion protein cadherin but also 
located in the cytoplasm. The β-catenin-cadherin-complex is located at cell-cell 
adherent junctions where β-catenin helps to link cadherin to the actin cytoskeleton. In 
the absence of Wnt-signaling free and unbound β-catenin is degraded rapidly by a 
complex which consists of axin, Glycogen Synthase Kinase 3 (GSK3), Caseine Kinase 
1 (CK1) and APC. Axin acts as the scaffold of this complex because it directly interacts 
with all components of this complex. Unbound β-catenin is first phosphorylated by CK1 
and GSK3 at highly conserved Serine/Threonin residues, ubiquitinated and finally 
degraded by proteasomes (Alberts 2002). 
As soon as the canonical Wnt-pathway is activated by Wnt binding to frizzled and LRP, 
Dishellved is recruited to the plasma membrane where it is activated and inhibits the 
axin-GSK3-APC-complex. β-catenin is therefore not proteolytically degraded and can 
now enter the nucleus and interact with Lymphoid Enhancer Factor/T-Cell Factor 
(LEF/TCF) transcription factor family. In the absence of β-catenin TCF acts as a 
transcriptional repressor by forming a complex with the protein Groucho. β-catenin 
displaces Groucho by interacting with TCF and converts it into an activator. Many TCF 
target genes have been identified in diverse biological systems including genes which 
are also involved in tumor progression. Examples for Wnt-controlled target genes are c-
myc, cyclin D, survivin, c-met, VEGF, proteinases like MMPs, CD44 but also FGF18 
and FGF20 (Behrens and Lustig 2004; Clevers 2006). 
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Figure 17: Wnt-signaling pathway 
(Picture from website: http://www.cstj.co.jp/reference/pathway/images/Wnt_beta_Catenin.jpg; 30.6.11) 
 
1.5.4.2.2  The role of APC and β-catenin in colorectal cancer 
The Wnt cascade is implicated in controlling cell fate along the crypt-villus axis. At the 
bottom of the crypts stem cells are located. Their progenies are moving upwards and out 
of the crypt where they form the epithelial lining of the gut. Stromal cells near the 
bottom of the crypt release Wnt proteins which affect the enterocytes at the bottom of 
the crypt. In these enterocytes intracellular β-catenin level is high, giving them a stem 
cell-like character. This leads to increased proliferation and increased differentiation of 
these cells based on the interaction with TCF/LEF transcription factors. By moving 
upwards the crypt towards the lumen, cells lose the stimulation via Wnt-signaling and 
proliferation is turned off due to β-catenin degradation. Cells are now differentiating 
and after 4 days they enter apoptosis (Weinberg 2007). Inhibition of Wnt-signaling 
results in the complete loss of crypts in adult mice which identifies Wnt as an essential 
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mitogen for crypt progenitor cells. On the other hand, over-activation of Wnt-signaling 
leads to a massive hyperproliferation of intestinal crypts (Clevers 2006). 
APC plays a crucial role in the early development of CRC. The APC gene is located on 
the long arm of chromosome 5 (5q21) and is mutated in 35-80% of all sporadic 
carcinomas and 29-63% of all sporadic adenomas (Powell et al. 1992). APC negatively 
controls β-catenin level in the cytosol and is essential for its degradation. APC is not 
expressed in the colonic crypts but its level increases with the upwards migrating cells 
out of the crypts. Mutated APC leads to an accumulation of β-catenin in the cells even 
without Wnt-signaling. Cells are proliferating but do not differentiate while migrating 
upwards the crypt. Finally, they are unable to migrate further and due to the increased 
proliferation they develop an adenomatous polyp in the crypt (Weinberg 2007).  
Even in colon carcinomas carrying the wild-type APC allele, intracellular level of β-
catenin was affected by epigenetic silencing of the APC promoter region or by point 
mutations of the β-catenin gene. Patients with point mutations in β-catenin, which affect 
its degradation or mutated axin2, display also a predisposition to CRC (Weinberg 
2007). 
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Figure 18: APC/ß-catenin and the biology of colonic crypts 
(Weinberg 2007) 
 
A germline APC mutation is the genetic cause for a hereditary cancer syndrome named 
Familial Adenomatous Polyposis (FAP). One defective APC allele results in subtle 
shifts in growth and differentiation control. It also destabilizes the genome so that the 
normal APC allele is lost causing development of benign polyps. People suffering from 
FAP develop hundreds of adenomatous polyps in the colon which are themselves not 
malignant but are susceptible to develop into carcinoma. FAP is relatively rare and is 
identified in less than 1% of all colon cancers in the western population. 
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Figure 19: Familial adenomatous polyposis 
On the left picture a section of the colon of a FAP patient is presented whereas on the right 
picture the colon of a healthy person is shown. The wall of the colon of a FAP patient is carpeted 
with adenomatous polyps (Weinberg 2007) . 
 
Aberrant Wnt-signaling might also play a role in other cancer variants. APC mutations 
are also present in 76% of sporadic gastric adenomas. Mutations in β-catenin were 
found in 40% of endometrial carcinomas, in ovarian carcinomas, in up to 70% of 
hepatoblastomas, 25% of hepatocellular carcinomas, 61% of sporadic anaplastic thyroid 
carcinomas, and in Wilms tumor (common childhood renal malignancy). In 30% of 
prostate cancer cases as well as in medulloblastomas Wnt-signaling is involved. High 
levels of β-catenin but not mutated β-catenin was also found in melanomas and 
osteosarcomas (Behrens and Lustig 2004). 
Mutation of APC has also been found to increase chromosomal instability. This derives 
from the fact that APC is also localized to components of the microtubule array and 
consequently also involved in the formation of the mitotic spindle. Loss of APC results 
in an inappropriate segregation of chromosomes during mitosis, which alters the 
number of critical growth-promoting and growth-inhibiting genes in the progeny cells 
(Weinberg 2007).  
 
1.5.4.3 K-ras, a member of the Ras-family 
The members of the Ras-family are small GTPase involved in cellular signaling 
transduction affecting cell growth, differentiation and survival. The name Ras is traced 
back to rat sarcoma because the Ras-gene was first identified in cancer causing viruses 
in rat sarcoma. There are three Ras genes designed: N-Ras, K-Ras and H-Ras. About 
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30% of human tumors have a hyperactive Ras mutation. Ras is anchored to the cell 
membrane at the cytoplasmic face and acts in two conformations: active when 
Guanosine Tri-Phosphate (GTP) is bound and inactive when Guanosine Di-Phosphate 
(GDP) is bound. Ras activation is controlled by two kinds of proteins called Guanine 
nucleotide Exchange Factors (GEFs) and GTPase-Activating Proteins (GAPs). GEFs 
stimulate the dissociation of GDP and the uptake of GTP from the cytosol. GAPs 
increase the hydrolysis of GTP and therefore inactivate Ras. Hyper-activating mutations 
of Ras inhibit the interaction with GAP and leave Ras permanently active (Alberts 
2002).  
 
 
Figure 20: The regulation of Ras activity  
(Alberts 2002) 
 
1.5.4.3.1 Ras signaling: the MAP-kinase and PI3-kinase pathway 
Receptor tyrosine kinases activate Ras by activating GEFs or inhibiting GAPs via Grb2 
protein. Grb2 protein binds through a SH2 domain specific phosphotyrosines on 
activated receptor tyrosine kinases and through a SH3 domain the proline-rich motif on 
a special GEF called Sos. Activated Ras itself activates various other signaling proteins.  
One of the downstream signaling pathways activated by Ras is the Mitogen-Activated 
Protein kinase (MAP-kinase) pathway. Ras activates Raf which again phosphorylates 
MEK. MEK finally activates the MAP-kinase ERK which phosphorylates gene 
regulatory proteins in the nucleus and other protein kinases and stimulates cell division.  
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Another pathway activated by Ras is the Phosphatidylinositol 3-kinase (PI3-kinase) 
pathway which is involved in the control of cell growth and cell survival. The PI3-
kinase can be activated by receptor tyrosine kinases as well as other types of cell-
surface receptors directly or G-protein-linked e.g. by Ras. PI3-kinase phosphorylates 
Inositol Phospholipids (PI) generating PI(3,4)P2 or PI(3,4,5)P3. The phosphorylated PI 
serve as docking sites for many intracellular signaling proteins, amongst them PDK1 
which in turn activates the Protein Kinase B (PKB), also called Akt. Once activated, 
Akt interacts with a variety of proteins for example BAD, a protein which encourages 
cells to undergo apoptosis. Akt further activates p70S6 kinase via mTor which 
phosphorylates and activates the S6 subunit of ribosomes and consequently increases 
translation (Alberts 2002). 
 
 
Figure 21: Ras signaling: MAP-kinase and PI3-kinase pathway  
(Cully et al. 2006) 
 
1.5.4.3.2 The role of K-Ras in colorectal cancer 
K-Ras is a proto-oncogene and is found mutated in 10% of adenomas smaller than 1cm, 
40-58% of larger adenomas and 47-60% of colorectal carcinomas (Vogelstein et al. 
1988). A single point mutation (mostly in codon 12) resulting in the substitution of one 
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amino acid leads to a growth factor independent persisting stimulation of K-Ras. 
Malignant CRC cell lines carrying a K-Ras mutation show typical features of 
transformed cells like the ability to grow anchorage independent. K-Ras mutation itself 
leads to self-limiting hyperplastic lesions in colorectal cells. K-Ras mutation occurring 
after a previous APC mutation promotes cancerogenesis (Weitz J. 2004).  
 
1.5.4.4 P53 
p53 is one of the most important tumor suppressor genes mutated or deleted in more 
than 50% of various human tumor types. As the “guardian of the genome” p53 plays a 
crucial role in the regulation of the cell cycle. The key role for p53 is to detect genomic 
stress and to decide whether DNA is repaired or the cell undergoes apoptosis. MDM2 
regulates p53 by recruiting it to the cytoplasm and inducing its degradation by 
ubiquitination. p53 itself stimulates its own degradation by stimulating the expression of 
MDM2 (Alberts 2002). 
Physical or chemical agents causing DNA damage induce p53-dependent physiological 
response. Gamma irradiation activates ATM which further activates p53 by 
phosphorylation. Phosphorylated p53 modifies the protein and inhibits the binding to 
MDM2. ATM also activates ABL which phosphorylates MDM2 and neutralizes its 
function as p53 inhibitor. Consequently, p53 is accumulated in the nucleus which 
arrests the cell cycle in G1. DNA repairing enzymes are activated and repair the DNA 
damage. Alternatively, instead of arresting the cell cycle p53 can induce apoptosis of 
the genomic stressed cell. But also other cellular disturbances like oncogene activation, 
hypoxia, or abnormal cellular ribonucleotide concentrations lead to the accumulation of 
p53 (Soussi 2000).  
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Figure 22: Pathways of p53 
(Picture from website http://en.wikipedia.org/wiki/File:P53_pathways.jpg, 02.07.11) 
 
Mutations of p53 are often accompanied by LOH and in most cases are caused by point 
mutations in four of the five evolutionary conserved domains of the protein. More than 
90% of mutations in p53 affect the DNA-binding affinity of the protein. Cells harboring 
mutated p53 are less stable by accumulating mutations and give rise to malignant 
potential. Mutations of p53 are rare in polyps but common in carcinomas, suggesting 
that they occur later during colon cancerogenesis. They are found in 50-60% of sporadic 
CRCs and occur preferentially during the transition of adenomas to invasive 
adenocarcinomas. Germline mutations of p53 lead to the Li-Fraumeni syndrome which 
predisposes affected members to cancer (Bartram 2004). 
 
1.5.4.5 LOH at chromosome 18: Smad2 and Smad4 
In 60% of human CRCs the long arm of chromosome 18 is affected by LOH. The 
identity of genes in this region contributing tumorigenesis is not completely clear so far. 
One candidate gene is DPC4/MADH4 which expresses Smad4, a protein involved in the 
transition of growth-inhibitory signals from TGF-β receptor to the cell nucleus. 
However, this gene is only mutated in fewer than 15% of colon cancers. Another 
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protein affected by LOH of chromosome 18 is Smad2 which is inactivated even less 
frequently than Smad4 (Weinberg 2007). Smad4 and Smad2 are considered as tumor 
suppressors regulating the TGF-β transduction pathway. TGF-β binds to a single-pass 
transmembrane serine/threonine kinase receptor which is then activated and binds 
intracellular Smad2 and Smad3 or Smad1, Smad5 and Smad8. Phosphorylation of these 
Smads leads to dissociation and binding to Smad4 with either one of the Smads. This 
complex moves into the nucleus where it associates with other transcription factors and 
activates specific target genes (Alberts 2002).  
 
 
Figure 23: TGF-β/Smad4 signaling  
(H. Lodish 2000) 
 
Target genes affect a diverse range of biological activities like cell cycle, differentiation, 
apoptosis, gastrulation and embryonic development. Furthermore, TGF-β-Smad 
signaling is implicated in epithelial growth and extracellular matrix proteins which are 
important for tumor development and metastasis.   
 
1.5.5 Tumor staging in colorectal cancer 
Survival rates of colon cancer are higher if the disease is diagnosed at an early localized 
stage than in patients with advanced tumors. Therefore, tumor staging is important for 
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therapy administration, as a prognostic factor, for statistical evaluation of therapy, for 
clinical and international information exchange and for cancer research. There have 
been established some systems for cancer classification and the first one was founded in 
1932 by Dr. Cuthbert Dukes, called the Dukes classification. This classification has 
been modified and complemented and today is known as the Astler-Coller-version of 
the Dukes classification (MAC) (Schölmerich J. 2005). 
Today the TNM-classification of malignant tumors for international clinical and 
pathological staging is used. The TNM-classification was developed 1943-1952 when 
Pierre Denoix tried to characterize solid tumor stages using the size and extension of the 
tumor, lymphatic involvement and presence of metastasis as parameters. Since that time 
the TNM-classification has been adapted and modified various times. 
T: describes size of primary tumor and invasion into nearby tissue (AJCC 26.6.2011) 
 TX: primary tumor cannot be assessed 
 T0: no evidence of primary tumor 
 Tis: carcinoma in situ: intraepithelial or invasion of lamina propria 
 T1: tumor invades submucosa 
 T2: tumor invades muscularis propria 
 T3: tumor invades through muscularis propria into pericolorectal tissue 
 T4a: tumor penetrates to the surface of the visceral peritoneum 
 T4b: tumor directly invades or is adherent to other organs or structures 
 
N: describes regional lymph node involvement (AJCC 26.6.2011) 
 NX: regional lymph node cannot be assessed 
 N0: no regional lymph node metastasis 
 N1: metastasis in 1-3 regional lymph nodes 
 N1a: metastasis in 1 regional lymph node 
 N1b: metastasis in 1-3 regional lymph nodes 
 N1c: Tumor deposit(s) in the subserosa, mesentery, or non-peritonealized pericolic or perirectal 
tissues without regional nodal metastasis 
 N2: Metastasis in 4 or more regional lymph nodes  
 N2a: Metastasis in 4–6 regional lymph nodes  
 N2b: Metastasis in 7 or more regional lymph nodes 
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M: describes the presence of distant metastasis (AJCC 26.6.2011) 
 M0: no distant metastasis  
 M1: distant metastasis  
 M1a: metastasis confined to one organ or site (for example, liver, lung, ovary, non-regional 
node)  
 M1b: metastases in more than one organ/site or the peritoneum 
 
Tumor stage is stated as I-IV and is determined by the TNM-classification. Most stage I 
tumors are curable and most stage IV tumors are inoperable. 
 
 
Table 1: Colorectal cancer staging according to the American Joint Committee of Cancer 
(AJCC 26.6.2011) 
 
Additional, the differentiation state of tumor tissue compared to normal tissue is 
determined by pathologists analyzing the tissue under the microscope. Tumor tissue is 
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divided into “low-grade” (G1, G2) and “high-grade” (G3, G4) groups (Schölmerich J. 
2005). 
 Gx: differentiation cannot be determined 
 G1: well differentiated, carcinoma shows normal histological and cellular characteristics 
 G2: moderately differentiated 
 G3: poorly differentiated, carcinoma shows different histological and cellular characteristics 
compared to normal tissue 
 G4: undifferentiated, no typical glandular or epithelial characteristics of the tumor tissue  
 
1.6 Receptor Tyrosine Kinases  
1.6.1 The function of receptor tyrosine kinases 
58 receptor tyrosine kinases (RTK) belonging to 20 families have been detected in the 
human genome. In general protein kinases transfer phosphate groups from Adenosine 
Tri-Phosphate (ATP) to a protein side chain. As this is a very rapid reaction that has 
high impact on protein domain structures, it is frequently used for intracellular signal 
transduction. RTKs use a tyrosine to bind phosphate groups in contrast to serine-
threonine kinase receptors. They consist of three main domains: an extracellular domain 
for ligand binding, signaling peptide and dimerization, a transmembrane domain and an 
intracellular domain containing the kinase domain and an auto- and 
transphosphorylation side. Whereas the extracellular ligand binding domain differs 
strongly between the different RTK-families the kinase domain is quite conserved 
(Alberts 2002).  
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Figure 24: Tyrosine kinase receptors 
(Picture from website http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_ 
summary_pr?p_JournalId=2&p_RefId=857184&p_IsPs=N; 30.6.11) 
 
The kinase domain contains an ATP-binding side and a substrate binding side. Ligand 
binding to the extracellular domain leads to receptor homo- or hetero-dimerization and 
the kinase domain is auto- or transphosphorylated. The resulting phosphotyrosines 
create the docking site for proteins containing a SH2 (Src Homology 2) or a PTB 
(Phosphor Tyrosine Binding) domain. Additionally, docking domains like the SH3 (Src 
Homology 3) and the PH (Pleckstrin Homology) domain recruit targets that transduce 
the signal further down-stream towards the nucleus. RTKs activate several signaling 
cascades controlling cell survival, proliferation and migration. Activated RTKs are then 
down-regulated by endocytosis and degradation (Alberts 2002).  
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Figure 25: Signaling pathways activated by the RTK FGFR  
(Acevedo et al. 2009) 
 
1.6.2 Receptor tyrosine kinases in cancer 
Due to the involvement of RTKs in cell proliferation, cell survival and cell migration 
they are often affected in various cancer types. Aberrations of RTK signaling are caused 
for instance by gene amplification, mutations, and increased transcription of the 
receptor but also by increased production of ligands and decrease of antagonists. 
Epidermal Growth Factor Receptor (EGFR)-family, Vascular Endothelial Growth 
Factor Receptor (VEGFR)-family, Insulin-like Growth Factor 1 Receptor 
(IGF1R/INSR)-family, and FGFR-family are mutated and act as oncogenes in cancer. 
One of the most prominent examples is HER-2 gene amplification in breast cancer 
(Slamon et al. 1987). Consequently, a lot of effort has been undertaken to target RTKs 
and since 1998 clinical application of RTK targeted therapies have been developed. 
RTKs can be targeted by antibodies or small molecule kinase inhibitors.  
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1.7 Fibroblast Growth Factor Receptors (FGFRs) 
1.7.1 FGFRs in general 
The importance of Fibroblast Growth Factor (FGF) signaling through their receptors 
(FGFRs) is extensive. Not only embryonic development (mesodermal patterning in the 
early embryo as well as organogenesis) but also different physiological functions in the 
adult organism like control of the nervous system, tissue repair, wound healing and 
angiogenesis are partly controlled by FGFs and FGFRs. They regulate cell proliferation, 
differentiation and survival and consequently play an important role in the development 
of cancer (Eswarakumar et al. 2005; Turner and Grose 2010).  
Germline mutations of FGFR which lead to a gain-of-function result in various diseases 
like craniosynostosis (malformed cranium due to premature closure of sutures of a 
developing skull), dwarfing syndromes or cancer. Especially germline mutations of 
FGFR2 and 3 cause distinctly different patterns of limb development – e.g. normal 
hands and feet in the Crouzon syndrome, broader thumbs and toes in the Pfeiffer 
syndrome and severe fusion of the bones in the hands and feet in the Apert syndrome. 
Most of the germline mutations which cause skeletal syndromes lead to the 
development of cancer when they are somatic. Heterozygous mutations of FGFR1-3 
contribute significantly to disorders of bone patterning and growth (Beenken and 
Mohammadi 2009; Webster and Donoghue 1997). 
 
1.7.1.1  Structure of FGF and FGFR 
FGFRs belong to the family of RTKs. Their extracellular domains consist of three 
Immunoglobulin-like (Ig) loops IgI, IgII, and IgIII. Between IgI and IgII a stretch of 
eight consecutive acidic residues (acid box) is located. IgII, IgIII and the linker between 
these two domains are important for ligand binding (Plotnikov et al. 1999). IgI and the 
acid box do not contribute to ligand binding but possess an auto-inhibitory function. 
The acid box interacts with the highly basic heparin-binding side of IgII. IgI interacts 
directly with the IgII-IgIII fragment (Olsen et al. 2004). 
Further diversity is also reached by alternative splicing of FGFR1-3. Especially the 
exon 8 and 9 in the IgIII leads to the expression of either the IIIb or IIIc receptor 
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isoform. These two isoforms are expressed in a tissue specific manner. Thus, the 
expression of the IIIb isoform is predominant in epithelia, whereas IIIc isoform is more 
expressed in mesenchymal tissue. Ligands can also distinguish between the two 
isoforms. For example the FGF7 subfamily is expressed in mesenchyme and binds 
preferentially to FGFR2IIIb, whereas the FGF8 subfamily activates IIIc splice forms of 
FGFRs and is expressed in epithelial tissue (Ornitz and Itoh 2001; Zhang et al. 2006). 
The intracellular domain consists of a juxta-membrane domain, a split kinase domain, 
and a carboxy-terminal tail. 
 
 
Figure 26:  Structure of FGFR 
(Beenken and Mohammadi 2009) 
 
1.7.1.2  Interaction between FGFR and FGF/extracellular matrix 
FGFs are glycoproteins and after secretion they are bound to the extracellular matrix 
and the cell surface by heparin or Heparan Sulphate Proteoglycans (HPSGs) (Hacker et 
al. 2005). HPSGs are polysulphated acidic glycoproteins which contain a larger 
carbohydrate than protein moiety. Specifically, they consist of a core protein, to which 
glycosaminoglycan chains are attached at specific sites. They reside in the extracellular 
matrix or are attached to the cell membrane.  
Heparin is a highly sulfated polysaccharide which due to its structural similarity mimics 
the action of heparan sulphates but is not expressed on the cell surface (Berman et al. 
1999; Ostrovsky et al. 2002). Heparins are shorter than heparan sulphate chains 
(Harmer 2006). 
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FGFs interact with the sulphated domains of heparan sulfate, heparan sulfate 
proteoglycans, and heparin. Heparan sulphate not only provides an extracellular 
reservoir of FGFs but also protects them from heat inactivation and proteolytic 
degradation (Vlodavsky et al. 1996) 
Heparinases, proteases and specific FGF-binding proteins release FGFs from the 
extracellular matrix HPSGs and FGFs can bind to the cell surface HPSGs (Turner and 
Grose 2010). HPSGs are low affinity receptors which do not transmit a biological signal 
(Eswarakumar et al. 2005).  
 
 
Figure 27: Ligand binding of FGF and receptor dimerization  
(Beenken and Mohammadi 2009) 
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1.7.1.3  FGFR dimerization 
Heparin facilitates the formation of FGF-dimers but also stabilizes the formation of 
FGF-FGFR-complexes (Ornitz et al. 1996). FGFR dimerization is induced by binding to 
an FGF-heparan proteoglycan/heparin sulphate complex. In the absence of heparan 
proteoglycan and heparin FGF is unable to bind to FGFR (Schlessinger et al. 1995). The 
length of glycosaminoglycan and heparin sulphation patters can also determine binding 
of different FGFs to different FGFRs and their isoforms (Ostrovsky et al. 2002). One 
heparan sulphate saccharide can bind multiple FGF complexes depending on its length 
and sulphation. This leads to the suggestion that signaling plaques are formed due to the 
building of FGFR aggregates co-localized on the cell surface (Harmer 2006). 
 
 
Figure 28: Molecular surface representation of the 2:2:2 FGF2-FGFR1-heparin-complex 
FGF2 is colorized orange and the IgII of FGFR1 is green. The view is from the top looking into 
the heparin canyon. Heparin is presented here only with the first 6 sugar rings (Schlessinger et al. 
2000). 
 
Two 1:1 FGF-FGFR complexes form a symmetric dimer. Interaction between both 
receptors of each FGF-FGFR complex as well as interaction between ligand and 
receptor stabilizes the dimer. There is no interaction between the two ligands observed. 
IgII domains of both receptors form a canyon of positive potential, where heparin binds 
and bridges the two receptor-ligand complexes (Plotnikov et al. 2000; Schlessinger et 
al. 2000). 
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The expression of heparan sulphate and its biosynthetic enzymes as well as the 
expression of the core proteins to which heparan sulphates are attached changes during 
the embryonic development suggesting an important mechanism to regulate FGF-
signaling (Allen and Rapraeger 2003). 
 
1.7.1.4 Receptor activation 
Ligand dependent dimerization of the FGFRs leads to conformational changes in the 
receptor structure which activate the intracellular kinase domain.  
Auto-phosphorylation of RTKs regulates catalytic activity and initiates downstream 
signaling. FGFR is auto-phosphorylated in trans by a strictly ordered reaction which 
indicates that different signaling pathways are recruited and activated within a certain 
time. For FGFR1 there are seven tyrosine residues which act as the major 
autophosphorylation sites: Y463, Y583, Y585, Y653, Y654, Y730, and Y766. Whereas 
pY766 acts as binding site for the SH2 domain of Phospholipase-Cγ, Y653 and Y654 
are in the active loop and essential for tyrosine kinase activation. The other tyrosine 
auto-phosphorylation sites act as docking sites for signal proteins. Y653 is first 
phosphorylated which enhances the catalytic activity of FGFR 50-100fold and recruits 
signal proteins. Y583, Y463, Y766, and Y585 are then phosphorylated and further 
recruit SH2- and PTB-domain containing proteins. Y654 is auto-phosphorylated 
subsequently and increases the catalytic activity up to 500-1000fold (Furdui et al. 2006; 
Knights and Cook 2010). 
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Figure 29: FGFR activation 
TM … transmembrane, JM … juxta-membrane; (Knights and Cook 2010) 
 
1.7.1.5 FGFR downstream signaling 
There are two main substrates of FGFRs: FGFR Substrate 2 (FRS2) and Phospholipase-
Cγ (PLCγ). Unlike other RTKs FGFRs do not directly bind Grb2, which links the 
activation of RTKs to the Ras/MAPK signaling pathway (Olsen et al. 2003). 
Phosphorylation of FGFR leads to the direct phosphorylation of the 90kDa Protein 
FRS2 and Shc. Shc and FRS2 both recruit Grb2/Sos-complex. FRS2 is associated with 
the cell membrane and contains a PTB domain, which binds the phosphotyrosine. FRS2 
phosphorylation is stimulated by FGF and Nerve Growth Factor (NGF) but not by 
Epidermal Growth Factor (EGF), Platelet-Derived Growth Factor (PDGF) or insulin 
(Wang et al. 2002). FRS2 is a key adaptor protein and quite specific for FGFR but it 
interacts also with other RTKs like Neurotrophic Tyrosine Kinase Receptor type 1 
(NTRK1), RET (Rearranged during Transfection) and Anaplastic Lymphoma Kinase 
(ALK) (Turner and Grose 2010). 
For maximal activation of Ras/MAPK signaling pathway, an adaptor protein Shb which 
binds to the tyrosine 766 is required. Shb regulates Shp2 phosphorylation and its 
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interaction with FRS2 (Feik et al. 2010). Recruitment of Grb2 and Shp2 are necessary 
for FGF-mediated MAPK activation, leading to cell proliferation and differentiation. 
Grb2 binds to FRS via a SH2 domain and a 2:2 complex of Grb2 and FRS recruits 
another protein Gab1, a guanine nucleotide releasing factor which is phosphorylated 
and activates PI3-kinase. Grb2 binds to a proline-rich region of Gab1 via its c-terminal 
SH3 domain. The binding and phosphorylation of Gab1 generates a binding site of the 
SH2 domain of p85, the regulatory subunit of PI3-kinase which leads to recruitment and 
activation of PI3-kinase (Hacker et al. 2005). PI3-kinase phosphorylates PIP2, 
generating PIP3 (Phosphatidylinositol-3,4,5-triphospate) which translocates Akt, a 
serine/threonine kinase to the plasma membrane. There Akt is phosphorylated and 
activated by the Phosphoinositide-Dependent Kinase (PDK) and phosphorylates by 
itself a variety of substrates like GSK3β, mTor, FOXO1 and FOXO3 (Katoh 2006a). 
Grb2 also binds to Sos, another guanine nucleotide releasing factor via its n-terminal 
SH3 domain. Sos activates G-proteins of the Ras-family and catalyzes the exchange of 
GDP by a GTP. Ras itself can activate different signaling pathways: RAF-MEK1/2-
ERK1/2, PI3K-PDK1-PKB and PLCε-IP3/DAG-PKC (Knights and Cook 2010). 
PLCγ by contrast binds directly to FGFR1 at the Y766. Since Y766 binds also the 
adaptor protein Shb, it is conceivable that PLCγ and Shb compete with each other for 
binding to activated FGFR. Probably, the activation of PLCγ or Shb differs temporarily 
or depends on different pools of activated receptors. 
PLCγ catalyzes the hydrolysis of the minor membrane phospholipid 
Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) which produces two intracellular 
secondary messengers: Diacylglycerol (DAG) and Inositol 1,4,5-trisphosphate 
(Ins(1,4,5)P3). Ins(1,4,5)P3 binds to Ins(1,4,5)P3 receptors which are large calcium 
channels and reside in the membranes of intracellular calcium stores like the 
endoplasmatic reticulum. Channels are opened by binding and Ca2+ is released into the 
cytosol where it activates Ca2+ dependent protein kinases like calmodulin-dependent 
kinases, Ca2+- and DAG-dependent proteins, and Protein Kinase C (PKC)-family of 
kinases (Knights and Cook 2010; Sugiyama et al. 2010b). 
There are also other pathways which are activated by FGF-signaling including Signal 
Transducer and Activator of Transcription (STAT) signaling (Turner and Grose 2010). 
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Constitutively activated FGFR1, FGFR3 and FGFR4 mutants showed activation of 
STAT transcription factors like STAT1, STAT3, STAT5a and STAT5b (Zhong et al. 
2006). How precisely FGFRs can activate STAT is unclear so far. 
ERK1/2 and PKB pathways promote cell cycle progression and cell survival for 
example by inhibiting pro-apoptotic proteins like BIM and BAD or by promoting 
expression of pro-survival proteins like BCL-xL or MCL-1 (Knights and Cook 2010). 
 
 
Figure 30: Intracellular FGF-dependent signaling  
(Knights and Cook 2010) 
 
1.7.1.6  Crosstalk between FGF- and Wnt-signaling 
FGF-signaling pathways and WNT-signaling pathways interfere with each other in a 
variety of cellular processes like early embryogenesis, body-axis formation, limb-bud 
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formation, neurogenesis, hematogenesis, hepatogenesis, gastrointestinal morphogenesis, 
MMTV-induced mammary carcinogenesis, and human colorectal carcinogenesis. 
FGF16, FGF18 and FGF20 are targets of the canonical Wnt-pathway (Katoh 2006b).  
Whereas GSK3β is responsible for the degradation of β-catenin in the canonical Wnt-
pathway, GSK3β is phosphorylated due to FGF-dependent signaling via PI3K and Akt 
which results in the down-regulation of GSK3β activity. GSK3β binds and 
phosphorylates SNAIL, a transcriptional repressor of CDH1 gene encoding E-cadherin. 
Phosphorylated SNAIL is cytoplasmically translocated and cannot repress the 
transcription of E-cadherin. This leads to the assumption that inhibition of GSK3β 
activity in the FGF-signaling pathway results in a development of EMT by down-
regulating E-cadherin (Katoh 2006a). 
 
 
Figure 31: Induction of EMT by FGF-signaling  
(Katoh 2006a) 
 
There is a cross-talk between Wnt- and FGF-signaling during a variety of cellular 
processes. Since FGF18 and FGF20 are target genes of the Wnt-pathway, activation of 
the canonical Wnt-pathway, for example during carcinogenesis, also influences and 
activates FGF-signaling. GSK3β is down-regulated by both Wnt- and FGF-signaling. 
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There might be different pools of GSK3β available for the two pathways. Furthermore, 
a simultaneous activation of FGF- and Wnt-signaling leads to a potentiation of the Wnt-
signaling because translocation of β-catenin is promoted by the FGF-signaling via 
PI3K-Akt (Katoh 2006a). 
 
 
Figure 32: GSK3β crosslinks Wnt-signaling and FGF-signaling pathways 
(Katoh 2006a) 
 
1.7.1.7  Regulation and termination of FGF-mediated signaling 
One possibility to regulate FGF-mediated signaling is auto-inhibition of the receptor. 
Auto-inhibition can be mediated by the IgI and the linker sequence IgI-IgII, the acid 
box. IgI directly interacts with the IgII-IgIII region of FGFR. The flexible nature of the 
IgI-IgII sequence facilitates also intramolecular interaction between the acid box and the 
highly basic heparin-binding site of IgII. These interactions lead to a low-affinity state 
of the FGFR where its affinity to FGF and heparin is reduced. The length of the IgI-IgII 
linker region as well as the number of consecutive acidic residues determines the 
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strength of auto-inhibition. FGFR1 has a very long linker region and therefore is 
stronger auto-inhibited as for example FGFR4 (Goldfarb et al. 2007). 
Another mechanism regulating FGF-signaling is via c-Cbl. In response to FGF 
stimulation, c-Cbl is recruited by Grb2 and binds to FRS2 which results in 
ubiquitination of FRS and FGFR. This process is highly significant because other 
proteins in the multi-protein complex associated with FRS like Grb2, Gab1, or Shp2 are 
not ubiquitinated (Yayon et al. 1991). 
Possible ways for termination of FGF-mediated signaling are achieved via a protein 
tyrosine phosphatase which has been identified in Caenorhabditis elegans so far but is 
currently unknown in mammalian cells (Knights and Cook 2010).  
Apart from receptor auto-inhibition and receptor degradation there are several ways to 
modify the FGF-signaling by feedback inhibition, above all affecting Ras-Raf-MEK1/-
ERK1/2 signaling pathway. MAPK phosphatases for example are expressed due to 
ERK1/2 activation and inactivate ERK1/2 by dephosphorylation (Knights and Cook 
2010).  
An efficient regulator of FGF, VEGF or EGF downstream signaling is Sprouty (Spry). 
Spry2 binds to Grb2 and inhibits FGF-induced MAPK pathway. Spry2 itself is activated 
by a protein phosphatase 2A (PP2A). Spry is synexpressed to FGFs and can also bind 
and inhibit Sos1 and Raf1 (Harmer 2006).  
 
 
Figure 33: Inhibition of FGF-mediated signaling by sprouty  
(Cabrita and Christofori 2008) 
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Thirdly, Similar Expression to FGF-genes (Sef) encodes a transmembrane protein and is 
also synexpressed to FGFs. Overexpression of Sef reduces FGF-mediated tyrosine 
phosphorylation of FGFR1 and FRS2 and therefore activation of ERK1/2 and Akt is 
inhibited (Ostrovsky et al. 2002). 
 
1.7.2 FGFR Family 
Four FGFRs (FGFR1-4) which share a protein homology of 55%-72% are known to 
date (Powers et al. 2000). A fifth FGFR has been described (FGFR5 or FGFRL1) that 
binds FGFs but lacks a tyrosine kinase domain. Its role has not been detected yet 
(Wiedemann and Trueb 2000). Due to the different expression patterns of all different 
FGFRs, including their splice variants, a remarkable FGFR diversity is achieved. 
Imbalances in FGFR signaling are associated with diverse pathologies like skeletal 
disorders and cancer.  
 
1.7.2.1  FGFR1 
There are three genetic disorders attributed to the mutation of FGFR1: Kallman’s 
syndrome, osteoglophonic dysplasia and Pfeiffer syndrome.  
A loss-of-function mutation of FGFR1 results in Kallman’s syndrome which is 
manifested in hypogonadotropic hypogonadism and anosmia, a deficiency of the sense 
of smell. The development of the olfactory bulb in humans is sensitive to FGFR1 (Dode 
et al. 2003). 
Osteoglophonic dysplasia is a bone disorder. Its symptoms are dwarfism, vertebral 
fragility, craniosynostosis, multiple unerupted teeth and failure to thrive. Missense 
mutation of FGFR1 leads to a constitutive activation of the receptor which is associated 
with the development of osteoglophonic dysplasia (Shankar et al. 2010). 
Pfeiffer syndrome is manifested in an autosomal dominant craniosynostosis syndrome 
with craniofacial anomalies and characteristic broad thumbs and big toes. A missense 
mutation of FGFR1 C755G causes a Pro252Arg substitution and is related to the 
Pfeiffer syndrome (Muenke et al. 1994). 
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Dominant gain-of-function mutation of FGFR1 causes craniosynostosis and fails 
morphogenesis of olfactory bulbs (Dode et al. 2003). In the kinase domain it also leads 
to glioblastoma (Rand et al. 2005). 
 
1.7.2.2  FGFR2 
Germline mutations in FGFR2 kinase domain are found in patients with various 
craniosynostosis syndromes like Crouzon’s syndrome and Pfeiffer syndrome. These 
mutations constitutively activate FGFR2 by disengaging an auto-inhibitory sequence in 
the kinase domain (Chen et al. 2007).  
The majority of mutations of FGFR2 occur in IgIIIa (exon 8) or IgIIIc (exon 10) or in 
the intron sequence flanking IgIIIc. Alternative splicing joins IgIIIa to IgIIIb or IgIIIc 
and generates different isoforms of FGFR2 which show different FGF-binding 
properties and are tissue specific. Mutations in IgIII also lead to Crouzon, Pfeiffer or 
Apert syndrome (Kan et al. 2002). 
Truncated forms of FGFR2, which result in a c-terminal deletion or aberrant splicing, 
have been described. The truncated forms interfere with receptor internalization and 
therefore prevent a potential mechanism for signal attenuation and increase receptor 
stability and activation. This was also observed in gastric cancer cell lines (Missiaglia et 
al. 2009; Yamaguchi et al. 1994). 
 
1.7.2.3  FGFR3 
Most FGFR3 mutations, which were found in cancer, are identical to the FGFR3 
mutations involved in skeletal disorders. A transmembrane mutation of FGFR3 leads to 
Gly380Arg and results in nearly all cases in achondroplasia, which is a common genetic 
form of dwarfism (Webster and Donoghue 1997). 
Germline mutations, which affect the kinase domain of FGFR3, cause three different 
dwarfing syndromes: hypochondroplasia (mild dwarfism syndrome with nearly normal 
cranial and facial characteristics), thanatophoric dysplasia type II (lethal neonatal 
skeletal dysplasia) and severe achondroplasia with developmental delay and Acanthosis 
 Introduction 
 
53 
nigricans syndrome (dwarfism syndrome with neurological disorders and a 
hyperpigmentation of the skin). 
 
1.7.2.4  FGFR4 
1.7.2.4.1 FGFR4 and its role in cancer 
FGFR4 plays an important role in the liver where it controls the systemic 
cholesterol/bile acid metabolism and lipid metabolism (Huang et al. 2009). Disruption 
of FGFR4 in the mouse germline does not show an aberrant phenotype. Mice are still 
fertile and also liver morphology is comparable to control mice. But liver-associated 
organs like gallbladder are affected. Gallbladder is small and depleted and the excreted 
and total bile pools are elevated which leads to an elevated cholesterol metabolism (Yu 
et al. 2000). 
The expression of FGFR4 is up-regulated in various cancer types like prostate cancer 
(Sahadevan et al. 2007; Wang et al. 2008), rhabdomyosarcoma (Taylor et al. 2009), 
breast and gynecological cancers (Jaakkola et al. 1993), or gastric cancer (Ye et al. 
2011). FGFR4 is clearly involved in initiation and progression of prostate cancer. All 
FGFs found in prostate cancer tissue are activators of FGFR4. Strong expression of 
FGFR4 in prostate cancer is associated with increased clinical stage and tumor grade 
and decreased patient survival (Wang et al. 2008). In breast cancer there is an 
association between up-regulated expression of FGFR4 and chemoresistance (Roidl et 
al. 2009). 
In contrast to FGFR1-3 there are no reports about splice variants in the Ig-loop III of 
FGFR4. However in human intestinal epithelial cell lines a 120bp shorter splice variant 
of FGFR4 was found. In this particular splice form exon 9, which encodes for the 
transmembrane domain, is substituted by an intron. This receptor is therefore not 
anchored in the cell membrane but is secreted as a soluble receptor. The soluble form of 
FGFR4 has not only been found in gastrointestinal epithelial cells but also in pancreas, 
gastric, colon and pancreatic cancer cell lines (Takaishi et al. 2000). 
FGF19 has high affinity for FGFR4 and binds nearly exclusively to this receptor. It is 
expressed in several tissues like fetal cartilage, skin, retina, adult gall bladder but also in 
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colon cancer cell lines like Colo201 (Xie et al. 1999). FGF19 and FGFR4 are both 
expressed in conjunction, e.g. in colon adenocarcinoma, lung squamous cell carcinoma 
and hepatocellular carcinoma. An anti-FGF19 monoclonal antibody which blocks the 
interaction of FGF19 with FGFR4 inhibits growth of colon carcinoma xenografts 
(Desnoyers et al. 2008). 
Drafahl et al showed a correlation between FGFR4 expression and the reduction of 
NFκB induced apoptosis. FGFR4 expression and/or FGF19 stimulated FGFR4 leads to 
a decrease of the kinase activity of IKKβ complex (which rescues NFκB from 
proteosomal degradation) as well as to a reduced nuclear localization of NFκB 
indicating a down-regulation of NFκB-signaling. Additionally in prostate cancer cells 
FGF19 stimulation results in a reduced TNFα-induced apoptosis (Drafahl et al. 2010). 
 
1.7.2.4.2 FGFR4 G388R polymorphism  
A single nucleotide polymorphism in the transmembrane domain has been described 
causing the exchange of a glycine to an arginine at position 388 (rs351855). FGFR4Gly 
(FGFR4-G388) is represented in the majority of the population and therefore referred to 
as the “wild-type” FGFR4. Usually charged amino acids like arginine do not occur in 
transmembrane domains of receptor tyrosine kinases and have been previously 
associated with diseases like achondroplasia and Crouzon syndrome (Bange et al. 
2002). The G388R polymorphism is prevalent in the white population with 
approximately 45% of the individuals studied so far are hetero- or homozygous for the 
FGFR4Arg (FGFR4-R388) allele (Wang et al. 2008).  
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Figure 34: Structure of FGFR4-G388R polymorphism 
 
1.7.2.4.3 The role of FGFR4 G388R polymorphism in various cancer types 
FGFR4 G388R polymorphism and its impact on tumor initiation, development, 
clinicopathological parameters like tumor stage and lymph node involvement, as well as 
disease free survival and overall survival has been studied and described in various 
publications for many cancer types. 2011 Frullanti et al. summarized 21 studies and 
published a “Meta and pooled analysis of FGFR4 Gly388Arg polymorphism as a cancer 
prognostic factor”. They included studies on G388R polymorphism in different types of 
cancers affecting brain, breast, colorectal, head and neck, larynx, lung, melanoma, 
prostate and sarcomas. The overall conclusion was a significant association between the 
Arg388Arg genotype and nodal involvement in the meta-analysis whereas in the pooled 
analysis the Arg-allele was correlated with increased hazard of poor overall survival 
compared to patients with a homozygous Gly-genotype. The FGFR4Arg allele was 
furthermore identified to be a potential risk factor for developing and progressing 
prostate cancer (Frullanti et al. 2011). FGFR4Arg promotes initiation and progression in 
prostate cancer probably due to increased stability and prolonged activity of the 
receptor. But also the “wild-type” variant FGFR4Gly is stabilized after ligand stimulation 
by another protein called HIP1 (Wang et al. 2008). 
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The presence of the FGFR4Arg allele in breast cancer cell lines correlates with high 
expression of FGFR4. FGFR4Arg is not associated with initiation of breast cancer and 
lung adenocarcinoma but is connected to aggressive tumor progression like high tumor 
stage and axillary lymph node involvement in breast cancer patients (Bange et al. 2002; 
Spinola 2005). Furthermore, FGFR4Gly was associated with motility inhibition in breast 
cancer and prostate cancer cell lines (Stadler et al. 2006; Wang et al. 2004). 
Similarly, in head and neck squamous cell carcinoma high expression of FGFR4Arg 
allele was significantly associated with reduced overall survival and advanced tumor 
stage (Dacostaandrade et al. 2007; Streit et al. 2004). In another approach FGFR4Gly 
was found to increase the risk for head and neck-squamous cell carcinoma and carriers 
of the FGFR4Arg allele showed an increased sensitivity for cisplatin (Ansell et al. 2009). 
In soft tissue sarcoma there are no differences regarding the phenotype compared to 
control which indicates no association of the FGFR4 single nucleotide polymorphism 
(SNP) with the initiation of soft tissue sarcoma. But FGFR4Gly homozygous patients 
seem to have a better prognosis concerning overall and metastasis-free survival. For 
osteosarcoma such observations concerning overall and metastasis-free survival were 
not found (Morimoto et al. 2003). 
 
1.7.2.4.4 The role of FGFR4 G388R polymorphism in colorectal cancer 
The situation of the G388R polymorphism in CRC is diffuse. Hitherto, very few reports 
have been published about this topic and these are contradictive. To date there are three 
reports about the FGFR4 G388R polymorphism in CRC available. Bange and his 
colleagues were the first who described the FGFR4 G388R polymorphism in 2002. 
They also found a significant correlation between the Arg-allele and metastatic lymph 
nodes as well as advanced tumor stage in 37 CRC patients. Furthermore they reported 
an association between the Arg-allele and a significantly reduced overall survival over a 
16-month follow up time. A long term follow up of seven years did not show this effect 
(Bange et al. 2002). 
2005 Spinola et al. published their study on 179 CRC patients compared to 220 controls 
but could not associate the Arg-allele to any kind of cancer risk, survival or other 
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prognostic parameters. In contrast to Bange and colleagues Spinola, despite a higher 
number of patients, found no association between the presence of an Arg-allele and 
nodal status in CRC (Spinola et al. 2005).  
In 2006, another work of Gordon and colleagues studied 21 germline polymorphisms to 
predict tumor recurrence on chemoradiation-treated rectal cancer patients. For this 
purpose, 90 patients with diagnosed stage II and III adenocarcinoma of the rectum, who 
have been treated with chemoradiation, were genotyped. In this study a risk tree was 
identified including not only node status, IL-8, intracellular adhesion molecule-1, TGF-
β but also FGFR4. These findings indicate a correlation between the FGFR4 
polymorphism and risk for developing tumor recurrence (Gordon et al. 2006). 
 
1.7.2.4.5 Interaction of FGFR4 G388 polymorphism with metalloproteinase 
FGFR4Arg was also found to induce and stabilize Membrane Type 1 Matrix 
Metalloproteinase (MT1-MMP, MMP14) and collagen invasion by decreasing 
lysosomal degradation of MT1-MMP. Because of its collagenase activity MT1-MMP is 
used by tumor cells for invasion and metastasis. Interaction of FGFR4Arg with MT1-
MMP also results in epithelial-mesenchymal transition (EMT) by preventing the 
accumulation of basement membrane and altering cadherin. FGFR4Gly also induces 
MT1-MMP phosphorylation but results more in down regulation of MT1-MMP 
(Sugiyama et al. 2010a; Sugiyama et al. 2010b).  
 
1.7.3 FGF-Family 
FGF-signaling has been implicated in different physiological and pathological processes 
reaching from angiogenesis to tumor development and progression. But the most 
important role of FGF-signaling is embryonic development. Studies with FGF-knockout 
mice show different phenotypes ranging from early embryonic lethality to very mild 
and no effects. This reflects the redundancy of the FGF-family and the uniqueness of 
their expression in specific tissue. 
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FGF Phenotype of knockout mouse Physiological role
FGF1 normal not established
FGF2 loss of vascular tone, slight loss of cortex
neurons
not established
FGF3 inner ear agenesis in humans inner ear development
FGF4 embryonic lethal cardiac valve leaflet formation, limb
development
FGF5 abnormally long hair hair growth cycle regulation
FGF6 defective muscle regeneration myogenesis
FGF7 matted hair reduced nephron branching in 
kidney
branching morphogenesis
FGF8 embryonic lethal Brain, eye, ear and limb development
FGF9 postnatal death, gender reversal lung
hypoplasia
gonadal development, organogenesis
FGF10 failed limb and lung development branching morphogenesis
FGF16 embryonic lethal heart development
FGF17 abnormal brain development cerebral and cerebellar development
FGF18 delayed long-bone ossification bone development
FGF19 increased bile acid pool bile acid homeostasis, lipolysis, gall
bladder filling
FGF20 no knockout model neurotrophic factor
FGF21 no knockout model fasting response, glucose
homeostasis, lipolysis and lipogenesis
FGF22 no knockout model presynaptic neural organizer
FGF23 hyperphosphataemia, hypoglycaemia, 
immature sexual organs
phosphate homeostasis, vitamin D 
homeostasis
 
Table 2: FGF-knockout mice: phenotype and physiological role of FGF1-23  
(Beenken and Mohammadi 2009) 
 
22 structurally related FGFs are known in mammals. They all have in common a 
homologous core region of 120-130 amino acids which is arranged into 12 antiparallel 
β-strands and is flanked by amino and carboxyl termini (Knights and Cook 2010). 
FGF11-FGF14 are not generally considered as members of the FGF-family. Although 
they share a high sequence identity with the FGF-family, they cannot activate the 
FGFRs. FGF15 is a mouse orthologue of human FGF19 (Beenken and Mohammadi 
2009). 
 
 Introduction 
 
59 
The mammalian FGF-family can be divided into three groups: 
1. Intracellular subfamily: FGF11 subfamily: FGF11-14 (iFGFs) 
2. Hormone-like subfamily: FGF19 subfamily: FGF19, 21 and 23 (hFGFs) 
3. Canonical subfamily: further divided into five subfamilies based on differences in 
sequence homology and phylogeny:  
• FGF1 subfamily: FGF1 and FGF2  
• FGF4 subfamily: FGF4, FGF5, FGF6 
• FGF7 subfamily: FGF3, FGF7, FGF10, FGF22 
• FGF8 subfamily: FGF8, FGF17, FGF18 
• FGF9 subfamily: FGF9, FGF16, FGF20 
 
 
Figure 35: Evolutionary relationship of mouse FGFs  
(Itoh and Ornitz 2008) 
 
1.7.3.1  Intracellular subfamily: FGF11-14 (iFGF) 
FGF11-14 share high sequence identity with the FGF9 subfamily. They all lack a 
secretory signal sequence but unlike the FGF9 subfamily FGF11-14 remain 
intracellular. Furthermore, they can bind heparin with high affinity but are not able to 
activate FGFRs (Olsen et al. 2003). 
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iFGF act in a FGFR-independent manner and bind to the intracellular domains of 
voltage-gate sodium channels which are expressed in excitable cells like neurons, 
skeletal muscle, and cardiac muscle and opened in response to membrane 
depolarization. They also bind to the neuronal MAP-kinase scaffold protein, islet-brain-
2, which is expressed in developing and mature neurons, olfactory epithelium, and 
pancreatic islet cells (Goldfarb 2005; Goldfarb et al. 2007; Olsen et al. 2003). 
Expression is almost exclusively occurring in neuronal cells (Goldfarb 2005). 
FGF13 is not detected in embryos or in normal trophoblastic stem cells (TS cells) but 
can be induced by 24h hyperosmolar stress (Zhong et al. 2006). 
FGF14 is expressed in the developing and adult central nervous system and suggests a 
role in neuronal development and adult brain function. FGF14-deficient mice are viable, 
fertile and anatomically normal but show muscle weakness and movement disorder 
probably due to aberrant basal forebrain activity (Wang et al. 2002).  
FGF12-deficient mice show little demonstrable phenotype like muscle weakness but 
less severe than FGF14-deficient mice (Goldfarb 2005). 
 
1.7.3.2  Hormone-like subfamily: FGF19, FGF21, FGF23 
Hormone-like FGFs have an endocrine function like regulating bile acid, cholesterol, 
glucose, vitamin D and phosphate homeostasis. The heparin binding affinity of 
hormone-like FGFs is reduced compared to the other FGFs whereas FGF19 and FGF23 
need a cofactor called klotho for binding to their FGF receptors (Itoh 2010). At high 
concentrations (compared to FGF1) they activate FGFRIIIc isoforms and FGFR4 
(Zhang et al. 2006). 
FGF19 is the human orthologue of FGF15 in the mouse (Ornitz and Itoh 2001). 
FGF15/19 plays an important role in the development of heart and brain at embryonic 
stages. FGF15-/- mice die because of heart defects. Furthermore bile excretion is 
elevated in FGF15-/- mice. FGF15/19 is highly involved in the regulation of bile acid 
metabolism in the liver. Intestinally produced FGF15/19 regulates hepatic bile acid 
synthesis by binding and activating hepatic FGFR4 (Inagaki et al. 2005; Itoh 2010) 
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FGF21 serves as a metabolic regulator by improving glycemic control (improved 
insulin sensitivity) and lipid metabolism (Berglund et al. 2009). Serum FGF21 level is 
elevated in obese people and associated with an increased risk for metabolic syndrome 
(Zhang et al. 2008) 
FGF23 is synthesized by osteocytes and osteoblasts and controls the phosphate balance 
by modulating phosphate excretion and absorption. It is also involved in the regulation 
of 1,25-dihydroxyvitamin D (calcitriol) (Prie and Friedlander 2010). Biallelic mutations 
of FGF23 result in hyperphosphatemic familial tumoral calcinosis or hyperostosis-
hyperphosphatemia syndrome (Ichikawa et al. 2010). FGF23 needs klotho, a membrane 
protein to bind to FGFRs (Prie and Friedlander 2010; Urakawa et al. 2006). 
 
1.7.3.3  Canonical subfamily 
Most FGFs of this group are secreted from the cell, bind to FGFRs and can act in a 
paracrine and an autocrine way. They also have binding sites for acidic 
glycosaminoglycans like heparin and heparin sulfate.  
 
1.7.3.3.1 FGF1 subfamily: FGF1 and FGF2  
FGF1 and FGF2 are the prototypic FGFs and were first isolated from bovine pituitary 
extracts. FGF1 has a high affinity to all FGFRs and their splice variants and probably 
defines the core FGF-binding domain (Ornitz et al. 1996). Both FGFs do not contain a 
signal peptide for the classical secretory pathway so they must be secreted by another 
way. FGF1 and FGF2 possess a nuclear localization signal so they are found in the 
cytosol and associated with the nucleus (Powers et al. 2000). Removal of the nuclear 
localization signal in FGF1 causes abrogation of its mitogen effect (Imamura et al. 
1990). FGF1 also stimulates DNA synthesis without binding to a cell-surface receptor 
(Wiedlocha et al. 1994). 
The physiological role of FGF1 and FGF2 remains still unclear. Both factors are found 
highly expressed in the adult brain, but in different compartments so a potential role of 
FGF1 and FGF2 for the brain development is suggested. FGF2-/- mice are fertile and 
viable and show relatively mild defects like changes in the number of neurons in the 
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cerebral cortex, a delay in the healing of epithelial wounds and defects in the regulation 
of blood pressure. No phenotypic defects at all could be seen in FGF1-/- mice. 
Interestingly a FGF1-FGF2 double knockout mouse shows only the same mild defects 
like the FGF2-/- mouse which excludes the suggestion that FGF1 and FGF2 compensate 
each other (Miller et al. 2000). 
It is also likely that FGF1 and FGF2 play a physiological role in the maintenance of 
vascular tone. Administration of FGF1 and FGF2 lowers blood pressure. FGF2 has also 
angiogenic properties like stimulating migration and proliferation of endothelial cell, 
anti-apoptotic activity as well as inducing development of large collateral vessels 
(Beenken and Mohammadi 2009). But also FGF1 shows angiogenic properties inducing 
microvascular branching of endothelial cells as well as antiapoptotic activity (Beenken 
and Mohammadi 2009; Uriel et al. 2006). 
By inducing proliferation of airway smooth muscle cells FGF2 seems to play a role in 
the development of asthma (Bosse and Rola-Pleszczynski 2008). FGF1 was found to 
stimulate human preadipocytes in a paracrine manner suggesting an important role in 
human adipogenesis (Hutley et al. 2004). It has also been associated with the 
regeneration of nerve injuries (Lin et al. 2005). 
Inhibiting FGF1 and FGF2 reveals a potential cancer therapy. Thalidomide, which 
inhibits FGF2-induced angiogenesis, as well as Suramin, which mimics heparin and 
therefore interferes with FGF-signaling, were tested in clinical trials and show benefits 
in prostate and renal cancer (Kathir et al. 2006; Kraemer et al. 2009; Vogelzang et al. 
2004). 
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Figure 36: 3-dimensional structure of FGF2, a prototypical FGF  
(Ornitz and Itoh 2001) 
 
1.7.3.3.2 FGF4 subfamily: FGF4, FGF5, FGF6 
Members of the FGF4 subfamily are expressed in epithelial and mesenchymal cells and 
specifically activate the FGFRIIIc splice variant (Ornitz et al. 1996).  
FGF4 is very important in developing processes which include the formation of cardiac 
valve leaflet or limb development (Sugi et al. 2003). FGF4-/- mice are not viable. 
Embryos undergo uterine implantation but cannot develop properly. In vitro the absence 
of FGF4 results in impaired proliferation of the inner cell mass (Feldman et al. 1995). 
FGF5 expression is found in hair follicles and negatively regulates hair growth. FGF5-/- 
mice show an abnormally long hair phenotype (Hebert et al. 1994; Housley and Venta 
2006). 
FGF6 expression is restricted to developing skeletal muscle and is also up-regulated 
after muscle injuries, suggesting that FGF6 affects myogenesis. FGF6-/- mice show 
defective muscle regeneration and increased fibrosis after freeze-crush injury (Armand 
et al. 2006). 
 
1.7.3.3.3 FGF7 subfamily: FGF3, FGF7, FGF10, FGF22 
Members of the FGF7 subfamily strongly activate FGFR2IIIb. FGF10 and FGF22 
additionally show a weak activity towards FGFR1IIIb. All the other FGFRs are not 
activated by this subfamily (Zhang et al. 2006). 
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FGF3 plays an important role in the development of the inner ear at a very early stage. 
Homozygous deletion of FGF3 leads to hereditary deafness in humans and a few dental 
defects like widely spaced teeth. (Tekin et al. 2007). 
FGF7 is also known as keratinocyte growth factor and is synthesized by skin 
fibroblasts. FGF7-/- mice develop matted fur but no abnormalities concerning epidermal 
growth or wound healing and are viable and fertile (Guo et al. 1996). FGF7 and its 
receptors are also expressed by or around the growing ureteric bud in the developing 
kidney suggesting a role in kidney morphogenesis. Kidneys of mature FGF7-/- mice 
show 30% fewer nephrons and exogenous FGF7 can increase the number of nephrons 
by approximately 50% (Qiao et al. 1999). 
FGF10 is expressed in mesenchymal tissue and signals to epithelial FGFR2IIIb. It is 
important for limb and lung formation in the embryo because it is required for a normal 
branching program and for proper proximal-distal patterning in the lung (Abler et al. 
2009; Zhang et al. 2006). FGF10-/- mice die at birth. They show development of trachea 
but fail to form a lung. Furthermore, mutated mice have truncated fore- and hind limbs 
(Sekine et al. 1999). 
Like FGF7 and FGF10 FGF22 is a presynaptic organizing molecule in the mammalian 
brain and may play a role in the synaptogenesis (Umemori et al. 2004). 
 
1.7.3.3.4 FGF8 subfamily: FGF8, FGF17, FGF18 
Members of the FGF8 subfamily are expressed in epithelial cells and exclusively 
activate FGFRIIIc (above all FGFR3IIIc) splice forms and FGFR4. The FGF8, 17 and 
18 are expressed in the midbrain-hindbrain area (Zhang et al. 2006).  
FGF8 is important for organizing the midbrain-hindbrain patterns in the embryonic 
development. FGF17 is expressed later and broader. FGF17-/- mice are born alive but 
reveal significant tissue loss in midbrain and vermis cerebellum whereas FGF8-/- mice 
do not undergo gastrulation and are not viable suggesting an important role for FGF8 in 
the early embryonic development of the brain (Xu et al. 2000).  
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FGF18 also plays a role in the regulation of endochondral, periosteal and 
intramembranous bone growth. FGF18-/- mice survive embryonic development but die 
in the early neonatal period. They are 10-15% smaller and die of cyanosis within the 
first 30min after birth, probably due to respiratory failure. They also show decreased 
expression of osteogenic markers and delayed long-bone ossification (Liu et al. 2002). 
 
1.7.3.3.5 FGF9 subfamily: FGF9, FGF16, FGF20 
The FGF9 subfamily binds to all FGFRIIIc isoforms, FGFR4 and FGFR3IIIb.  
FGF9 is expressed in epithelial-like and neuronal tissues during the embryonic 
development and is important for lung, heart, inner ear, digestive system, and testes 
development (Zhang et al. 2006). FGF9-/- mice die at birth because of lung hypoplasia. 
Additional FGF9 seems to play a role in sex determination and testicular embryogenesis 
because until E18.5 mice undergo a male-to-female sex reversal (Colvin et al. 2001a). 
The FGF9 subfamily signals from epithelium to mesenchyme whereas the FGF7 
subfamily signals in a reciprocal way from mesenchyme to epithelium. Therefore, FGF9 
stimulates the mesenchymal expression of the FGF7 subfamily members. By knocking 
out FGF9 this epithelial-mesenchymal signaling loop is disturbed and the reduced 
mesenchymal proliferation leads to an decrease of FGF3, 7, 10 and 22 which is the 
proximate cause for lung hypoplasia in FGF9-/- mice (Beenken and Mohammadi 2009; 
Colvin et al. 2001b). 
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FGF16 is required for embryonic heart development. Elimination of FGF16 expression 
in mice results in hemorrhage in the heart and ventral body region of the embryo as well 
as facial defects and embryonic death because of cardiac defects (Lu et al. 2008).  
A single nucleotide polymorphism which leads to an increased translation in FGF20 has 
been related with Parkinson disease (van der Walt et al. 2004).  
 
Figure 37: Role of different FGF-splice variants in the tissue crosstalk  
(Heinzle et al. 2011) 
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Figure 38: Binding affinity of FGF towards their receptors 
 #... not tested (Ornitz et al. 1996; Zhang et al. 2006) 
 
1.7.4 Deregulation of FGF-signaling in cancer 
Deregulation of FGF-signaling promotes tumor development by driving cancer cell 
proliferation and survival as well as supporting tumor angiogenesis. 
Genomic aberrations like activating mutations, gene amplifications, and translocations 
lead to ligand independent constitutive activation of FGFRs. Another way to deregulate 
FGF-signaling is the alterations of autocrine production of FGFR ligands in the cell or 
paracrine production of ligands by stromal cells. 
 
1.7.4.1  Activating mutation 
Activating mutations of FGFRs occur in various cancer types. For instance in bladder 
cancer a lot of FGFR mutations have been described. In more than 30% of all bladder 
cancers there are somatic mutations of FGFR3 which correspond to the germline 
mutations found in skeletal dysplasia syndromes (Martinez-Torrecuadrada et al. 2005). 
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More than half of the FGFR3 mutations in bladder cancer occur in the extracellular 
domain at a single position which leads to a constitutive dimerization and activation of 
the receptor. There are also mutations found in the transmembrane domain and in the 
kinase domain (Trudel et al. 2006). 
Apart from bladder cancer, activating mutations of FGFR3 are also found in cervical 
carcinoma (1,7% mutation rate in FGFR3 worldwide) (Giri et al. 1999), in multiple 
myeloma (an incurable B-cell malignancy), prostate cancer (above all in low-grade 
cancers) (Nicholes et al. 2002), as well as in colon carcinoma (Desnoyers et al. 2008) 
and benign skin tumors (Logie et al. 2005). 
Extracellular mutations of FGFR2, which cause craniosynostosis syndromes in 
germlines, were also found as somatic mutations in gastric (Desnoyers et al. 2008), 
endometrial, cervical and squamous lung cancer (Powers et al. 2000). 
Somatic mutations of FGFR4 in the kinase domain lead to overexpression of FGFR4 
and are associated with increased risk of rhabdomyosarcomas (Taylor et al. 2009). 
 
1.7.4.2  FGFR gene amplification 
Gene amplifications have been described especially for FGFR1 and 2. FGFR2 gene 
amplification is mainly observed in gastric cancer. Amplification and activating 
mutations have been found in FGFR2 in approximately 10% of primary gastric cancer 
(Knights and Cook 2010; Turner and Grose 2010). Gastric cancer cell lines with 
amplified FGFR2 showed good response to a VEGFR/FGFR inhibitor (Kunii et al. 
2008). Their proliferation and survival is dependent on FGFR2 expression. Blocking of 
FGFR2 leads to growth arrest and in some cases to apoptosis. There seems to be a 
crosstalk between FGFR2 and EGFR family kinases, because in FGFR2-amplified cell 
lines EGFR and Erbb3 phosphorylation was elevated dependent on FGFR2 kinase 
activity (Kunii et al. 2008). 
In normal breast tissue FGF and FGFRs are highly expressed during ductal 
morphogenesis. Therefore, FGFs are potent mitogens in the mammary gland which, 
when deregulated could lead to mammary tumorigenesis. In 10-15% of breast cancers 
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the amplicon 8p11-12p which includes FGFR1 was found. In 4-12% of breast cancers 
the 10q26 amplicon including FGFR2 is present (Berman et al. 1999). 
Further FGFR1 amplification were found in oral squamous cell carcinoma (Simon et al. 
2001), ovarian cancer (Gorringe et al. 2007), in 3,4% of bladder cancer (Freier et al. 
2007), squamous cell lung cancer (Weiss et al. 2010), and in rhabdomyosarcoma (Cha 
et al. 2009). 
 
1.7.4.3  Chromosomal translocation 
Chromosomal translocations occur mostly in haematological malignancies. Several 
intragenic translocations affecting FGFRs have been identified. They result typically in 
a fusion protein where the N-terminus of a transcription factor is fused to an FGFR 
kinase domain (Turner and Grose 2010).  
Multiple myeloma: due to translocation on chromosome 14 FGFR3 is brought under the 
control of the IgH enhancer region and therefore the expression is elevated. FGFR3 
inhibition in FGFR3-positive multiple myeloma cell lines showed decreased 
proliferation and increased apoptosis (Knights and Cook 2010). 
8p11 myeloproliferative syndrome (EMS): chimeric proteins which contain the kinase 
domain of FGFR1 fused to a number of unrelated partners are very frequent in EMS. 
Ligand-independent dimerisation of the fusion protein results in an activation of FGFR1 
kinase (Knights and Cook 2010). 
 
1.7.4.4  Autocrine and paracrine signaling 
Deregulation of autocrine and paracrine production of FGFR ligands can also lead to 
aberrant signaling. An autocrine loop between FGF2 and FGFR1 could be shown in 
melanoma (Wang and Becker 1997). In ovarian cancer tissue amplification of FGF1 
showed increased angiogenesis which results in paracrine and autocrine stimulation of 
cancer cells (Birrer et al. 2007). 
In different cancer types there are elevated plasma levels of FGF2 and other FGFs 
which results partly from tumor invasion and degradation of extracellular matrix and 
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consequently release of FGFs. Tumor cells induce the release of FGF2 from stromal 
inflammatory infiltrate which also promotes angiogenesis and therefore acts in a 
paracrine loop (Turner and Grose 2010).  
FGF2 is up-regulated in prostate cancer cells that were stimulated in a paracrine way 
through elevated expression of FGF2 by surrounding stromal and endothelial cells. 
Additional, FGFR1 and FGFR2 are both over-expressed in prostate cancer epithelial 
cells (Giri et al. 1999). 
FGF2 is up-regulated in lung cancer where it shows intracrine action. In rapid growing 
lung cancer cells for example a large fraction of FGF2 is not secreted but stored in the 
cells where it stimulates proliferation. Due to the intracrine activity of FGF2 in lung 
cancer these cells are insensitive to exogenous modulation of FGF2-signaling. In later 
stages a paracrine activity of FGF2 may occur by cytolysis of the cells within the tumor 
tissue and therefore release of FGF2 (Berger et al. 1999). In breast cancer stroma there 
are also higher levels of FGF1, FGF2, and FGF7 than in normal breast stroma (Turner 
and Grose 2010).  
Over-expression of FGF5 has been observed in many tumor types, e.g. renal cell 
carcinoma, prostate carcinoma, breast cancer cell lines (Hanada et al. 2001), in 
astrocytic brain tumor tissue (Allerstorfer et al. 2008) and in melanomas (Metzner et al. 
2011).  
Elevated levels of hormonal FGFs like FGF19 lead to hepatocellular cancer in 
transgenic mice, which shows an endocrine action in the tumor. FGF19 was also found 
over-expressed in liver, colonic and lung squamous carcinomas (Nicholes et al. 2002). 
Blockage of FGF19 inhibits interaction with FGFR4 and leads to inhibition of growth of 
colon tumor xenografts (Desnoyers et al. 2008). 
 
1.7.4.5  Germline single nucleotide polymorphism 
Germline polymorphisms can be associated with different susceptibilities for various 
diseases like diabetes, hypertension and also cancer but also other non-pathological 
phenotypes. There are numerous examples of these cancer-associated genetic variations 
in humans (Hunter and Crawford 2006). A SNP in intron 2 of FGFR2 was associated 
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with an increased risk for breast cancer (Furdui et al. 2006). Little is known about how 
the SNP in FGFR2 increases the breast cancer risk. One possible explanation is the 
modification of the binding site of two transcription factors OCT1 and RUNX2 (Turner 
and Grose 2010). 
Another SNP is described in FGFR4. The importance of the G388R polymorphism in 
cancer is explained in detail in chapter 1.7.2.4.3. 
 
1.7.4.6  Alteration of FGFR-splicing 
There are a variety of FGFR isoforms generated by differential splicing of the FGFR 
RNA. Differential splicing in the IgIII-loop region results in two isoforms: IIIb and IIIc. 
The two isoforms IIIb and IIIc occur in FGFR1-3 but not in FGFR4 and display 
different ligand-binding characteristics. Furthermore, they can be expressed in different 
tissues, e.g. FGFR2IIIb isoform which is only expressed in epithelial cells and 
FGFR2IIIc which is exclusively expressed in mesenchymal cells (Eswarakumar et al. 
2005). 
In malignant cells altered splicing leads to the expression of mesenchyme-specific 
FGFR (IIIc) which expands the range of binding FGFs (Zhang et al. 2006). Therefore, a 
switch of IIIb to IIIc expression can result in tumor progression, EMT and invasiveness. 
For example FGFR2IIIb down-regulation is associated with bladder cancer (Ricol et al. 
1999) and prostate cancer (Matsubara et al. 1998). 
In CRC FGFR3IIIb is down-regulated. The IIIc/IIIb ratio is therefore increased but not 
due to a higher expression of FGFR3IIIc. Inhibition of FGFR3IIIc in CRC results in 
decreased growth and survival in vivo and in vitro (Sonvilla et al. 2010). 
 
1.7.5 Role of FGF-signaling in colorectal cancer 
FGF7 and FGFR2IIIb were found to be co-expressed in colon cancer tissue. A high 
FGF7 expression was also detected in neuroendocrine cells which are lying in close 
proximity to the cancer cells suggesting an autocrine and paracrine stimulation of FGF7 
in colon cancer cells (Watanabe et al. 2000). FGF7, which is usually expressed by 
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mesenchymal cells and acts via FGFR2IIIb on epithelial cells, raises the expression of 
VEGF-A whereas the expression of FGF2 and hepatocyte growth factor (HGF) remains 
low in colorectal cell lines. VEGF-A, FGF2 and HGF are very important angiogenic 
growth factors contributing to the formation of microvessels adjacent to the tumor cells. 
The reason why FGF7 stimulates VEGF-A but not FGF2 and HGF remains unclear 
(Narita et al. 2009). FGF2, which acts as a lymphangiogenic growth factor, was found 
to be down-regulated in human CRC tissue compared to normal mucosa (Sundlisaeter et 
al. 2009). 
FGFR3 is expressed ubiquitously in normal human colorectal epithelial cells. In human 
CRCs the expression of FGFR3 is decreased by aberrant splicing which results in 
altered and inactive FGFR3 transcripts (Jang et al. 2000). Whereas FGFR3 (FGFR3IIIb) 
expression is decreased, expression of FGFR1 (FGFR1IIIc) in CRC cell lines is 
elevated. Disruption of FGFR1 expression leads to an increase of FGFR3 expression, 
which assumes a reciprocal relationship between the expression of FGFR1 and FGFR3 
(Jang 2005). Another study reported a strong correlation of FGFR1 over-expression and 
presence of liver metastasis in CRC patients (Sato et al. 2009). 
Although there are only few reports about the role of FGFR4 in CRC, one group found 
FGFR4 to be elevated in blood serum of CRC patients by using a protein microarray 
(Babel et al. 2009). The impact of the FGFR4 G388R polymorphism in CRC has 
already been described in chapter 1.7.2.4.4 
There might be a potential involvement of FGF19 and FGFR4 interaction with the 
regulation of E-cadherin/β-catenin system. Exogenous FGF19 stimulates the tyrosine 
phosphorylation of β-catenin which leads to a loss of E-cadherin/β-catenin binding and 
results in increased cell growth and invasiveness in colon carcinoma cell lines. Blocking 
of FGF19 or FGFR4 leads to an inhibition of β-catenin activation and also shows 
impact on β-catenin target genes (Pai et al. 2008).  
The Wnt-pathway is often affected in CRC. FGF18, which is another ligand to FGFR4, 
is a target of the canonical Wnt-pathway and consequently affected by Wnt-signaling 
alterations. Furthermore, FGF18 has an oncogenic role in CRC. In a small cohort of 
CRC specimen FGF18 was found to be almost generally over-expressed compared to 
normal mucosa. This could also be shown in vitro: adenoma cell lines showed lower 
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FGF18 expression than CRC cell lines. Up-regulation of FGF18 in CRC stimulates both 
cell proliferation and cell survival (Sonvilla et al. 2008).  
Apart from FGF18 also FGF16 and FGF20 are targets of the canonical Wnt-pathway. 
FGF20 together with FGF2 are the major FGFs implicated in embryogenesis and tissue 
regeneration in colon. Like FGF18 FGF20 is up-regulated in CRC with activated Wnt-
signaling (Katoh 2006b).  
 
1.7.6 Therapeutic strategies affecting FGF-signaling in cancer 
Since FGFR deregulation in cancer leads to activation of Raf-MEK1/2-ERK1/2 and 
PI3K-PKB pathways, inhibition of FGFRs results in decreased proliferation and 
induced apoptosis. Therefore, different approaches for inhibition of FGFRs should be 
considered. 
 
1.7.6.1  Small molecule FGFR kinase inhibitors  
Several small molecule inhibitors against FGFRs have been developed in the past 
decade but have not been successful in clinical trials so far. Because of the broad 
expression pattern of FGFRs throughout the whole body, the side effects of FGFR-
inhibitors can be severe. For instance PD173074 is a small molecule FGFR kinase 
inhibitor which inhibits FGFR1-3 and therefore FGFR-dependent growth and survival 
in different cancer cell lines. Due to toxicity issues PD173074 has been dropped from 
clinical development (Knights and Cook 2010; Kunii et al. 2008).  
Most of the FGFR kinase inhibitors also act on VEGFR and PDGFR because of their 
structural similarities to the FGFR. This means that VEGFR kinase inhibitors also act 
on FGFR. Therefore, it is not surprising that most FGFR kinase inhibitors which have 
reached clinical phase II/III are combined with VEGFR and/or PDGFR inhibitors. 
Although the inhibition spectrum is broader the side effects (fatigue, hypertension and 
gastrointestinal complications) are quite mild compared to conventional cytotoxic 
chemotherapies (Knights and Cook 2010).  
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1.7.6.2  Antagonistic antibodies to FGFRs 
Due to their high specificity antibodies can not only be produced against each FGFR but 
also target different splice variants which are over-expressed in tumor cells. This high 
specificity should also result in less systemic side effects. 
A ligand-competitive antibody binding to FGFR3 stopped cell proliferation in bladder 
carcinoma cells (Martinez-Torrecuadrada et al. 2005) and in multiple myeloma cell 
lines (Qing et al. 2009; Trudel et al. 2006). It is active against wild-type and mutated 
forms of FGFR3 and did also enter into clinical trial. 
Another antibody blocking FGFR1IIIc variant could indeed block potently FGF-
signaling but also resulted in severe anorexia in an animal model (Sun et al. 2007). 
These results demonstrate that even in the case of high specific targeting of FGFR3 side 
effects can still represent a relevant problem. 
A more successful strategy could be targeting autocrine/paracrine FGFs like FGF19 
which blocks interaction with FGFR4 and inhibits growth of colon tumor xenografts in 
mice (Desnoyers et al. 2008). Unfortunately no comments on side effects of the 
antibody are given from this study. 
Both small molecule kinase inhibitors and blocking antibodies have been described 
successfully for FGFR1-3. FGFR4 is less affected by these strategies; at least there are 
only few reports about effectually targeting FGFR4. As described in Table 3 the IC50 
values for many FGFR kinase inhibitors are much higher for FGFR4 than for the other 
FGFRs. This leads to the assumption that the kinase domain of FGFR4 may be different 
compared to FGFR1-3. These findings together with the fact that FGFR4-/- as well as 
FGF19-/- mice develop normally without gross abnormalities (Desnoyers et al. 2008) 
identify the FGFR4 as an interesting therapeutic target. 
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compound 
Activity towards specific receptors 
IC50 in nM 
FGFR1 FGFR2 FGFR3 FGFR4 VEGFR1/2 PDGFR EGFR 
BIBF1120 70 40 110 610 13-34 60 >50000 
CHIR-258 8 n.d. 9 n.d. 10-13 200 20000 
PD173074 20-30 18 >50000 
PD166866        
brivanib 148 n.d. n.d. n.d. 380 >6000 >1900 
pazopanib 140 n.d. 130 800 10-50 70-80 n.d. 
ponatinib 2.2    1.5 1.1  
SU5402 20-30 20-30 20-30  0.4 60 100000 
RO4383596 29 44 33 310 
 
Table 3: FGFR kinase inhibitors  
(Heinzle et al. 2011) 
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2 Aims of this project 
So far there are few reports concerning the impact of FGFR4 signaling on colorectal 
cancer. Regarding the role of FGFR4 G388R polymorphism the reports are even 
contradictive. Hence it was the intention of this work to clarify the role of FGFR4 and 
the G388R polymorphism in human colorectal cancer. For this purpose the following 
issues were to be addressed: 
• The cellular effects of FGFR4 over-expression in colorectal cancer cell lines. 
• Differences in biological impact in vitro and in vivo between FGFR4Arg and the 
FGFR4Gly polymorphic variants.  
• The role of the FGFR4 expression and the G388R polymorphism in the 
pathogenesis of human colorectal cancers and in relation to histopathological 
parameters. 
• Assessment of FGFR4 inhibiting strategies for growth inhibition in colorectal 
cancer.  
Conclusions from evaluated data should discuss the suitability of FGFR4 and FGFR4 
G388R polymorphism as a therapeutic target in colorectal cancer at best. 
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3 Materials and methods 
3.1 Cell Biology 
3.1.1 Materials used for cell culture 
Petri dishes, 10cm and 6 cm:    Sarsted, Nümbrecht, G 
6-well plates, 24-well plates and 96-well plates:  Sarsted 
Eagles Minimal Essential Medium (MEM):  Sigma-Aldrich, St. Louis, MO, US 
RPMI-1640 Medium 10x:     Sigma 
Penicillin/Streptomycin (Penstrep):    PAA, Pasching, A 
Fetal Calf Serum (FCS):     PAA 
Phosphate Buffered Saline (PBS):    Sigma 
PBS/EDTA: 10mM EDTA in PBS   Merck, Darmstadt, G  
Trypsin/PBS 10x: for use diluted 1:10 in PBS,  PAA 
L-Glutamine 200mM:     PAA 
Bovine Serum Albumin (BSA):    Sigma 
G418 (Genticin):      PAA 
Doxycycline:       Sigma 
Puromycine:       Sigma 
 
3.1.2 Cell lines 
Cell lines used are SW480, HCT116 and HT29 and were obtained from the American 
Type Culture Collection (ATCC). 
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Cells Source Characteristics Medium Doubling
time
SW480 human colorectal
adenocarcinoma, 
male
Chromosome number is hypertriploid, 
elevated expression of p53, positive 
expression of c-myc, K-ras, H-ras, N-ras, 
myb, sis and fos oncogenes, mutation in 
codon 12 of ras protooncogene
MEM with 
10% FCS and 
4% Penstrep
24h
HCT116 human colorectal 
carcinoma, male
diploid, mutation in codon 13 of ras
protooncogene
MEM with 
10% FCS and 
4% Penstrep
24h
HT29 human colorectal
adenocarcinoma, 
female
hypertriploid, elevated expression of 
p53 antigen, positive expression of c-
myc, K-ras, H-ras, N-ras, myb, sis and 
fos oncogenes,
MEM with 
10% FCS and 
4% Penstrep
36h
 
Table 4: Description of CRC cell lines  
 
3.1.3 Passaging of cells 
SW480, HCT116 and HT29 cells are split when they reach a confluence of 90%. 
Medium is aspirated and cells are washed with 5-10ml of PBS/EDTA. After removal of 
PBS/EDTA cells are trypsinyzed with 0,5ml Trypsin/PBS and incubated for 5-10min at 
37°C. The detached cells are taken up in 10ml medium and passaged into new 10cm 
Petri dishes. SW480 and HCT116 are usually split 1:10, for HT29 a ratio of 1:5 was 
used. 
 
3.1.4 Viability assays 
3.1.4.1 Neutral red uptake 
Neutral red is taken up by intact cells and stored in their lysosomes, where due to the 
acidic pH-value it changes its color into pink red. Dead cells cannot store neutral red 
and are therefore not stained.  
Cells were seeded at different densities (from 1*104-5*104 in 24-well plates, from 
1*103-1*104 in 96-well plates). After treatment or after specific time a neutral red 
solution is prepared by dissolving 50µg neutral red (Merck) per 1ml serum free medium 
(SFM) and incubated for 1h at 37°C. After filtration 500µl are added to each 24-well 
(200µl for each 96-well) and the plates are incubated at 37°C for 2h. Neutral red 
solution is aspirated, cells are washed with PBS and incubated with 250µl (100µl in 96-
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well) 70% Ethanol + 1% acetic acid for 5min at room temperature on a shaker. Color 
extinction is measured at 562nm wavelength using 620nm wavelength as reference by 
microplate reader Synergy H1 (Szabo Scandic, Vienna, A). 
  
3.1.4.2 MTT assay: EZ4U 
Water soluble yellow tetrazolium salt is taken up by viable cells and reduced to an 
intense colored formazan by chemical reduction through mitochondrial enzyme 
succinate dehydrogenase and NADH/NADPH producing enzymes of the endoplasmatic 
reticulum.  
1*103 cells are seeded into 96-well plate and after treatment or various time points 
medium is replaced by 100µl of freshly prepared EZ4U solution (EZ4U, Biomedica, 
Vienna, A). Cells are incubated for 2h and color extinction is measured at 450nm 
wavelength with 620nm as a reference each 15min for 1h by microplate reader Synergy 
H1 (Szabo Scandic). 
 
3.1.5 Colony formation assay 
Cells are seeded at very low density (100 and 200 cells/well) into 6-well plates. 
Therefore cells are forced to attach and grow independently without any cell-cell-
contact. After 24h medium is replaced and the plates are incubated for various days. 
After reaching a desirable size of the colonies, medium is aspirated. The plates are 
washed with PBS and fixated with 100% methanol for at least 20min at -20°C. After 
removing methanol the plates are washed with PBS and stained for 5min with 0,01% 
crystal violet solution in PBS. The plates are washed two times with PBS and dried 
colonies are counted. 
 
3.1.6 Filter migration assay 
PET track-etched membranes (VWR, Vienna, A) with a pore size of 8µm are connected 
to 24-well plates. 800µl medium is added to the lower chamber whereas cells are seeded 
at a concentration of 2*104 cell/200µl medium on the membrane. After 48h (SW480 
and HCT116) or 72h (HT29) migration time the membrane filters are removed and 
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migrated cells in the lower chamber are grown for another three days. Wells are washed 
with PBS and cells are fixed with 100% ice cold methanol for 20min at -20°C. After 
washing with PBS cells are stained with 0,01% crystal violet solution in PBS for 5min. 
Wells are washed two times with PBS, dried and stained area is calculated by Lucia 
Morphometry Software (Laboratory Imaging, Praha, CZ) 
 
3.1.7 Anchorage independent growth: soft agar assay 
Soft agar assay is an advanced version of colony formation assay and used to determine 
malignant growth of cells. Cells are forced to grow in 3-dimensional colonies without 
attachment to a surface suspended in an agar matrix. 
51 ml soft agar medium is prepared freshly following the recipe: 
10ml   10x RPMI  
2ml   1,31M NaHCO3  
1ml   L-Glutamine 
17ml   A. bidest 
50µl folic acid solution (20mg folic acid diluted in 10ml 1,31M NaHCO3) 
pH-value is adjusted on 8 and the solution is sterile filtered. 20ml FCS and 1ml Penstrep 
are added.  
6-well plates are coated with 1,5ml of a 1:1 mixture of 1% agar and soft agar medium. 
On the next day 5.000 cells are diluted in 750µl soft agar medium and 750µl 0,5% agar 
and are carefully plated on the prepared agar plates, strictly avoiding air bubbles. After 
2-3 weeks colonies of five representative fields of view of each well are counted under 
the microscope. 
 
3.1.8 H3-thymidine incorporation 
H3-thymidine is incorporated into new synthesized DNA strands during mitotic 
division. Therefore the H3-thymidine incorporation assay gives information about the 
proliferation activity of cells. 
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Cells are seeded into 96-well plates at three different concentrations: 2.500, 5.000 and 
10.000 cells per well. After 24h the medium is replaced by 50μl H3-thymidine solution 
(1mCi/ml) (Perkin Elmer, Waltham, MA, US) and incubated for 90min for SW480 and 
HCT116 and 3h for HT29. H3-thymidine solution is discarded and cells are washed 
three times with 200µl PBS. Cells are lysed with 100µl lysis buffer (0,2 % TritonX100 
and 2mM EDTA in PBS) and transferred into scintillation vials. 100µl PBS are added to 
the wells and transfused to the corresponding vial. 2ml scintillation buffer (Zinsser 
Analytic, Frankfurt, G) are added to each vial and H3-thymidine incorporation is 
measured by a Liquid Scintillation Analyzer (Canberra Packard, Meriden, CT, US) for 
2min per vial. 
 
H3-thymidine solution:  
5 μl   H3-thymidine (1ml H3-thymidine = 37MBq (1mCi)) 
1 ml  MEM  
 
3.1.9 Fluorescence Activated Cell Sorting (FACS) 
FACS is used to divide cells according to their size, complexity and fluorescence 
emission. Single cells pass an excitation laser and the emitted light is evaluated by 
different filters and a photomultiplier.  
 
3.1.9.1 Cells expressing GFP 
Cells expressing a GFP protein are trypsinyzed and washed twice with PBS. Finally, the 
pellet is resuspended in 200-500µl PBS, transferred into FACS vials and measured by 
FACS Calibur (BD, Franklin Lakes, NJ, US). 
 
3.1.9.2 Immuno-flow-cytometry with PE directly labeled antibody: FGFR4 
Cells are trypsinyzed after reaching a confluence of 50-70%. After counting, 0,25-1*106 
cells for each sample are washed with PBS and resuspended in 100µl PBS. Cells are 
blocked with 30µl FCS for 10min. 13µl PE-conjugated FGFR4 antibody (PE anti-
human CD334, #324305, Biolegend, San Diego, CA, US) (to reach a final dilution of 
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1:10) are added and incubated for 2h at room temperature avoiding light. For negative 
control a Rat Anti-Mouse IgG1 PE antibody (RAM γ1, #340270, BD) is used in same 
concentration. Cells are washed twice with PBS, resuspended in 200-500µl PBS and 
transferred into FACS vials and measured by FACS Calibur. 
 
3.1.9.3 Immuno-flow-cytometry with PE indirectly labeled antibody: E-Cadherin 
Immuno-flow-cytometry with E-Cadherin antibody is performed as described in chapter 
3.1.9.2 except for using 10µg E-Cadherin antibody (monoclonal antibody to E-cadherin 
(HECD-1), #ALX-804-201-C100, Eubio, Vienna, A) per ml instead of 13µl PE-
conjugated antibody. After 2h incubation on ice cells are washed two times with PBS 
and incubated with 20µl Rat Anti-Mouse IgG1 PE antibody (RAM γ1; #340270, BD) 
under light protection for 1h on ice. After washing with PBS cells are transferred into 
FACS vials and measured by FACS Calibur.   
 
3.1.9.4 Cell cycle distribution 
Trypsinyzed cells are washed with PBS and lysed with 1ml Nuclear Isolation buffer for 
5min on ice. Nuclei are prepared and separated using a syringe. Quality of isolated 
nuclei is checked under the microscope. Nuclei are centrifuged at 2.000rpm for 5min at 
4°C and the pellet is resuspended in 0,5ml staining solution and transferred into FACS 
vials. Vials need to be light protected. Cell cycle is measured using FACS Calibur. 
 
Nuclear Isolation buffer   RNAse stock solution 
10,5g   citric acid    10mg   RNAse A 
0,5ml   Tween 20    10ml   PBS 
up to 100ml aqua bidest    incubate 15 min 100°C 
put on ice immediately; store at -20°C 
 
Propidium Iodide (PI) stock solution  Staining solution 
5mg   Propidium Iodide   0,05ml  RNAse stock solution 
10ml   PBS     0,05ml  PI stock solution 
     5ml   PBS 
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3.1.9.5 Induction of Apoptosis: JC-1-FACS 
At higher mitochondrial membrane potential the green-fluorescent monomer JC-1 forms 
red-fluorescent “J-aggregates” which can be measured by FACS. JC-1 is obtained by 
Sigma. 
Figure 39: Chemical structure of JC-1 
(Picture from website: http://www.sigmaaldrich.com/ 
catalog/ProductDetail.do?lang=de&N4=T4069|SIGMA&
N5=SEARCH_CONCAT_PNO|BRAND_KEY&F=SPEC
; 11.7.2011) 
 
Harvested cells by trypsination are centrifuged down and resuspended in JC-1-solution 
(10µg JC-1 per 1ml MEM). Negative control for each sample is not mixed with JC-1-
solution. After 10min light protected incubation at 37°C cells are washed two times 
with PBS and resuspended in 200-500µl PBS. Apoptosis is measured by FACS Calibur. 
 
3.1.10 Cell Sorting 
Cells are trypsinyzed after reaching 50-70% confluence and spun down. Cell pellet is 
resuspended in 1ml SFM with Penstrep and transferred into FACS vials. Cells 
expressing a fluorescent protein (e.g. GFP) are sorted directly whereas non-fluorescent 
cells are first incubated with PE-conjugated antibodies according to the protocol 
described in chapters 3.1.9.2 and 3.1.9.3. Sorting is carried out by FACS Calibur and 
cells are sorted into BSA-coated 50ml tubes which contain 5ml medium. Sorted cells 
are centrifuged and transferred into Petri dishes with prewarmed medium.  
 
3.1.11 Immunofluorescence staining 
2*104 cells are seeded on collagen coated glass slides in 96-well flexiPERM (Greiner-
Bio-One, Frickenhausen, G) and incubated over night. After removing the flexiPERM 
and washing the slides two times with cold PBS, cells are fixed either with 
methanol/aceton 3:1 for 2-5min at -20°C or 4% formaldehyd-solution (Roti®-Histofix 
4%, Carl Roth GmbH + Co. KG, Karlsruhe, G) for 30min at room temperature. 
Formaldehyd fixed cells are additionally incubated with 47mM NH4Cl solution for 
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5min. After washing with cold PBS for 5min, incubating with 0,5% TritonX in PBS for 
5min and again washing with cold PBS for 5min, the cells are blocked with 0,2% fish 
gelatine in PBS for 30min at room temperature. 1st antibody is diluted 1:100 in 0,2% 
fish gelatine/PBS solution and is added for 1h after discarding the blocking solution. 
Slides are then washed three times with cold PBS each for 5min and the 2nd antibody 
(1:1.000 in blocking solution) is added for 45min. TO-PRO-3 iodide (642/661) 
(Invitrogen, San Diego, CA, US) was used as counterstaining and diluted at a 
concentration of 1:10.000 into the 2nd antibody-solution. 
After incubation slides are washed three times with PBS and one time with A.bidest. 
Cells are mounted with a few drops Mowiol and a 24x40mm cover slide. 
 
1st Antibodies 
Purified Mouse Anti-β-Catenin, (# 610154, BD)  
Purified Mouse Anti-E-Cadherin, (#610182, BD) 
 
2nd Antibody 
Alexa Fluor 488 goat anti-mouse IgG (H+L) (#A-11001, Invitrogen)  
 
3.1.12 Plasmids 
Plasmids are circular double-stranded DNA-molecules which are naturally found in 
bacteria. They are a separate form of DNA and can also be replicated independently 
from the chromosomal DNA. Because they are transferable genetic elements, plasmids 
play a crucial role for gene-transfer into eukaryotic cells, multiplication and expression 
of particular genes. Plasmids used for genetic engineering are called ‘vectors’. They 
usually contain a polylinker or multiple cloning sites, which consist of dozens of 
restriction enzyme recognition sites. Multiple cloning sites are essential for excision or 
insertion of any DNA fragment. Apart from the multiple cloning site plasmids also have 
two selection markers which are usually gene-sequences for a particular antibiotic-
resistance. One antibiotic-gene serves for bacterial selection marker and the other one 
for eukaryotic selection marker. 
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Name Promoter Resistance
in E.coli
Resistance in 
human cells
Description
pcDNA3 VSV/FGFR4 
G388R
CMV Ampicilin G418 Mammalian expression vector for FGFR4 which
consists of a transmembrane point mutation glycine
to arginine at position 388 with VSV tag
pcDNA3 VSV/FGFR4 
WT
CMV Ampicilin G418 Mammalian expression vector for FGFR4 with VSV
tag
pK5-IRESneo CMV Ampicilin G418 See 3.3.1.1
pcDNA3 CMV Ampicilin G418 Mammalian expression vector which is used as
control vector
EGFP CMV Kanamycin G418 Mammalian expression vector which encodes for
green fluorescent protein (GFP)
pTet-Off-Advanced CMV Ampicilin G418 See 3.3.1.2
pTRE-Tight Tet-responsive 
Ptight prometer
Ampicilin --- See 3.3.1.3
 
Table 5: Vectors used in this work 
Both FGFR4 over-expression vectors were kindly provided by Axel Ullrich.  
 
3.1.13 Transfection 
There are various ways to integrate a DNA sequence into cells: physical, chemical and 
viral. One of the easiest ways is lipofection. For this purpose, DNA is packed into lipid 
micelles which can attach to the cell surface and are taken up by the cell via 
endocytosis. For stable integration of DNA sequences into the cellular genome the 
transfected vector needs a selection marker which is usually an antibiotic resistance 
gene. Antibiotic treatment after transfection kills all cells which have not integrated the 
plasmid into their genome. 
24-48h before transfection 6-well plates are inoculated with 3*105 cells per well. 
Medium is aspirated before transfection and 1,5ml new medium is added. Transfection 
is carried out with TransFectinTM Lipid Reagent (Bio-Rad, Philadelphia, PA, US). 10µl 
TransFectin is mixed with 250µl SFM. 2µg plasmid is mixed with 250µl SFM. Plasmid 
and TransFectin solution are gently mixed together and after 20min added to the plate. 
After 6h DNA-TransFectin complexes are replaced by new medium. 
 
3.1.14 Selection 
24h after transfection cells are transferred from 6-well plates into 10cm Petri dishes. For 
most of our experiments Geneticin (G418) is used as selection agent and added 48h 
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after transfection. G418 is an aminoglycoside antibiotic which blocks protein synthesis. 
For each transfection untransfected cells were used as G418-negative control and 
therefore as a marker for the selection efficiency. After 3-5 weeks the first clones were 
picked by using cloning rings or cells were grown to mixed clone population. The 
concentration of G418 necessary for selection depends on the cell line (see Table 6) 
 
Cell line G418 concentration for 
selection [mg/ml]
G418 concentration for 
cell culture [mg/ml]
SW480 0,6 0,3
HCT116 1,0 0,5
HT29 0,9 0,45
 
Table 6: Selection conditions for cell lines 
 
3.1.15 Small interfering RNA (siRNA) mediated gene knock down 
Small interfering RNAs are double-strand RNAs and consist of 21-28 nucleotides. After 
entering the nucleus they are integrated into a protein complex called RNA-Induced 
Silencing Complex (RISC) and bind specifically to the mRNA. Due to the endonuclease 
activity of RISC the mRNA is degraded. Three different siRNAs against FGFR4 
(#4390824, Ambion, Applied Biosystems, Carlsbad, CA, US) were tested and two are 
used for experiments. A scrambled siRNA Silencer Select Negative Control 
(#4390844, Ambion) was used as negative control. 
Cells are seeded at various densities into plates (6-well plate: 3*105/well, 24-well plate: 
1*104/well; 96-well plate: 2,5*103, 5*103 and 1*104/ well). After 24-48h medium is 
replaced. For transfection siLentFectTM Lipid Reagent (Bio-Rad) is mixed with SFM 
according to the instruction manual (for 6-well plate: 3µl/125µl SFM; 24-well plate: 
1µl/25µl SFM; 96-well plate: 0,2µl/10µl SFM). In a separate vial siRNA is mixed with 
SFM (125µl, 25µl or 10µl) so that a final concentration of 10nM is reached. siRNA and 
siLentFect are gently mixed together and after 20min added to the cells. Medium is 
aspired after 6h (SW480) or after 24h (HCT116 and HT29) and new medium is added. 
48h after transfection HCT116 are used for assays. 72h after transfection SW480 and 
HT29 are seeded for assays. 
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3.1.16 Luciferase 
For the dual-luciferase reporter system two different constructs are essential: a vector 
carrying a firefly luciferase which is the “experimental reporter” downstream of the 
promoter element of interest and a vector carrying a renilla luciferase downstream of a 
constitutive promoter which acts as a “control reporter”. The activity of the 
experimental reporter is normalized to the activity of the control reporter and therefore 
differences in pipetting volumes, transfection efficiency etc. are minimized. 
Renilla and firefly luciferase are both capable to catalyze a chemical reaction that 
causes light to be emitted. 
 
 
 
Figure 40: Bioluminescent reaction catalyzed by firefly and renilla luciferase  
(Picture from website: http://www.promega.com/paguide/chap8.htm; 11.7.2011) 
 
In our experiments ß-catenin dependent promoter activity was determined using two 
different firefly luciferase constructs: Top and Fop. The Top promoter element consists 
of repeats of the ß-catenin-binding consensus sequence so that luciferase vector can be 
expressed, when β-catenin is localized into the nucleus and binds to the luciferase 
promoter region. Fop sequence serves as a negative control because it carries a mutation 
preventing β-catenin binding to the promoter and therefore no luciferase can be 
expressed.  
To carry out the luciferase assay the Dual-Luciferase Reporter Assay System from 
Promega (Madison, WI, US) is used. 5*104 cells are seeded in each well of a 24-well-
plate. On the next day cells are transfected with 1ng renilla plasmid and with either 1µg 
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Top or 1µg Fop plasmid by using Transfectin (Bio-Rad) and the corresponding protocol 
(see chapter 3.1.13). 24h later cells are treated with 10mM lithiumchlorid. After waiting 
another 24h cells are washed with PBS and lysed with 100µl Passive Lysis Buffer by 
shaking for 15min at room temperature. Lysates are transferred into Eppendorfer tubes, 
exposed to ultrasound for 10min, and centrifuged for 5min at 15.000rpm. 10µl 
supernatant is pipetted onto a 96-well plate (Greiner-Bio-One) and 50µl Luciferase 
Assay Reagent II (LAR II) is added. LAR II leads to light emission triggered by firefly 
and chemoluminescence is measured for 10sec at the luminoscan RS-luminometer 
(Labsystems, Franklin, MA, US). By adding 50µl Stop&Glow-reagent firefly luciferase 
activity is inhibited and renilla luciferase is activated. Chemiluminescence is again 
measured for 10sec. 
 
3.2 Molecular Biology: RNA 
3.2.1 RNA isolation 
The culture supernatant is aspirated. 1ml Trifast (Peqlab, Erlangen, G) is added per 
10cm Petri dish and incubated for 5min on ice. Cells and Trifast are scraped of the dish 
using RNAse free scrapers (incubated for 10min in 0,1N NaOH, then 10min in 70% 
EtOH) and transferred into an Eppendorfer tube. 200µl (1/5 of the Trifast amount) 
Chloroform is added and the tube is vortexed for 30sec and incubated on ice for 10min. 
The tubes are centrifuged for 15min at 15.000rpm and 4°C. The transparent phase is 
collected and transferred into a new tube. 500µl isopropanol is added, the tube is 
vortexed for 30sec and incubated on ice for 10min for the RNA to precipitate. After 
centrifugation at 12.200rpm for 10min at 4°C the RNA pellet is washed with 1ml 75% 
EtOH, centrifuged at 15.000 for 15min at 4°C and dried. The pellet is then dissolved 
into 30-50µl RNAse-free-water (DEPC water) and heated for 10min to 65-70°C to 
denature and dissolve the RNA. The amount of RNA is measured photometrically at 
260/280nm by Nano Drop spectrophotometer (Peqlab). RNA is stored at -80°C. 
 
OD (260nm) x 40 x dilution factor 
Calculation of quantity:  μg/μl = 
1.000 
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3.2.2 Complementary DNA (cDNA) synthesis 
cDNA is complementary to the RNA and synthesized by a reverse transcriptase 
enzyme.  
5µg RNA in 10µl nuclease free water is prepared into sterile PCR-Tubes (Biozym, 
Hessisch Oldendorf, G). 2,5µl Random Hexamer Primer Master Mix (100µM) is added 
and heated up to 70°C using a PCR cycler. After 5min 6,5µl Master Mix is added and 
incubated at 25°C for another 5min. Finally, 1µl Revert AidTM M-MuLV reverse 
transcriptase is added and first incubated 10min at 25°C, then heated up to 42°C for 
60min before incubating for 10min at 70°C. 80µl nuclease free water is added and the 
cDNA is stored at -20°C. (Hexa-Primer, dNTP, RNAse Inhibitor and Revert AidTM M-
MuLV reverse transcriptase are obtained from Fermentas, St. Leon-Rot, G)  
 
Random Hexamer Primer Master Mix Master Mix 
Hexa-Primer 100µM  1µl  5x first strand buffer   4µl 
DEPC water   1,5µl  dNTP-Mix    2µl 
      RNAse Inhibitor (20 units)  0,5µl 
 
3.2.3 Standard Polymerase Chain Reaction (PCR) 
Based on total RNA expression any gene of interest can be qualified and at least semi-
quantified by PCR. For this purpose cDNA is used as the template. To separate the 
double strands cDNA is first denaturized by heating. By lowering the temperature small 
oligomeres, called primers, can bind to specific sequences of a gene. Primers flank a 
defined sequence of a defined length of the gen of interest. The temperature is raised 
again so the Taq polymerase, a heat stable polymerase derived from the bacterium 
Thermus aquaticus, can bind to the primer and extends the strand in 5’-3’ direction. 
This cycle (denaturation, annealing and extension) is repeated various times. 
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Figure 41: The principle of Standard PCR  
(Picture from website http://universe-review.ca/I11-50-PCR.jpg; 18.7.2011) 
 
PCR is performed on an “iCycler” (Bio-Rad). Components of PCR are pipetted into 
PCR strips. GAPDH is always taken as reference. (PCR mastermix is obtained from 
Fermentas) 
 
Components  
3´primer  1µl 
5´primer  1µl 
cDNA   1µl 
Mastermix  12,5µl 
DEPC water  9,5µl 
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Conditions  
Initial denature:   2 min   94°C  
Denature:    40 sec   94°C  
Annealing:    40 sec   56°C 
Elongation:    40 sec   72°C 
Final extension:   7 min   74°C 
 
Name Sequence:
- upstream
- downstream
Annealing
temperature (°C)
Product size
(bp)
Cycles
FGF1 GAAGCCCAAACTCCTCTACTGTAGC
TGTTGTAATGGTTCTCCTCCAGC
57 259 45
FGF2 CTGTACTGCAAAAACGGG
AAAGTATAGCTTTCTGCC
45 349 45
FGF6 AACGTGGGCATCGGCTTTCACCTCC
CCCGCTTTACCCGTCATTTGC
56 301 40
FGF16 ACGTGCCCTTAGCTGACTCC
GTTTAGTCCTGTATCCCTCCCG
56 467 40
FGF17 TGCTGCCCAACCTCACTC
TCTTTGCTCTTCCCGCTG
53 361 35
FGFR4 AGCACTGGAGTCTCGTGATG
CATAGTGGGTCGAGAGGTAG
56 525 35
GFP TCGTGACCACCCTGACCTGG
TCTTTGCTCAGGGCGGAC
54 500 39
GAPDH 53° CGGGAAGCTTGTGATCAATGG
GGCAGTGATGGCATGGACTG  
53 369 22
GAPDH 68° GGCTCTCCAGAACATCATCCCTGC 
GGGTGTCGCTGTTGAAGTCAGAGG   
68 269 22
 
Table 7: Primer for standard PCR 
 
3.2.4 Polyacrylamid Gel Electrophoresis 
DNA is negatively charged so that it migrates towards the positively charged anode in 
gel electrophoresis. Due to the net-like gel matrix the DNA is separated according to its 
size.  
6% polyacrylamid gels are cast in a casting stand using 1mm spacers and the reaction 
mix listed below. When the polymer has formed, 10µl of the PCR-product together with 
2µl of 6x loading dye (Fermentas) are loaded onto the gel. For marker, 1µl of a 100bp 
ladder (Fermentas) with 2µl 6x loading dye is used. The gel is run for 1h at 95V in 
TAE-buffer. (Gel apparatus and casting stand are obtained from Bio-Rad). Then the gel 
is stained with ethidiumbromide (0,5mg/ml PBS) (Sigma) that can intercalate in the 
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DNA. The bands are visualized with UV-light using the Gel Doc2000 (Bio-Rad) and 
quantified using the corresponding software ImageQuant® Version 5.0 (Molecular 
Dynamics). 
 
6% polyacrylamide gel     50x TAE  
TAE 50x   150µl   Tris   242g 
Acrylamide 40%  1,125ml  acetic acid  57,1ml 
H2O bidest   6,175ml  0,5 M EDTA  100ml 
TEMED   5µl   A. bidest  up to 1l 
APS 10%   50µl 
 
6x loading buffer  
urea    0,24g 
sucrose   0,4g 
bromphenolblue  1mg 
xylenolblue   1mg 
1x TAE   up to 1ml 
 
3.2.5 Real-time PCR  
The principles of a real-time PCR are quite similar to the Standard PCR but additionally 
the PCR products can be quantified in real-time (which means at each time point during 
the PCR) by measuring fluorescence. One possibility is the use of TaqMan® probes that 
are labeled with a fluorescent reporter dye and with a quencher molecule. As long as the 
reporter is close to the quencher, no light can be emitted by the reporter. Due to the 
exonuclease activity of the polymerase the reporter is released from the probe and 
fluorescence can be measured. 
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Figure 42: The principles of real-time PCR  
(Picture from website: http://biommed.lsu.edu/images/PCR_TPM.gif; 11.7.2011) 
 
Another possibility to measure fluorescence during real-time PCR is to use a dye which 
intercalates into the DNA: SybrGreen. The more PCR product is produced the more dye 
can be integrated and the more light is emitted. To avoid unspecific light emission (for 
example primer dimers) a melting curve analysis is performed after the PCR run. 
Double stranded DNA is heated to 95°C for denaturation. The temperature at which the 
DNA strands are separated is specific for the exact sequence. Larger PCR products have 
higher melting temperatures than shorter primer dimers so that they can be easily 
distinguished. 
 
3.2.5.1 TaqMan Assays 
TaqMan gene expression arrays consist of primers and 6-carboxyfluorescein (FAM) 
labeled TaqMan® probes as well as a dihydrocyclopyrroloindole tripeptide minor 
groove binder (MGB) as a quencher. The assay is performed on a 96-well plate for real-
time arrays. Gene expression quantification is performed as a two-step reverse 
transcription PCR on the ABI PRISM 7000 instrument using the corresponding 
software. Gene expression is normalized to a housekeeping gene GAPDH. All 
TaqMan® Assays, cycler, probes and material are obtained from ABI (Applied 
Biosystems, Carlsbad, CA, US). 
 
 Materials and methods 
 
96 
Components 
cDNA    1µl 
TaqMan® probe  1µl 
Master Mix   10µl 
DEPC water   8µl 
 
Conditions 
Initial denature   10 min  95°C  
Denature:    15 sec   95°C 
Annealing/Elongation  1 min   60°C 
40 cycles 
 
Name Assay number Exon
FGFR4 Hs01106913_g1 5-6
FGFR4 Hs00242558_m1 8-9
FGF19 Hs00391591_m1 3
FGF18 Hs00818572_m1 4-5
FGF9 Hs00181829_m1 2-3
E-Cadherin Hs00170423_m1 3-5
GAPDH Hs99999905_m1 3
 
Table 8: TaqMan® assay kits  
 
3.2.5.2 TaqMan® Genotyping assay for FGFR4 
A TaqMan® Genotyping assay is performed, whereas the probe for Arg388 is labeled 
with FAM and the probe binding to Gly388 is labeled with VIC. Both probes contain a 
MGB as a quencher. Components are pipetted on a 96-well Fast plate for real-time PCR 
and the assay is carried out on the ABI PRISM 7500 instrument using the corresponding 
software.  
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Components 
3´Primer   0,09µl 
5´Primer   0,09µl 
Probe Arg388   0,01µl 
Probe Gly388   0,01µl 
cDNA    2µl 
Genotyping Master Mix 5µl 
DEPC water   2,8µl 
 
Conditions 
Initial denaturation:   2 min   50°C  
Denaturation:    10 sec   95°C  
Annealing:    15 sec   95°C 
Elongation:    1 min  60°C 
40 cycles 
 
Sequences 
Probe Arg388: FAM-CTG GCC AGG CTG AT-MGB 
Probe Gly388: VIC-TGG CCG GGC TGT A-MGB 
 
Primer FGFR4:  forward:  5’ CGG GAG AGC TTC TCC ACA CT 3’ 
reverse:  5’ GCC AGG TAT ACG GAC ATC ATC CT 3’ 
 
3.2.5.3 SybrGreen 
QuantiTect Primer assays (Quiagen) are used and the assay is performed on a 96-well 
plate for fast real-time arrays. Gene expression quantification is performed as a two-step 
reverse transcription PCR on the ABI PRISM 7500 instrument using the corresponding 
software. Gene expression is normalized to a housekeeping gene GAPDH. Primers are 
the same also used for standard PCR and described in Table 7. 
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Components 
4μl  MaximaTM SYBR Green qPCR Master Mix (Fermentas) 
0,3μl  3’ Primer 
0,3μl  5’ Primer 
0,1μl  cDNA 
3,3μl  nuclease free water 
 
Conditions 
Initial denaturation   10 min  95°C  
Denaturation:    15 sec   95°C 
Annealing/Elongation  1 min   60°C 
40 cycles 
 
3.2.6 Restriction Fragment Length Polymorphism (RFLP) for FGFR4 
3.2.6.1 PCR 
A standard PCR is performed using the protocol described in chapter 3.2.3. 
 
Conditions 
Initial denature:   12 min   94°C  
Denature:    30 sec    94°C  
Annealing:    30 sec    66(first 5 cycles)/62°C  
Elongation:    40 sec    72°C 
Final extension:   7 min    72°C 
35 cycles 
 
Primer 
Reverse:  5´-TGC-TGG-AGT-CAG-GCT-GTC-AC-3´ 
Forward:  5´-GGC-CAG-TCT-CAC-CAC-TGA-CC-3´ 
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3.2.6.2 Restriction enzyme digest 
PCR product, enzyme and buffer are prepared in a tube and incubated with Msp1 for 1h 
at 37°C and afterwards brought to a polyacrylamid gel. 
 
Reaction mix 
PCR product   10µl 
10x Tango buffer  1,5µl 
MspI enzyme   1µl 
Water    2,5µl 
 
3.2.6.3 Gel 
5µl digested PCR product is loaded together with 1µl 6x loading dye on a 
polyacrylamid gel. The gel is run for 1h at 125V and stained with ethidiumbromide 
(0,5μg/ml aqua bidest) as described in chapter 3.2.4. 
 
 
Gel compounds 
5x TBE   2,4ml 
Polyacrylamid 40%  2,76ml 
Water    6,48ml 
APS    100µl 
TEMED   10µl 
 
Undigested PCR product:  167bp 
Arg388:   ~50bp and 115bp 
Gly388:   ~30bp, ~50bp and 85bp 
 
Figure 43: Gel of RFLP of FGFR4 G388R polymorphism 
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3.3 Tet-Off advanced inducible gene expression system  
Tetracycline-controlled transcriptional activation systems are used to induce the 
transcription of a gene of interest in a reversible mode by presence or absence of the 
antibiotic tetracycline or one of its derivatives. In this work the Tet-Off® Advanced 
system (Clontech, Mountain View, CA, USA) and Doxycycline as a tetracycline 
derivative was utilized. 
 
3.3.1 Principles of the tet-off-system 
Using the tet-off-system two vectors are necessary: a tet-off-vector and a tetracycline 
sensitive vector. Both vectors need to be introduced to the cell either by cotransfection 
or by independent transfection. The tet-off-vector contains the sequence for a 
tetracycline-controlled transactivator protein (tTA-protein) whereas the tetracycline 
sensitive vector contains the gene of interest under the control of a Tet-responsive 
element (TRE). In the absence of tetracycline the tTA-protein binds to the tet-operator 
(tetO) which is located on the TRE-sequence. Once bound to the tetO, a coupled and 
modified CMV-promoter is activated which leads to the transcription of the gene of 
interest. By adding tetracycline, tTA is hindered to bind to the TRE and the gene of 
interest cannot be transcribed.  
 
 
Figure 44: Principles of the Tet off system 
(Kohan 2008) 
 
Plasmids used for tet-off gene expression system used in this work are K5, pTet-Off-
Advanced, pTRE-Tight, and GFP. 
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3.3.1.1 K5-vector  
The K5-vector contains a dominant negative FGFR4-construct. The kinase-domain of 
the FGFR4 was substituted by a cyan fluorescent protein (CFP)-molecule which results 
in a 78kDa artificial protein acting as a decoy-FGFR4. Additionally, an Internal 
Ribosome Entry Site (IRES) segment is located between the K5 construct and the 
selection marker neomycin for eukaryotic cells. The IRES-segment forces the cell to 
translate the K5 construct together with the selection marker and therefore reduces the 
occurrence of ‘fake clones’. An ampicillin-resistance-gene serves as a selection marker 
in bacteria. 
 
Figure 45: K5-vector: a dominant negative construct for FGFR4 
 
3.3.1.2 pTet-Off-Advanced-Vector  
The pTet-Off-Advanced-vector expresses a completely synthetic protein which is a 
tetracycline-controlled transactivator protein called tTA-Advanced. This protein 
consists of 1-207 amino acids of a Tet-Repressor (TetR) and 39 amino acids which 
contain three minimal transcriptional activation domains from the VP16 protein of 
herpes simplex virus. The vector contains also a neomycin-resistance for eukaryotic 
cells and an ampicillin-resistance for bacteria.  
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Figure 46: pTet-off-Advanced vector 
 
3.3.1.3 pTRE-Tight-vector  
The pTRE-Tight-vector is the response plasmid to pTet-off-Advanced vector and 
contains a multiple cloning site (MCS) for the insertion of the gene of interest 
downstream of the Tet-responsive Ptight promoter. The Ptight promoter contains a 
modified Tet response element (Tetmod) with seven direct repeats of a 36bp sequence 
that contains a 19bp Tet-Operator sequence (TetO). The Tetmod is located upstream of a 
minimal CMV promoter (PminCMVΔ) which lacks the enhancer (part of a complete CMV-
promoter). Ptight is silenced if no binding to the TetO-sequence occurs. The pTRE-Tight-
vector contains an ampicillin-resistance gene for bacteria but no resistance gene for 
eukaryotic cells. Consequently a linear puromycin-marker is cotransfected to permit 
selection of stable transfectants.  
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Figure 47: pTRE-Tight-vector: the response plasmid  
 
3.3.2 Restriction digest 
DNA is cut using restriction enzymes at a very specific nucleotide sequence, the 
restriction site. The conditions for the restriction digest vary with the restriction 
enzyme. Each enzyme needs a specific 10x-restriction-buffer. Enzymes and buffers are 
obtained from Fermentas. 
 
For control restriction digests the following approach was used: 
• 50-150ng Plasmid 
• 0,5-1µl enzyme 1 
• 0,5-1 µl enzyme 2 
• 1µl 10x restriction buffer 
fill up with A.bidest to 10µl 
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For preparative restriction digests the following approach was used: 
• 4-5µg Plasmid 
• 2-3µl enzyme 1 
• 2-3µl enzyme 2 
• 10µl 10x restriction buffer 
fill up with A.bidest to 1000µl 
 
Restriction digest approaches were incubated over night at 37-38°C. 
Digested fragments were loaded on a 1% agarose-gel and proper bands were monitored 
and eventually cut out of the gel. 
 
Big DNA-fragments (e.g. plasmid) need to be incubated with a Calf Intestinal Alkaline 
Phosphatase (CIAP) (Promega, Madison, WI, USA) enzyme before added to the gel. 
CIAP prevents the recircularization and relegation of linearized cloning vehicle DNA 
by removing phosphate groups of the 5’-end of the molecule by hydrolysis. 
2µl CIAP were added to 100µl of the preparative restriction digest approach and 
incubated 30min at 37°C and then 30°C at 50°C. This procedure is repeated once more 
with another 2µl CIAP. To inactivate the enzyme, tubes are incubated 15min at 85°C. 
 
3.3.3 DNA-isolation with gel-extraction-kit  
DNA is isolated from the gel according to the protocol of the QIAquick Gel Extraction 
Kit (Quiagen, Hilden, G). The gel containing the DNA is dissolved by adding three 
volumes of the buffer QG and incubating for 10min at 50°C. One gel volume of 
isopropanol is added and the sample is applied to the QIAquick column which is 
centrifuged for 1min. The DNA binds in the column and the flow-through is discarded. 
Another 0,5ml of the QG buffer is added to the column and centrifuged again for 1min. 
The bound DNA is washed with 0,75ml of the PE buffer which needs to be removed 
completely by centrifugation at 17.900g for 1min. The DNA is eluted with 50µl 10mM 
Tris-Cl, pH8.5.  
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3.3.4 Ligation 
Before ligating the gene-fragments (containing the gene of interest) with the vector, the 
open and linearized vector needs to be incubated with CIAP (see chapter 3.3.2). For 
ligation of the cut vector with an insert 40-60ng vector and 50-90ng insert were used. 
1µl ligase and 1µl 10x ligase-buffer were added and filled up with A.bidest to 10µl. 
Approaches were incubated at 16°C over night.  
 
3.3.5 Transformation of bacteria 
For transformation in this work a XL1Blue E.coli bacteria strain was used. 3µl of a 
50ng/µl plasmid-solution was added to 100µl bacteria and incubated for 30min on ice. 
After incubating 1min on 42°C, 1ml SOC-media with a temperature of 4°C was added. 
Bacteria were agitated for 1,5h on 37°C and finally centrifuged and plated on agar-
plates containing ampicillin. Plates were incubated over night at 37°C and clones were 
picked on the next day for mini-, midi-, or maxi-preps. 
 
3.3.6 Plasmid preparation: Mini-, midi-, and maxi-preps  
For mini-preps the boiling-lysis-preparation method was used. 2ml bacteria culture 
with appropriate antibiotic selection was incubated over night. On the next day 1ml was 
transferred into a tube and centrifuged for 1min at 16.000g. The supernatant was 
discarded and the pellet was resuspended in 700µl STET-buffer (50mM Tris pH8,0; 
50mM EDTA pH8,0; 8% sucrose; 5% tritonX) with 13µl lysozyme (10mg/ml) and 
incubated for 1min at 99°C. Tube was centrifuged for 10min at 14.000g and the pellet 
was removed with a sterile pipette-tip and discarded. 750µl isopropanol was added and 
incubated for 20min at -20°C. After centrifugation for 10min at 20.000 and 4°C, 
supernatant was poured off and pellet was washed briefly with cold 70% ethanol. Tube 
was centrifuged for 5min at 16.000g and supernatant was discarded while pellet was 
dried. Pellet was dissolved in 15µl TE-buffer with 0,2µl RNAse A. 
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For midi- and maxi-preps the Pure YieldTM Plasmid Midiprep System from Promega 
was used.  
For midi-prep 100ml and for maxi-prep 200ml bacteria culture with appropriate 
antibiotic selection is incubated over night. Bacteria are centrifuged at 5.000g for 10min 
and the pellet is resuspended in 3ml/6ml of a resuspension solution. 3ml/6ml of a lysis 
buffer is added and tubes are inverted 3-5 times. Bacteria are lysed for 3min and lysis is 
stopped by adding 5ml/10ml neutralization buffer. Lysated bacteria are centrifuged for 
15min at 15.000g. Lysate is added to a clearing column which was previously added to 
a binding column. Using a vacuum manifold the supernatant passes through the clearing 
and binding column. The clearing column is removed and the DNA which binds in the 
binding column is washed with 5ml endotoxin removal washing buffer and finally with 
20ml column washing solution. Binding column is dried for 30-60sec and the DNA is 
eluted with 400-600µl nuclease free water using the EluatorTM vacuum Elution Device. 
 
3.4 Protein Chemistry 
3.4.1 Western blotting 
During the western blot procedure proteins are isolated and immunologically detected 
using specific antibodies. Equal amounts of protein lysates are brought on a 
polyacrylamid gel containing Sodiumdodecylsulfate (SDS). Secondary and tertiary 
structures (hydrogenbonds and disulfid bridges) of protein are dissolved by adding SDS 
and β-Mercaptoethanol (in sample buffer) to the lysates and heating prior gel 
electrophoresis. SDS also charges the proteins negatively so the proteins can be 
separated via gel electrophoresis due to their size. Proteins are transmitted onto a 
Polyvinylidene Fluoride (PVDF) membrane and incubated with antibodies specific for a 
certain protein. A secondary antibody contains an enzymatic label, a horse radish 
peroxidase, which oxidizes a chemiluminescent substrate. A photosensitive film detects 
the emitted light. 
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3.4.1.1 Total protein isolation 
Cells are washed with cold tris-buffered saline (TBS) containing phosphatase inhibitors 
(1µl/ml Na3VO4 and 10µl/ml 1M NaF) and lysed with hepes lysis buffer. Cell lysates 
are homogenized by forcing them three times through a 0,6-mm-in-diameter needle and 
transferred into Eppendorfer tubes. Lysates are held on ice and during a period of 30-
45min and vortexed three times. Afterwards, the tubes are exposed to ultrasound for 
10min and centrifuged at 15.000rpm for 5min. Supernatant is transferred into new 
tubes. 
 
Hepes lysis buffer 
1ml   1M Hepes 
10ml   1M NaCl 
40µl   0,5M EDTA solution 
200µl   1M NaF solution 
100µl   1M NaVO4 solution 
200µl   Igepal (NP40) 
30µl   1M MgCl2 solution 
2 tablets  complete (phosphatase inhibitor cocktail tablet) 
8,03ml   aqua bidest. 
 
3.4.1.2 Membrane Protein Isolation 
Adherent cells are scraped down from the Petri dish, transferred into an Eppendorfer 
tube and washed two times with ice-cold PBS. Cells are resuspended in 3ml ice-cold 
Dounce buffer and incubated for 10min on ice. To break the cell structure suspended 
cells are forced 50 times through a 0,6-mm-in-diameter needle and checked 
microscopically. 1ml Tonicity buffer is added and destroyed cells are centrifuged for 
5min at 500g and 4°C. Supernatant is transferred in a tube for ultracentrifugation and 
80µl 0,25M EDTA (pH 7,6) is added (to reach a final concentration of 5mM EDTA) 
and centrifuged for 90min at 100.000g and 4°C. Supernatant is discarded and pellet is 
resuspended in hepes lysis buffer (see chapter 3.4.1.1) 
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Dounce Buffer     Tonicity Buffer 
10mM Tris HCl, pH 7,6   10mM Tris HCl, pH 7,6 
0,5 mM MgCl2    0,5 mM MgCl2 
20µl/ml complete    0,6M NaCl 
10µl/ml 0,1M PMSF (in isopropanol) 5µl/ml complete 
      10µl/ml 0,1M PMSF (in isopropanol) 
 
3.4.1.3 Evaluation of protein concentration: Coomassie blue assay 
Standard curve as well as protein sample is determined in duplicates. For standard curve 
BSA solution (1µg/µl) and hepes lysis buffer are pipetted into a 96-well plate 
conforming to following scheme: 
BSA concentration [µg/µl] 0 1 2 3 4 5 6 7 8 9 
Aqua bidest [µl] 9 8 7 6 5 4 3 2 1 0 
Hepes lysis buffer [µl] 1 1 1 1 1 1 1 1 1 1 
BSA [µl] 0 1 2 3 4 5 6 7 8 9 
Total volume [µl] 10 10 10 10 10 10 10 10 10 10 
 
For protein samples 1µl protein lysate and 9µl A. bidest are mixed in a 96-well. 150µl 
of a 1:5 diluted Coomassie Protein Assay Dye Reagent Concentrate (Bio-Rad) solution 
is added to each well of the standard curve and protein samples. 
Absorption is measured at 590nm by microplate reader Synergy H1 (Szabo Scandic) 
and protein concentration of samples is calculated according to the standard curve. 
 
3.4.1.4 SDS-Polyacrylamid Gel Electrophoresis (PAGE) 
First a SDS separating gel is prepared and overlaid with ethanol. After 45min the 
separating gel is polymerized and ethanol is removed neatly using filter paper. The 
separating gel is overlaid with a SDS collecting gel. 
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Before loading the gel, 20-40µg protein are mixed with 4x sample buffer and heated up 
to 80°C for 5min. 5µl protein ladder (PageRulerTM Prestaind Protein Ladder, Fermentas) 
is also loaded. The gel is running in electrophoresis buffer first for 15min with 60 Volt 
and then for 1h hour at 125 Volt. Gel electrophoresis apparatus was obtained from Bio-
Rad. 
 
SDS separating gel  7%   10% 
40% Acrylamid   0,875 ml   1,5 ml 
1,5M Tris pH 8,8   1,25 ml   1,75 ml 
A. bidest    2,8 ml    2,15 ml 
10% SDS    50 μl    50 μl 
10% APS    25 μl    25 μl 
TEMED    2,5 μl    2,5μl 
 
SDS collecting Gel      2x Sample buffer 
40% Acrylamid  0,25 ml    SDS    4% 
1,5M Tris pH 6,8  0,313 ml    Glycerol   20% 
A. bidest   1,9 ml     2-mercaptoethanol  10% 
10% SDS   25 μl     Tris/HCl pH 6.8  0,125 M 
10% APS   12,5 μl    Bromphenolblue  traces of 
 
Electrophoresis buffer 
Glycin   72g 
Tris   15g 
SDS   5g 
A. bidest  fill up to 500ml 
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3.4.1.5  Western blot 
Proteins are blotted on a PVDF membrane (VWR) using a wet-blot system (Bio-Rad). 
The blotting sandwich is prepared (avoiding air bubbles) according following order: 
1. thick pad 
2. 3 filter papers 
3. PVDF membrane (activated in methanol) 
4. gel 
5. 3 filter papers 
6. thin pad  
The blot is running at 25V over night at 4°C in blotting buffer. The negative charge is 
on the side of the gel so the negatively loaded proteins can run to the positively charged 
membrane.  
After blotting the membrane is washed in water, dried with methanol and can now be 
stored at 4°C. 
 
10x Blotting buffer     1x Blotting buffer 
Glycin  72g      10x blotting buffer  10% 
Tris   15g      Methanol   20% 
SDS   1g      A. bidest   70% 
A. bidest to 500 ml 
 
3.4.1.6 Ponceau S staining 
For visualizing all proteins on the membrane it is incubated in Ponceau S (Sigma) 
solution for 10min. Ponceau S binds to the positively charged amino groups of the 
protein and is therefore used to check the transfer quality from the gel to the membrane. 
The stained membrane can be photocopied and destained with A. bidest or washing 
buffer (see 3.4.1.7). 
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3.4.1.7 Immunological detection of protein 
The membrane is incubated over night with the primary antibody solution (antibody 
diluted in 3% BSA in TBST or 1% non-fat dry milk in PBST) at 4°C. On the next day 
the membrane is washed 3-5 times during a period of 30min-1h before incubating with 
the secondary antibody solution (horse radish peroxidase (HRP) conjugated antibody in 
3% BSA in TBST or 1% non-fat dry milk in PBST) for 1h at room temperature. After 
washing 3-5 times for 30min-1h the membrane is covered with detection solution (ECL 
Plus Western Blotting Detection System, AmershamTM, GE Healthcare, UK) and 
exposed to an x-ray film. Bands are semiquantified by scanning and analyzing using 
ImageQuant® Version 5.0.  
 
Washing buffer (TBST or PBST) 
TBS or PBS   1l 
Tween    1ml or 0,5ml 
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1st antibody company dilution 2nd antibody dilution buffer molecular weight
FGFR4 (H121), #sc-9006, N-terminal Santa Cruz (Santa Cruz, CA, US) 1:250 rabbit 1:20.000
1% milk in PBS-
Tween (0,05%) 95/110kDa
Β-actin AC-15, #A5441 Sigma-Aldrich 1:500 mouse 1:2000 1% milk in PBS-Tween (0,05%) 42kDa
MAP Kinase 1/2 (ERK1/2-CT), 
#06-182
Upstate
(Lake Placid, NY, US) 1:5000 rabbit 1:20.000
5% BSA in TBS-
Tween (0,05%) 42/44kDa
Phospho-MAP Kinase (pERK1/2)
(Thr202/Tyr204), #9101
Cell signaling
(Danvers, MA, US) 1:1000 rabbit 1:20.000
3% BSA in TBS-
Tween (0,05%) 42/44kDa
S6 Ribosomal Protein (5G10), #2217 Cell signaling 1:2000 rabbit 1:20.000 5% BSA in TBS-Tween (0,05%) 32kDa
pS6 Ribosomal Protein (Ser240/244),  
#2215 Cell signaling 1:2000 rabbit 1:20.000
5% BSA in TBS-
Tween (0,05%) 32kDa
FRS (M02), clone 1F7-1D6, 
#H00010818-M02
Abnova
(Taipei City, Taiwan) 1:100 mouse 1:2000
3% BSA in TBS-
Tween (0,1%) 57,5kDa
pFRS-α(Tyr196), #3864 Cell signaling 1:1000 rabbit 1:20.000 3% BSA in TBS-Tween (0,1%) 85kDa
GFP, #11814460001 Roche (Mannheim, G) 1:1000 mouse 1:2000
4% milk in PBS-
Tween (0,05%) 27kDa
TetR, #631108 Clontech (Mountain View, CA, US) 1:1000 mouse 1:2000
1% milk in PBS-
Tween (0,05%) 25kDa
pGSK3β, #9323 Cell signaling 1:1000 rabbit 1:20.000 3% BSA in TBS-Tween (0,05%) 46kDa
GSK3β, #9315 Cell signaling 1:1000 rabbit 1:20.000 3% BSA in TBS-Tween (0,05%) 46kDa
Phospho-PLCγ1(Tyr783), #2821 Cell signaling 1:1000 rabbit 1:20.000 3% BSA in TBS-Tween (0,1%) 155kDa
PLCγ1, #2822 Cell signaling 1:1000 rabbit 1:20.000 3% BSA in TBS-Tween (0,1%) 155kDa
Src (Phospho-Tyr418), #Y011091 Abm(Richmond, BC, CA) 1:1000 rabbit 1:20.000
3% BSA in TBS-
Tween (0,1%) 60kDa
Src (Ab-529), #Y21168 Abm 1:1000 rabbit 1:20.000 3% BSA in TBS-Tween (0,1%) 60kDa  
Table 9: Antibodies used for western blot 
 
2nd Antibodies 
Goat Anti-Mouse HRP-conjugated (#1858413, Pierce, Thermo Scientific, Rockford, IL, 
US) 
Goat Anti-Rabbit IgG-h+I HRP (#A120-201P, Bethyl Laboratories Inc, Montgomery, 
TX, US) 
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3.5 In vivo experiments 
3.5.1 Tissue specimens 
Tissue specimens of colorectal carcinoma and normal mucosa were obtained from 81 
patients undergoing surgery for colorectal cancer. The experiments were examined and 
approved by the ethics commission of the Vienna municipal hospitals (votum EK 05-
004-VK, 24.3.2005) and all patients gave informed consent before tissue collection. 
Tissue specimens were snap frozen in liquid N2 after surgery and stored until RNA 
extraction. 
 
3.5.2 Blood samples 
The study population consists of two cohorts and has already been described, analyzed 
and published in another context (Feik et al. 2010). Blood samples were taken and 
analyzed in the lab of Andrea Gsur by Gerhard Führlinger. Statistical analysis was 
evaluated by Andreas Baierl. 
From 2003 to 2006 there has been a province-wide screening project “Burgenland 
gegen Dickdarmkrebs” initiated by BAKS (Burgenländer Arbeitskreis für Sozial- und 
Vorsorgemedizin). During this time fecal occult blood tests were taken from 144.588 
male and female residents of the Province Burgenland from which 17.028 were found 
positive. Patients were divided into groups of false positive, low risk adenoma, high risk 
adenoma and carcinoma. 3.471 blood samples from the study in Burgenland were 
evaluated in this approach. 
Additionally, 14 blood samples of colon carcinoma patients in Vienna which have been 
collected at the Department of Surgery of the SMZ Süd (by Dr. Stefan Stättner) were 
integrated. From the same patients also tissue specimens were taken as described above. 
The whole study population evaluated in this work can be divided into: 
85  carcinoma 
278  high risk adenoma 
928  low risk adenoma 
1.660  control 
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3.5.3 Local tumor growth in SCID mice 
1*106 cells are suspended in 50μl SFM and injected subcutaneously into the right flank 
of Severe Combined Immunodeficiency (SCID) mice. Tumor size (longitudinal and 
lateral) is measured periodically using a Vernier caliper. Mice are sacrificed as soon as 
the tumor reaches a size of 5.000mm3 or mice showed symptoms of morbidity. Tumor 
and eventually other organs like lung or liver are harvested, washed with PBS and fixed 
for 24h in 4% formaldehyde-solution (Histofix). Tumors are washed with PBS and 
stored in 70% ethanol at 4°C.  
 
longitudinal x lateral2 
Calculation of tumor volume: 
   2 
 
All experiments were carried out according to Austrian regulations and Federation of 
European Laboratory Animal Science Associations (FELASA) guidelines for animal 
care and protection. 
 
3.5.4 Metastatic in vivo model: tail vein injection 
1*106 cells are obtained in 100μl serum free media and injected into the tail vein of 
SCID mice. Animals are weighted every 2-3 days to find any alterations. 9 weeks after 
injection mice are all sacrificed and lungs as well as liver and kidney are removed and 
fixed as described in chapter 3.5.3. 
 
3.5.5 Tissue fixation and paraffinization 
Tissue is cut into small pieces and transferred into tissue caps. Final fixation and 
paraffinization are performed at the Kos Microwave histoSTATION (milestone, 
Bergamo, I). 
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Conditions 
25min  65°C  ethanol absolute 
55min  68°C  isopropanol 
1h15min 82°C  melted paraffin 
 
Fixed tissue is finally sealed into paraffin blocks and cut into 4μm slides using a 
microtome (HM 355 S, Microm, Thermo Fisher Scientific, Waltham, MA, US). 
 
3.5.6 Hämatoxylin-Eosin staining 
First tissue is deparaffinized incubating the slides according to the following protocol:  
2x 1min  xylol 
2x 1min  ethanol 100% 
2x 1min  ethanol 70% 
2x 1min  water 
Nuclei are stained with hämatoxylin (Merck) for 5min. Slides are cleaned with water 
and incubated shortly (5sec) in Sott’s solution (Morphisto, Frankfurt am Main, G). 
Slides are cleaned for 5min in floating water. Counter staining is done with Eosin 
(Sigma) for 1min. Slides are washed in water and dried in an ethanol range in ascending 
order: 
1x dipping 3 times  ethanol 70% 
2x 1min    ethanol 96% 
2x 1min    ethanol 100% 
1x 1min    ethanol:xylol, 1:1 
2x 1min    xylol 
Slides are mounted with Entellan (Sigma). 
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3.5.7 Immunohistochemical staining 
Slides are first incubated for 10min at 65°C and then deparaffinized as described in 
chapter 3.5.6. To remove peroxidases slides are incubated 10min in 0,3%H2O2 (in PBS) 
at room temperature. After washing 2x3min in PBS slides are cooked in a steamer in 
10mM citrate buffer for 30min and cooled down. Slides are washed 3min in PBS-
Tween (0,1%). Tissue on the slide is circuited with a fat marker. For detection the 
Ultravision LP Large Volume Detection System HRP Polymer (Ready-To-Use) kit 
(Thermo Scientific, CA, USA) is used. Tissue is first incubated for 5min with ultra V 
block and then for 30-60min with the first antibody solution: Antibody + goat serum 
(1:100) in PBS-Tween (0,1%). 
Slides are washed 2x3min in PBS-Tween (0,1%) and then incubated for 10min with 
primary antibody enhancer. Slides are again washed 2x3min in PBS-Tween (0,1%) and 
incubated for 15min with HRP polymer. After washing 2x3min in PBS-Tween (0,1%) 
slides are incubated for 2-10 min with DAB substrate (Dako North America, CA, USA) 
and washed with water. Counter staining is done by very short incubation (2sec) in 
hämatoxylin (Gill III, Merck). Slides are washed with water and dried in ethanol range 
(70%, 80%, 96%, 100% and n-butyl-acetate). Slides are mounted with Entellan.  
 
Antibodies used for immunohistochemical staining 
Cytokeratin 20 (Ab-5), mouse anti human, (#DLN-14712, Dianova, Asker, N) 
Ki-67, rabbit anti human, (#A047, Dako) 
 
3.6 Statistical evaluation of data 
Results obtained from cell culture assays were analyzed by student’s t-test or Kruskal-
Wallis test depending on the results of normality testing. To evaluate local tumor 
growth in SCID mice a 2-way ANOVA test was used. For tissue expression a paired 
sample t-test after obtaining the Gaussian distribution was used. To determine the 
impact of FGFR4 allelotype on tumor stage, all different stages were compared to stage 
I using contingency tables and χ2 test. Significances are indicated as *, **, and *** for 
significant increase and #, ##, ### for significant decrease at p≤0,05, 0,01, and 0,001 
respectively.  
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4 Results 
4.1 FGFR4 in human colorectal cancer  
4.1.1 Genotyping FGFR4 G388R polymorphism in blood samples 
To link the FGFR4 G388R polymorphism with the risk of developing CRC, 3471 blood 
samples of control, low-risk adenoma, high-risk adenoma and carcinoma patients in the 
course of a prevention study in Burgenland were analyzed in matters of their allelic 
expression of FGFR4. Table 10 shows the distribution of FGFR4Arg homozygous, 
FGFR4Gly homozygous and FGFR4Arg/Gly heterozygous genotypes over the four 
analyzed study-population groups. Evidently, most of the analyzed people have an 
FGFR4Gly homozygous genotype (~50%). Another 41% display a heterozygous 
genotype whereas only a small portion of ~9% is FGFR4Arg homozygous. In the 
carcinoma group however the percentage of FGFR4Arg homozygotes is increased 
compared to the two adenoma groups or the control group. 
 
FGFR4Arg FGFR4Gly FGFR4Arg/Gly number
missing 9,9% 51,6% 38,5% 384
control 8,1% 48,4% 43,4% 1.738
low-risk adenoma 8,9% 49,7% 41,4% 970
high-risk adenoma 5,5% 52,7% 41,8% 292
carcinoma 12,6% 48,3% 39,1% 87
 
Table 10: Categories of study population and their genotype in relation to allelic FGFR4 expression 
 
To analyze the involvement of FGFR4 G388R in colorectal tumor development the 
FGFR4 genotype was correlated with the carcinoma group, the carcinoma group plus 
the high-risk adenoma group and finally carcinoma plus high-risk plus low-risk 
adenoma group. Distribution of the FGFR4 genotype over these three groups was 
compared to the control group. p-values were calculated against the FGFR4Gly 
homozygous group referring this group as the “wildtype”-FGFR4-variant. 
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In this study no significant correlation between the presence of FGFR4Arg (both 
heterozygotes and homozygotes) and the risk of getting colorectal carcinoma or 
diagnosed carcinoma was found. Remarkably, the p-value in the FGFR4Arg homozygous 
group, although not significant, decreases with increasing carcinoma incidence whereas 
the FGFR4Arg heterozygous group behaves conversely. 
 
Carcinoma    
Genotype Control Cases p-value 
FGFR4Gly 802 42 0,000 
FGFR4Gly/Arg 723 33 0,574 
FGFR4Arg 135 10 0,350 
    
Carcinoma + high-risk adenoma  
Genotype Control Cases p-value 
FGFR4Gly 802 190 0,000 
FGFR4Gly/Arg 723 148 0,210 
FGFR4Arg 135 25 0,360 
    
Carcinoma + high-risk + low-risk adenoma 
Genotype Control Cases p-value 
FGFR4Gly 802 642 0,000 
FGFR4Gly/Arg 723 542 0,267 
FGFR4Arg 135 107 0,865 
 
Table 11: Genotype of FGFR4 polymorphism and carcinoma incidence  
p-values are calculated against FGFR4Gly-homozygous group. 
 
4.1.2 FGFR4 expression and G388R polymorphism in human CRC tissue 
specimen 
4.1.2.1 FGFR4 expression in human CRC tissue specimen 
To assess correlations between the FGFR4 expression and histopathological tumor 
parameters like size, stage, grade, and in particular invasiveness of the tumor, 81 tissue 
pairs consisting of a sample from colon carcinoma tissue and normal mucosa tissue of 
the same patient were analyzed. Additionally, the allelic expression of the tissue pairs 
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was assessed and also correlated with histopathological parameter as well as FGFR4 
expression.  
FGFR4 expression was determined in mucosa and tumor tissue of 81 patients by 
quantitative real-time PCR using TaqMan assays for FGFR4. Δ-ct-values were 
calculated using GAPDH as control for normalization. X-fold change of FGFR4 
expression in tumor tissue was presented as ratio of tumor to normal mucosa (T/N 
ratio). In 10 cases bad quality of either the tumor or the normal mucosa mRNA revealed 
no evaluation of the FGFR4 expression. 
FGFR4 expression was significantly up-regulated in 48% (34/71) of the tumor tissue 
compared to normal tissue (p=0,0152) with a mean of 2,73 and a standard error of 
0,6952. 25% of the tumor specimen displayed even a 2-fold or higher expression of 
FGFR4 compared to the normal mucosa. The relative expression levels ranged from 
0,04 to 33,76. 
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Figure 48: FGFR4 expression of 71 colorectal tumor tissues normalized to normal mucosa.  
Results are presented as tumor/normal mucosa ratio (T/N). The red line indicates equal expression. 
 
4.1.2.2 Correlation of FGFR4 expression and TMN-staging  
Depending on the FGFR4 expression ratio tissue pairs were classified into two groups: 
using 1,5-fold FGFR4 over-expression as a cut-off point tissue pairs were divided into 
FGFR4 up-regulated tissues (T>N) and FGFR4 unchanged or even down-regulated 
expression (T≤N). 22 tumor tissue pairs had a relative up-regulation of more than 1,5-
fold whereas 49 tumor tissue pairs were classified into the T≤N group. Relating these 
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two groups to histopathological parameters like tumor stage, grade, size and lymph 
node metastasis resulted in no significant correlations indicating that FGFR4 expression 
had no impact on these parameters in this study. 
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Figure 49: Correlation of FGFR4 expression in CRC with histopathological parameters  
Tissue pairs were divided into up-regulated FGFR4 expression (T>N) and un- or down-regulated FGFR4 
expression (T≤N) groups. Results are presented as percentage of the parameter corresponding 
classifications. 
 
4.1.2.3 Allelic expression of FGFR4 in human CRC tissue specimen 
Allelic expression of tissue specimen was assessed by using a TaqMan® Genotyping 
assay. For this purpose at first a calibration experiment was performed by using 
FGFR4Arg and FGFR4Gly expression vectors mixed in defined ratios, namely 8:1, 3:1, 
2:1, 1:1, 1:2, 1:3, 1:8. Log2 of the ratios was calculated and plotted against the ∆ct-
values (FGFR4Arg-FGFR4Gly). Using the linear equation of the calibration curve (see 
Figure 50) tissue specimens were related to the mixing ratios by measuring ct-values 
and calculating ∆ct-values. 
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Figure 50: Straight calibration line to analyze allelic expression of FGFR4 in tissue specimen  
Straight calibration line was calculated by using FGFR4Arg and FGFR4Gly expression vectors and mixing 
them in different ratios with each other. Ct-values were measured by real-time PCR and Δct-values were 
calculated and plotted against log2 of the mixing ratios.  
 
Allelic expression was determined from both the tumor tissue and adjacent normal 
tissue. 45% (35/78) of the analyzed normal mucosa presented a FGFR4Gly homozygous 
expression whereas only 6% (5/78) had the FGFR4Arg homozygous expression. In 13% 
(10/78) of the cases a shift from FGFR4Gly to FGFR4Arg and in 19% (15/78) a shift from 
FGR4Arg to FGFR4Gly expression could be observed between normal mucosa and the 
tumor. The remaining 53 tissue pairs showed no shift of allelic FGFR4 expression.  
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Figure 51: Allelic expression of FGFR4 in colon tumor and normal mucosa tissue  
Tissues were grouped into nine different categories presenting different mixture ratios of the Arg- and the 
Gly-allele expression. 
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4.1.2.4 Correlation of allelic FGFR4 expression and TMN-staging 
To correlate FGFR4 expression with histopathological parameters like tumor grade, 
stage, size or lymph node metastasis tumor tissues were separated into two categories: 
tumors presenting the Arg-allele (homo- or heterozygote) and tumors with a Gly-
homozygous genotype. A comparison between FGFR4 expression and allelic 
expression in tumor tissue with a mean of 2,853 T/N ratio for Arg and a mean of 2,677 
T/N ratio for Gly showed no correlation. The level of FGFR4 expression is therefore 
independent of the allelic genotype of FGFR4. 
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Figure 52: FGFR4 expression versus allelotype in human CRC tissue 
Tissue specimens are divided into Arg- and Gly-expressing groups. Results are presented as 
tumor/normal mucosa ratio (T/N ratio) 
 
To correlate the FGFR4 G388R polymorphism with histopathological parameters in 
human CRC the study population was enlarged by adding 55 carcinoma cases from the 
Burgenland-study (see chapter 3.5.2) to the 81 tissue specimens. Although in the 
Burgenland-study results were taken from blood samples and not from tumor tissues 
histopathological parameters of genotyped Arg-patients, Gly-patients and heterozygous 
patients were available and were added to the preexisting results of the tumor 
specimens.  
Concerning tumor grade and size no differences between the Arg- and the Gly-group 
could be found. However, the Arg-group did reach a higher classification concerning 
lymph node metastasis compared to the Gly-expressing group.  
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Figure 53: Correlation of FGFR4 genotype with tumor histopathological parameters in human CRC 
Patients were divided into Arg- and Gly-expressing groups. Results are presented as percentage of the 
parameter corresponding classifications. 
 
The Arg-allele was more prevalent at higher tumor stages in our study. In stage I the 
Arg-allele is present in 25% of the cases. This percentage increases with higher stage 
until 58-59% in stage III and IV. Results of all stages were compared to stage I. For all 
stages a significant change in the allelic expression was found. 
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Stage FGFR4Gly FGFR4Arg Arg(% of total)
different from 
stage I (p-value)
I 15 5 25 -
II 28 30 52 0,0383
III 16 23 59 0,0134
IV 8 11 58 0,0368
 
Table 12: Correlation of FGFR4 genotype with tumor stage in human CRC 
Patients were divided into FGFR4Arg homo- or heterozygous and FGFR4Gly homozygous groups. The 
percentage of FGFR4Arg positive tumors was calculated for each stage and the different stages were 
compared to stage I using the χ2-test.  
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4.2 Expression data of CRC cell lines 
4.2.1 FGFR4 expression in CRC cell lines 
One aim of this study was the establishment of a FGFR4 over-expression model for 
both the FGFR4Gly and the FGFR4Arg allele as well as the identification of a proper cell 
model for FGFR4 down-regulation experiments. To find an appropriate cell model all 
cell lines available in the laboratory were screened concerning their FGFR4 expression 
by real-time PCR. Results were normalized using GAPDH as a housekeeping gene. 
SW480 cell line expresses very low levels of FGFR4 and therefore all other data were 
presented as “fold expression of SW480”. 
There is another splice variant of FGFR4 existing. In this variant the transmembrane 
domain of the receptor is lacking and the receptor may act as a decoy receptor to 
regulate the cell signaling for the FGFR4 pathway. Therefore, the expression of the 
soluble FGFR4 was also detected. The results were normalized to GAPDH expression 
and presented as “fold expression of SW480”. 
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Figure 54: FGFR4 expression of CRC cell lines 
FGFR4 expression of all available CRC cell lines was assessed by quantitative real-time PCR. On the left 
panel FGFR4 expression and on the right panel the expression of a soluble FGFR4 splice variant is 
shown. Results are normalized to GAPDH expression levels and presented as “fold expression of 
SW480”. 
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4.2.2 Expression of FGFR4 ligands in CRC cell lines 
Apart from the FGFR4 the mRNA expression of diverse FGF’s binding to FGFR4 was 
evaluated. Not for all of them TaqMan probes were available. FGF9, 18, and 19 were 
evaluated by using real-time PCR whereas for FGF 1, 2, 6, 16, and 17 standard PCR 
was carried out. For some FGF’s only four cell lines with different expression levels of 
FGFR4 were tested: SW480, SW620 which is a metastasis cell line obtained from the 
same patient as SW480, the adenoma cell line LT97-2, and Caco-2. 
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Figure 55: Expression of FGFR4-ligands in CRC cell lines 
The expression of FGF1, 2, 6, 9, 16, 17, 18, and 19 in CRC cell lines was assessed using quantitative real-
time PCR (FGF 9, 18 and 19) or standard PCR (FGF 1, 2, 6, 16 and 17). Results were normalized to the 
expression of GAPDH and presented as fold expression of SW480 or percentage of GAPDH.  
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To assess the allelic expression of CRC cell lines a standard PCR was performed using 
primer which anneal next to the polymorphism side. Afterwards the PCR product was 
digested by the endonuclease MspI. The existence of an Arginine at position 388 masks 
an enzyme cleavage side resulting in a 2-band-pattern for Arg388 and a 3-band-pattern 
for Gly388 (see protocol in chapter 3.2.6).  
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Figure 56: G388R polymorphism in CRC cell lines  
Restriction fragment length polymorphism of CRC cell lines. Gly388 homozygotes show three bands at 
~30bp, ~50bp and 85bp, Arg388 homozygotes show two bands at ~50bp and 115bp. Heterozygotes present 
all bands at ~30bp, ~50 bp, 85bp, and 115bp. 
 
Six of the eleven cell lines tested are Gly388 homozygous, five cell lines are 
heterozygous and only one could be identified as Arg388 homozygous.  
Based on the expression results three cell lines were selected for the further 
experiments: SW480, HCT116 and HT29. SW480 expresses very low amounts of 
FGFR4 and is Gly388 homozygous and consequently serves as a good model for 
investigation on the effects of transfected FGFR4 over-expression in vitro. HCT116 is 
also homozygous and contrary to SW480 expresses higher amounts of FGFR4 and 
represents a good model for the effects of FGFR4 down-regulation in vitro. HT29 
expresses also high amounts of FGFR4 but unlike SW480 and HCT116 this cell line is 
heterozygous and expresses predominantly the Arg388 allele. Furthermore, all three cell 
lines are easily transfectable in contrast to the only Arg388 homozygote cell line Caco-2. 
Caco-2 cells are very difficult to transduce and were therefore not chosen for our 
experiments. 
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Table 13: CRC cell lines chosen for FGFR4 over-expression and down-regulation models  
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4.3 FGFR4 G388R polymorphism in CRC cell lines 
4.3.1 Establishment of FGFR4Gly and FGFR4Arg over-expressing cells 
The cell lines chosen for our experiments were transfected each with a control vector 
(empty pcDNA3 or pcDNA3-GFP), FGFR4Arg and FGFR4Gly over-expressing vectors 
by lipofection and electroporation. 
All following experiments and results of SW480 have been carried out with three 
differently transfected batches. To facilitate the presentation of the results all three 
batches of SW480 transfectants were pooled. For HCT116 and HT29 only one batch of 
transfectants was used.  
 
HCT116
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SW480
HT29
FGFR4Gly pcDNA3
 
Figure 57: Pictures of SW480, HCT116 and HT29 FGFR4 transfectants 
Pictures of FGFR4 transfectants and controls were taken from SW480, HCT116 and HT29 at a 
magnification of 10x.  
 
Cells were transfected by lipofection and selected with G418 for approximately 3-4 
weeks. All clones were combined to one clone pool per group. FGFR4 expression was 
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assessed both on mRNA- and protein-level. Cells were seeded at densities of 50-70% 
confluence and RNA- and protein-lysates were harvested 24-48h later, depending on 
individual growth rate.  
FGFR4-mRNA expression was measured by both standard and real-time PCR. At least 
two results of each batch and group were pooled and are presented in Figure 58. Results 
are normalized to GAPDH expression and presented as percentage of control. 
 
Figure 58: FGFR4 RNA expression of 
transfected SW480, HCT116 and HT29 
stable clone pools  
FGFR4 expression was measured by 
both standard and real-time PCR. Results 
are presented as percentage of control. 
Arg…FGFR4Arg, Gly…FGFR4Gly  
 
 
FGFR4 protein expression was evaluated by western blot for total FGFR4 protein and 
by FACS-analysis with a PE-labeled FGFR4-specific antibody which determines 
FGFR4 at the surface. Western blot was performed with two batches of transfected 
SW480 and β-actin was used as an internal loading control. For both batches total 
FGFR4 protein was increased for FGFR4Arg as well as FGFR4Gly transfected cells 
compared to control. 
 
 
 
 
FGFR4 expression of stable clones
S
W
48
0 
I
S
W
48
0 
II
SW
48
0 
III
H
C
T1
16
H
T2
9
0
200
400
600
800
1000
Arg
Gly
100
%
 o
f 
c
o
n
tr
o
l
 Results 
 
131 
β-actin
FGFR4
Arg I Arg II Gly I Gly II control
SW480
 
Figure 59: Total FGFR4 protein expression of SW480 transfectants  
Total FGFR4 protein expression of two batches of transfected SW480 expressing either FGFR4Arg or 
FGFR4Gly were analyzed by western blot. β-actin was used as an internal loading control. 
Arg…FGFR4Arg, Gly…FGFR4Gly 
 
FACS analysis was carried out at least two times for each cell line. Results were 
presented as fold-expression of control. In all transfected cell lines the over-expression 
of the FGFR4Arg-protein at the cellular surface was higher than the FGFR4Gly-protein. 
The expression of FGFR4Arg ranges from 11-12-fold in SW480 and HT29 to 4-fold in 
HCT116 compared to control. FGFR4Gly-expression was 3-4-fold in SW480 and HT29 
and 1,4-fold in HCT116 compared to control. 
 
Figure 60: Cell surface expression of 
FGFR4 in SW480, HCT116, and HT29 
FGFR4-transfectans  
Cell surface expression of FGFR4 was 
evaluated by FACS analysis. Results are 
presented as fold control. 
Arg…FGFR4Arg, Gly…FGFR4Gly 
 
 
4.3.2 Viability of FGFR4 over-expressing cells 
To determine FGFR4 impact on cell growth viability assays were performed for each 
transfected cell line. Cells were seeded at low densities (1*104 cells per well) into 24-
well plates and after five days neutral red assays (see chapter 3.1.4.1) were performed. 
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For each group six wells were evaluated and the assay was repeated at least three times 
for each cell line. 
Surprisingly, the over-expression of FGFR4 (for both the Arg-variant and the Gly-
variant) did not affect cell viability in any cell line. Results are presented in Figure 61 as 
percentage of control. 
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Figure 61: Viability of FGFR4Arg and FGFR4Gly tranfectants  
Viability was evaluated by performing a neutral red assay. Results are presented as percentage of control 
and pooled from three different approaches, each six values. Arg…FGFR4Arg, Gly…FGFR4Gly 
 
4.3.3  Proliferation of FGFR4 over-expressing cells 
In addition proliferation of FGFR4 transfectants was analyzed using a H3-thymidine 
incorporation assay (according to the protocol described in chapter 3.1.8) three times for 
each cell line. For each group eight values were measured per approach. 
In all cell lines the DNA synthesis of FGFR4 over-expressing cells was higher at lower 
cell densities compared to the control. At higher densities FGFR4 over-expression did 
not show any effect concerning cell proliferation in SW480. In HCT116 proliferation 
was FGFR4-dependently increased in low- and intermediate- density cultures. In HT29 
proliferation was significantly increased at all cell densities with FGFR4Arg over-
expression. 
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Figure 62: Proliferation of FGFR4 over-expressing cells  
SW480, HCT116 and HT29 cell lines over-expressing FGFR4Gly and FGFR4Arg were seeded at three 
different densities and H3-thymidine incorporation assay was performed to assess proliferation. Results 
are presented as percentage of control and pooled from three different approaches each eight values. *, 
**, and *** = significantly increased as compared to control at p≤0,05, 0,01, and 0,001 respectively; 
Arg…FGFR4Arg, Gly…FGFR4Gly 
 
4.3.4  Migration of FGFR4 over-expressing cells 
To assess the impact of FGFR4 variants on cell migration a filter migration assay was 
performed according to the protocol described in chapter 3.1.6. For each group 
triplicates were evaluated and the assay was repeated at least three times for all cell 
lines. 
Migration was stimulated 60- and 30-fold respectively for both FGFR4 over-expressing 
forms in SW480. Above all FGFR4Arg did significantly stimulate migration also when 
compared to FGFR4Gly (p=0,0032). Also in HCT116 FGFR4 over-expression increased 
migration significantly and again the effects were stronger in FGFR4Arg expressing cells 
than in FGFR4Gly-expressing cells. In HT29 the case was different: FGFR4Gly 
expressing cells showed a significant (p=0,0004) decrease in migration whereas the 
FGFR4Arg transfected cells displayed no difference compared to the control. 
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Figure 63: Migration of FGFR4 over-expressing cells  
Migration of FGFR4 tranfectants was assessed by using a transwell-filter-migration assay. In the upper 
panel results are presented as percentage of control and pooled from three different approaches each three 
values. In the lower panel pictures of migrated SW480 transfectants are shown. *, **, and *** = 
significantly increased as compared to control at p≤0,05, 0,01, and 0,001 respectively; ### = significantly 
decreased as compared to control at p≤0,001; Arg…FGFR4Arg, Gly…FGFR4Gly 
 
4.3.5  Colony formation of FGFR4 over-expressing cells 
Colony formation assay was carried out at least three times according to the protocol 
described in chapter 3.1.5.  
In all three cell lines it was observed that FGFR4Gly over-expressing cells showed 
increased colony formation compared to control and to FGFR4Arg over-expressing cells 
which did not differ from the control. (SW480 FGFR4Gly: p<0,0001; HCT116 
FGFR4Gly: p<0,0001; HT29 FGFR4Gly: p<0,0001) 
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Figure 64: Colony formation of FGFR4 over-expressing cells  
Formation of single clones of FGFR4Arg and FGFR4Gly over-expressing cells was assessed by colony 
formation assay. Results are presented as percentage of control in the upper panel and pooled from three 
different approaches each six values. In the lower panel pictures of colony formation assays form SW480 
transfectants are shown. *** = significantly increased as compared to control at p≤0,001; 
Arg…FGFR4Arg, Gly…FGFR4Gly  
 
4.3.6  Anchorage independent growth of FGFR4 over-expressing cells 
The outgrowth of colonies in an anchorage independent manner reflects another 
characteristic of aggressive tumor cells. Cells were embedded into a soft agar matrix 
according to the protocol described in chapter 3.1.7. After 2-3 weeks colonies were 
counted microscopically. Soft agar assay was performed three times for each cell line 
and in triplicates for each group.  
SW480, which expresses low levels of endogenous FGFR4, showed a significantly 
increased (p<0,0001) soft agar growth when FGFR4 was over-expressed. Also in HT29 
FGFR4 over-expression significantly stimulated anchorage independent growth 
independent from allelic expression (p<0,0001). FGFR4 over-expressing HCT116 cells 
showed a different effect. Whereas with FGFR4Gly no increased soft agar growth was 
observed, FGFR4Arg expression decreased growth significantly (p<0,0001). 
 
 Results 
 
136 
SW480 transfectants: soft agar
Arg Gly
0
100
200
300
400
%
 o
f c
on
tr
ol
HCT116 transfectants: soft agar
Ar
g
Gl
y
0
100
200
300
400
%
 o
f c
on
tr
ol
HT29 transfectants: soft agar
Arg Gly
0
100
200
300
400
%
 o
f c
on
tr
ol
***
***
*** ***
***
###
*
controlArg Gly  
Figure 65: Anchorage independent growth of FGFR4 over-expressing cells 
The upper panel shows the effect of FGFR4Arg and FGFR4Gly over-expression on anchorage independent 
growth in all three transfected cell lines. Results are presented as percentage of control and pooled from 
three different approaches each three values. In the lower panel pictures of soft agar plates from SW480 
transfectants are shown. *** or ### = significantly increased or decreased as compared to control at 
p≤0,001; Arg…FGFR4Arg, Gly…FGFR4Gly 
 
4.3.7  Signaling of FGFR4 over-expressing cells 
Total protein lysates and lysates of membrane proteins from SW480 FGFR4Arg, 
FGFR4Gly and control cells were isolated according to the protocol described in chapters 
3.4.1.1 and 3.4.1.2. Activation and phosphorylation of direct FGFR signaling targets 
FRS and PLCγ at the cell membrane and also as total protein were analyzed by western 
blot. Alterations of downstream signaling due to FGFR4 over-expression was described 
by detection of both the phosphorylated forms and the total protein levels of ERK, S6, 
GSK3β and Src in total protein lysates. β-actin was used as loading control. For final 
semi-quantification of signaling proteins ImageQuant® software (Version 5.0) was 
used. 
At the cell membrane FRS phosphorylation was induced by both FGFR4Arg and 
FGFR4Gly compared to the control. The presence of the FRS at the cell membrane was 
decreased in FGFR4Arg expressing SW480 compared to FGFR4Gly and control. The 
specific phosphorylation of membrane-localized FRS was increased in both FGFR4Gly 
and FGFR4Arg expressing SW480 cells compared to control. 
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Total protein of PCLγ was up-regulated in the two FGFR4 over-expressing cells. In 
FGFR4Gly expressing SW480 the PCLγ was increasingly localized at the cell 
membrane. However phosphorylation of PCLγ at the cell membrane was down-
regulated by FGFR4 over-expression compared to control.  
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Figure 66: Impact of FGFR4 over-expressing SW480 on FRS and PCLγ 
In the left panel western blots of total proteins and in the middle panel of membrane localized proteins are 
shown. Antibodies detecting phosphorylated FRS (pFRS), FRS, phosphorylated PCLγ (pPCLγ), PCLγ 
and β-actin as loading control where used.  
In the right panel relative phosphorylation of FRS and PLCγ membrane protein is shown. Results are 
presented as percentage of phosphorylated protein to unphosphorylated protein and analyzed by semi-
quantification of membrane protein. Arg…FGFR4Arg, Gly…FGFR4Gly 
 
Downstream of FRS we found no alterations of ERK in the FGFR4 over-expressing 
SW480 cells. Phosphorylation of GSK3β was induced by FGFR4 over-expressing 
SW480 compared to control. Both S6 protein and phosphorylation were up-regulated by 
FGFR4Gly and even more by FGFR4Arg.  
Src phosphorylation was not up-regulated when normalized to total src-protein in 
FGFR4 over-expressing cells. Src protein level was increased however in FGFR4Arg but 
not FGFR4Gly expressing SW480. 
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Figure 67: Impact of FGFR4 over-expressing SW480 on ERK, S6, GSK and Src 
Western blot of down-stream signaling and Src of FGFR4 over-expressing SW480 and control are shown 
in the left panel. Antibodies detecting phosphorylated ERK (pERK), ERK, phosphorylated S6 (pS6), 
phosphorylated GSK3β (pGSK), GSK3β, phosphorylated Src (pSrc), Src and β-actin as loading control 
where used.  
On the right side protein semi-quantification is presented. In the upper panel quantified proteins are 
displayed as percentage of phosphorylated to total protein. In the lower panel total protein is presented 
normalized to β-actin. Arg…FGFR4Arg, Gly…FGFR4Gly  
 
4.3.8  FGFR4 over-expressing SW480 xenografts in SCID mice 
106 SW480 cells over-expressing FGFR4Arg and FGFR4Gly as well as SW480 expressing 
GFP were injected subcutaneously into SCID mice. For each group four male SCID 
mice were selected. Tumor volume was measured every 48-72 hours and mice were 
sacrificed as soon as the tumor volume exceeded a size of 5.000mm3 or when mice 
showed symptoms of morbidity. Tumors and organs like lung, kidney and liver were 
harvested, fixed and embedded in paraffin. Serial sections were obtained and stained as 
described in chapters 3.5.6 and 3.5.7. 
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In the control group one mouse died four weeks after injection without developing a 
tumor. Consequently, in the group of the control mice only three mice were taken for 
the experimental analysis.  
FGFR4Gly xenografts showed more rapid growth of local tumor than FGFR4Arg and 
control xenografts (2-way ANOVA, p=0,0002). Mice in the FGFR4Gly-group did also 
develop larger tumors and were sacrificed earlier than mice in the control- or FGFR4Arg-
group.  
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Figure 68: Local tumor growth of SW480 FGFR4Arg, FGFR4Gly and GFP xenografts in SCID mice 
SW480 transfectants were subcutaneously injected into male SCID mice and tumor volume was 
measured every 2-3 days. Arg…FGFR4Arg, Gly…FGFR4Gly 
 
4.3.8.1  Immunohistological evaluation of tumor xenografts 
Tumors were stained with hematoxylin & eosin (H&E), cytokeratin 20 and Ki67. 
Hematoxylin colors the nuclei blue whereas eosin stains eosinophilic structures of the 
cell and extracellular proteins. Eosinophilic structures are basic like collagen, most part 
of the cytoplasm and red blood cells which are stained intensely pink. H&E staining 
was done to compare the morphology of the tumor cells.  
Cytokeratins are expressed in a determined pattern in all organs and tissues. Cytokeratin 
20 is mainly expressed in the GIT and identifies the cells derived from the injected 
SW480 transfectants.  
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Ki67 is a nuclear protein and associated with cell proliferation. Therefore Ki67 is a 
proliferation marker because it is present in the nucleus in all active phases of the cell 
cycle but absent in resting cells. 
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Figure 69: Immunohistochemical stainings of FGFR4 over-expressing tumor xenografts 
Figure 69 represents for each group two tumor sections stained immunohistochemically by cytokeratine 
20 and Ki67 as well as H&E-staining. For cytokeratin 20 and Ki67 a magnification of 40x was used. For 
H&E staining pictures of different magnifications were taken. Arg…FGFR4Arg, Gly…FGFR4Gly  
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Cytokeratin 20 positive areas were taken to analyze incidence of mitosis and apoptosis 
in the tumors. Therefore pictures were taken of five different cytokeratin 20 positive 
areas per tumor at a magnification of 40x and mitotic and apoptotic cells were 
evaluated. Total cell number was determined by counting and the percentage of 
apoptotic and mitotic cells was calculated. Ki67 positive cells were also counted in five 
different areas at a magnification of 40x and the percentage of Ki67 positive cells was 
calculated. 
Surprisingly, in the FGFR4Gly xenografts significantly more apoptotic nuclei per field in 
average could be counted than in FGFR4Arg and control, whereas mitotic rate was the 
highest in the control group. Regarding proliferation FGFR4Gly had significantly more 
Ki67 positive nuclei per field than FGFR4Arg and control. 
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Figure 70: Apoptotic-, mitotic-, and proliferation-rate of FGFR4  tumor sections  
All cells in five different fields were counted and apoptotic, mitotic and proliferating nuclei were 
calculated as percentage of total cell number. *, **, and *** = significant increase between two 
comparable groups p≤0,05, 0,01, and 0,001; Arg…FGFR4Arg, Gly…FGFR4Gly  
 
Noticeably the number of cells per field of vision at a magnification of 40x varied 
significantly between the three groups. In the FGFR4Arg group the cell count was 
highest amounting to about 800 cells, significantly higher than in FGFR4Gly tumors with 
about 600 cells and controls with about 400 cells per field. The difference in cell 
number per field was highly significant for all three groups. 
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Figure 71: Cell density of FGFR4Arg, FGFR4Gly and control tumor sections  
Cell count of five different fields per tumor section was determined. *** = significant increase between 
two comparable groups at p≤0,001; Arg…FGFR4Arg, Gly…FGFR4Gly  
 
4.3.8.2 Immunohistological evaluation of lung sections and metastasis  
Metastatic tumor cells injected subcutaneously detach from the local tumor and 
dislocate via the blood stream to the lung where they settle down and grow into 
metastasis. To detect any metastatic cells lung sections were stained with Ki67 
antibody. Lung cells are resting cells and do not proliferate. Consequently, Ki67 
positive cells in the lung have to be derived from an actively proliferating origin like a 
tumor. Lungs were classified into five groups depending on number and position of 
Ki67 positive cells or areas. For each group scores were given increasing with severity 
of metastasis (see Table 14) 
 
Score Description
0 ≤ 3 positive nuclei per section
1 4-10 isolated positive nuclei per section
2 more than 10 isolated or/and small aggregations of positive nuclei per section
3 large aggregations and multiple isolated positive nuclei, also close to blood vesselsper section
4 extensive areas of positive nuclei per section
 
Table 14: Classification of metastatic score for Ki67 positive stained lungs 
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In all of the FGFR4Arg xenografted mice micrometastasis could be found. In this group 
there was no mouse without any Ki67 positive nuclei and two animals reached scores of 
3 and 4 whereas in FGFR4Gly xenografted mice two mice had no positive staining for 
Ki67 and the other two reached a score of 2. The control group reached scores of 1 and 
2. Consequently, the calculated metastatic score was the highest in the FGFR4Arg-group 
where it was nearly twice as high as in the FGFR4Gly-group or in the control-group. 
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Figure 72: Ki67 staining and classification of FGFR4 over-expressing xenograft lungs  
Pictures were selected to illustrate metastatic impact. For determination of metastatic score the whole 
section was evaluated and classified. Mouse 1 died four weeks after tumor injection and was therefore not 
available for examination. Arg…FGFR4Arg, Gly…FGFR4Gly  
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Figure 73: Metastatic score of FGFR4 over-expressing xenografts and control  
Metastatic score was calculated by evaluating Ki67 positive cells in rodent lungs of four different sections 
and classification according Table 14. Arg…FGFR4Arg, Gly…FGFR4Gly 
 
4.3.9  In vivo metastasis model of FGFR4 over-expressing SW480 transfectants 
To evaluate the metastatic potential of FGFR4 over-expressing transfectants in vivo 
1*106 cells were injected into the tail vein of four male SCID mice per group. Body 
weight of the mice was observed for a period of 65 days every 2nd or 3rd day to identify 
signs of morbidity. Mice were sacrificed at day 65 and lungs were obtained to assess 
metastatic score.  
A rapid loss of body weight could be an indicator for tumor growth. However, body 
weight of the animals increased steadily throughout the experiment. In the FGFR4Arg-
group the weight of the mice was slightly higher than in the FGFR4Gly- and the control-
group.  
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Figure 74: Body weight of FGFR4 transfectants in  metastasis model in vivo  
1*106 cells of SW480 FGFR4-transfectants and control were injected into the tail vein of SCID mice. 
Body weight was controlled every 2nd or 3rd day. Arg…FGFR4Arg, Gly…FGFR4Gly  
 
From the blood stream cells should preferentially settle in the lung. To find micro-
metastastsis lungs were again stained with Ki67. All lungs except one lung in the group 
of FGFR4Arg were completely Ki67 negative. The Ki67 positive lung showed small 
stained nodules and single stained nuclei. 
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Figure 75: Ki67 positive nodules of SW480 FGFR4Arg metastasis in rodent lung  
Cells were injected in the tail vein and only one mouse (FGFR4Arg-group) established metastasis. 
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4.4 FGFR4 G388R polymorphism and its role in EMT 
To find evidence of a connection between the FGFR4 G388R polymorphism and EMT, 
E-cadherin expression and β-catenin localization were assessed. 
 
4.4.1 E-Cadherin 
4.4.1.1 mRNA expression: real-time PCR  
mRNA-expression of E-cadherin was measured by quantitative real-time PCR. Cells 
were seeded and harvested on the next day. RNA was isolated and real-time PCR was 
performed. This has been carried out 2-3 times. Unfortunately, there were large inter-
experimental variations for HCT116 and HT29. For HCT116 values differed from 86%-
209% in FGFR4Arg and from 120%-275% in FGFR4Gly whereas in HT29 values reached 
from 28%-100% in both groups respectively to control values. E-cadherin mRNA 
expression of FGFR4 over-expressing HCT116 and HT29 was not significant. SW480 
FGFR4 transfectants had a decreased E-cadherin expression compared to control which 
was statistically significant in FGFR4Gly (p=0,0067) and failed significance in 
FGFR4Arg (p=0,0597).  
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Figure 76: E-cadherin mRNA expression of FGFR4 over-expressing cells  
E-cadherin expression was determined by quantitative real-time PCR and results are presented as 
percentage of control. ** = significantly increased as compared to control at p≤0,01; Arg…FGFR4Arg, 
Gly…FGFR4Gly  
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4.4.1.2 Protein expression: FACS 
On the protein level expression of E-cadherin was measured by FACS analysis 
according to the protocol described in chapter 3.1.9.3.  
E-cadherin FACS analysis was carried out two times for SW480 and HCT116 cell line 
and only once for HT29. Although differences between the two measurements 
concerning E-cadherin expression were remarkably high, the results of FACS analysis 
reflect results of E-cadherin expression on mRNA level. In SW480 the FGFR4 over-
expressing clones showed lower expression of E-cadherin compared to the control. The 
E-cadherin expression of HCT116 and HT29 FGFR4 over-expressing cells measured by 
FACS was comparable to the control. 
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Figure 77: FACS analysis of E-cadherin in FGFR4 over-expressing cells  
E-cadherin expression was measured by FACS analysis. Results are given as percentage of control and 
pooled for the SW480 and HCT116 cells from two approaches whereas for HT29 only one value per 
group was available. Arg…FGFR4Arg, Gly…FGFR4Gly 
 
4.4.1.3 Protein expression: immunofluorescence staining 
To visualize the expression of E-cadherin FGFR4 over-expressing SW480, HCT116 
and HT29 were seeded on glass slides, fixed and incubated with an anti-E-cadherin-
antibody. The second antibody was coupled to FITC. TO-PRO3-iodide was used as 
counterstain. Pictures were taken using a confocal microscope at a magnification of 
60x. 
In SW480 E-cadherin is not highly expressed but in FGFR4 over-expressing cells E-
cadherin expression was even further down-regulated compared to the control. 
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Concerning HCT116 and HT29 there was no clear difference between FGFR4 over-
expressing cells and control visible in the confocal microscope. 
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Figure 78: Immunofluorescence staining of E-cadherin in FGFR4 over-expressing  
Pictures were taken under the confocal microscope at a magnification of 60x. Arg…FGFR4Arg, 
Gly…FGFR4Gly 
 
4.4.2  β-catenin 
4.4.2.1 Protein expression: immunofluorescence staining 
FGFR4 over-expressing cells were seeded on glass slides, fixed and incubated with an 
anti-β-catenin antibody. Slides were incubated with a FITC-labeled secondary antibody 
and visualized using a confocal microscope at the magnification of 60x. 
Figure 79 shows the local expression of β-catenin in all three cell lines and their 
transfectants. β-catenin was higher expressed in SW480 than in HCT116 and HT29 
where it was predominantly located at the cell periphery. By contrast, the protein was 
found mostly in the cytoplasm and nucleus in SW480 cells. Differences between 
FGFR4 over-expressing cells and the control could not be observed. 
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Figure 79: Immunofluorescence staining of β-catenin in FGFR4 over-expressing  
Pictures were taken under the confocal microscope at a magnification of 60x. Arg…FGFR4Arg, 
Gly…FGFR4Gly  
 
4.4.2.2 β-catenin localization: luciferase assay 
Cells were seeded into 24-well-plate and transfected in triplicates with either a Top 
vector, where luciferase can only be expressed in the nuclear presence of β-catenin, or a 
Fop vector, whose binding site for β-catenin is mutated and serves as a negative control. 
Renilla, a third vector is a positive transfection control and co-transfected with either 
Top or Fop. 48h later cells were harvested and luciferase activity was measured from 
the lysates. The assay was carried out two times for all three cell lines. 
There was remarkable inter-experimental variation for SW480 cells so that the tendency 
for higher β-catenin-dependent promoter activity observed in the FGFR4 transfectants 
(see Figure 80) did not reach significance. 
In HCT116 and HT29 cells over-expressing FGFR4 β-catenin-dependent reporter 
activity was down-regulated. FGFR4Arg over-expressing HCT116 and HT29 show 
significantly reduced promoter activity of β-catenin in the nucleus (p=0,0130 and 
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p=0,0204). FGFR4Gly over-expressing HCT116 had a highly significant reduction of 
nuclear β-catenin (p<0,0001).  
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Figure 80: FGFR4 over-expression and β-catenin dependent promoter activity 
β-catenin-dependent luciferase expression of FGFR4 over-expressing SW480, HCT116 and HT29 was 
detected using the Dual-Luciferase® Reporter Assay System. Results are presented as percentage of 
control and pooled from two different approaches each three values. **, and *** = significantly increased 
as compared to control at p≤0,01, and 0,001 respectively; Arg…FGFR4Arg, Gly…FGFR4Gly  
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4.5 Down-regulation of FGFR4 
Three different approaches were used for inhibiting FGFR4-gene-expression and 
studying the biological consequences of down-regulation: siRNA, dominant negative 
adenoviral vector, and dominant negative vector under the control of a tetracycline-
dependent promoter. The three CRC cell lines SW480, HCT116 and HT29 used for the 
FGFR4 over-expression experiments were taken for FGFR4 down-regulating strategies. 
 
4.5.1 Down-regulation of FGFR4 via siRNA 
Two different siRNAs were obtained and named si1 and si2. First optimization 
experiments were performed using different siRNA-concentrations, time points and 
other conditions like change of media after transfection were evaluated. The 
experiments were done individually for each cell line (SW480, HCT116, and HT29). 
Transfection was achieved by lipofection using the protocol described in chapter 3.1.15. 
Based on the outcome of a series of experiments for optimization the following 
conditions were chosen:  
• 10nM siRNA was used 
• media replacement after 6h in SW480, after 24h in HCT116 and HT29 
• best knock down efficiency after 48h in HCT116 and after 72h in SW480 and 
HT29 
 
4.5.1.1  Knock down efficiency of FGFR4 on mRNA- and protein-level 
Efficiency of knock down was determined from RNA and protein isolated from 
HCT116 (48h after transfection), SW480 and HT29 cells (72h after transfection). 
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FGFR4 knock down: RNA expression
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Figure 81: mRNA expression of FGFR4 after knock down in CRC cell lines 
For each cell line optimized knock down conditions were applied. HCT116 mRNA was harvested 48h 
after transfection, HT29 and SW480 72h after transfection. FGFR4 expression was determined with 
TaqMan real-time PCR. Values are presented as percentage of scrambled control. si1/si2 … 
siRNA1/siRNA2 
 
In Figure 81 FGFR4 knock down efficiency is shown on mRNA level. For each cell line 
the optimal conditions for the most effective FGFR4 knock down result were applied. 
Both siRNAs had similar efficacy and reduced FGFR4 mRNA to 20-30% in SW480 
and HCT116 cells and to 10% in HT29. This is also true for Figure 82 which shows 
FGFR4 knock down efficiency on protein level. Western blot with total protein lysates 
was performed for SW480 treated with siRNA1 and siRNA2 against FGFR4. A 
scrambled RNA served as a knock down control. β-actin was used as loading control.  
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Figure 82: FGFR4 protein knock down efficiency of SW480 – western blot 
Protein expression of FGFR4 in SW480 72 hours after FGFR4 knock down was detected by western blot. 
As a loading control β-actin is shown. si1/si2 … siRNA1/siRNA2; scram … scrambled control; ut … 
untreated cells 
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To evaluate the FGFR4 knock down efficiency for HCT116 and HT29, surface 
expression of FGFR4 was determined by FACS analysis using a directly PE-labeled 
FGFR4 antibody. Surface FGFR4 expession was decreased by both siRNAs to 20-43% 
compared to scrambled control.  
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Figure 83: FGFR4 protein knock down efficiency of HCT116 and HT29 - FACS  
Cell surface FGFR4 was evaluated by FACS analysis using a PE-labeled FGFR4 specific antibody for 
HT29 and HCT116. Knock down efficiency is presented as percentage of scrambled control. si1/si2 … 
siRNA1/siRNA2;  
 
4.5.1.2  Viability 
Viability was measured using a neutral red assay three days after transfection in three 
independent experiments for each cell line. Si2 significantly reduced viability in all cell 
lines with a p-value of 0,0002 for SW480 and in HCT116 and HT29 with p<0,0001. 
With si1 no significant changes in viability of SW480 compared to control were 
observed, but HT29 showed significantly reduced viability (p=<0,0001). Surprisingly, 
HCT116 viability was significantly increased after using si1 for FGFR4 (p=<0,0001). 
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Figure 84: Cell viability after FGFR4 knock down in CRC cell lines  
Viability was evaluated by neutral red assay. Values are presented as percentage of scrambled control. 
Results are pooled from three different approaches each at least four values. *** or ### = significantly 
increased or decreased as compared to control at p≤0,001 respectively; si1/si2 … siRNA1/siRNA2 
 
4.5.1.3  Proliferation 
Cell proliferation was assessed by H3-incorporation assay after FGFR4 knock down 
according to the protocol described in chapter 3.1.8. For each group eight wells were 
evaluated. H3-Thymidine incorporation for FGFR4 knock down was performed three 
times for all three cell lines. 
In SW480 cells FGFR4 knock down at low and intermediate cell densities did not result 
in differences in proliferation as compared to scrambled control. This changed in high 
density cultures were both siRNAs significantly reduced proliferation (p=<0,0001 and 
p=0,0002). 
By contrast, in HCT116 no effect of FGFR4 knock down was detected in intermediate 
and high density cultures but in the low density group FGFR4 knock down reduced 
proliferation significantly (si1 p= 0,0126 and si2 p= 0,0033).  
The strongest effects were measured in HT29 cell lines. Si2 inhibited proliferation 
significantly at all cell densities as compared to scrambled control (p=0,0071 for 1.000 
cells; p=0,0004 for 5.000 cells, and p=0,0010 for 10.000 cells respectively). Si1 was 
effective in cells with intermediate (p=0,0007) and high density (p=0,0043).  
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Figure 85: Proliferation of FGFR4 knock down in CRC cell lines  
Proliferation was assessed by H3-incorporation assay. Cells were seeded at the indicated densities and H3-
thymidine uptake was assayed 24 hours later. Values are presented as percentage of scrambled control 
and pooled from three approaches each eight values. #, ## and ### = significantly decreased as compared 
to control at p≤0,05, 0,01 and 0,001 respectively; si1/si2 … siRNA1/siRNA2 
 
4.5.1.4  Colony formation 
Clonogenicity was determined using a colony formation assay described in chapter 
3.1.5. For each group six wells were used and assay was repeated three times for each 
cell line. 
Colony formation was not reduced by FGFR4 knock down in SW480, it was rather up-
regulated significantly with si1 (p=<0,0001). In HCT116 only si2 had an impact on 
colony formation which was significantly reduced (p= 0,0163). Colony formation was 
inhibited considerably in HT29 with a p-value of <0,0001 for both siRNAs. 
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Figure 86: Colony formation of FGFR4 knock down in CRC cell lines  
Colony counts are presented on the left as percentage of scrambled control pooled from three experiments 
with six values each. On the right representative photos of colony formation assay from HT29 cell line 
are shown. #, ## and ### = significantly decreased as compared to control at p≤0,05, 0,01 and 0,001 
respectively; *** = significantly increased as compared to control at p≤0,001; si1/si2 … siRNA1/siRNA2  
 
4.5.1.5  Migration 
Migration assays were performed following the protocol described in chapter 3.1.6. 
Assays were carried out in duplicates or triplicates and repeated three times for all three 
cell lines. 
FGFR4 knock down did not inhibit migration in SW480. By contrast, migration in these 
cells was even stimulated. This was also the case for HCT116 with si1 which stimulated 
migration significantly (p=0,0224), while si2 effectively decreased migration in 
HCT116 (p=0,0375). The strongest inhibitory effect of FGFR4 knock down was 
observed with HT29: si2 reduced migration in HT29 significantly with a p-value of 
0,0003.  
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Figure 87: Migration of FGFR4 knock down in CRC cell lines  
On the left side results from three approaches each three values pooled experiments are presented as 
percentage of scrambled control. On the right side representative pictures of HT29 migration and FGFR4 
knock down with siRNA1 and siRNA2 as well as scrambled control are shown. #, ## and ### = 
significantly decreased as compared to control at p≤0,05, 0,01 and 0,001 respectively; * = significantly 
increased as compared to control at p≤0,05; si1/si2 … siRNA1/siRNA2 
 
4.5.1.6  Anchorage independent growth 
Anchorage independent growth was assessed by soft agar assay performed according to 
the protocol described in chapter 3.1.7. For each group duplicates were performed and 
the assay was repeated three times for all three cell lines. 
Inhibition of anchorage independent growth was only achieved in SW480 with si2 
(p=<0,0001). In the other cell lines FGFR4 knock down via siRNA resulted in an 
increase of growing colonies under anchorage independent conditions which was in 
some cases significant (HCT116: si1 p=0,0052, si2 p=0,0295). 
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Figure 88: Anchorage independent growth of FGFR4 knock down in CRC cell lines  
Values are presented as percentage of scrambled control and pooled from three different experiments with 
ten values each. ### = significantly decreased as compared to control at p≤0,001; * a nd ** = significantly 
increased as compared to control at p≤0,05 and 0,01; si1/si2 … siRNA1/siRNA2 
 
4.5.1.7  Signaling 
The effects of FGFR4 knock down on cell signaling were evaluated from total protein 
lysates which were obtained according to the protocol described in chapter 3.4.1.1. 
Phosphoproteins were analyzed by western blot and phosphorylation of ERK and S6 
were evaluated.  
In HT29 phosphorylation of S6 was stimulated whereas in SW480 it was decreased 
compared to scrambled controls. Also ERK phosphorylation was stimulated in SW480 
compared to scrambled controls. 
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Figure 89: Signaling of FGFR4 knock down via siRNA in HT29 and SW480 
Phosphorylation of ERK and S6 were evaluated by western blot. β-actin served as a loading control. 
si1/si2 … siRNA1/siRNA2; scram … scrambled control; ut … untreated cells 
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4.5.2 Down-regulation of FGFR4 via dominant negative adenovirus 
Besides using siRNAs for down-regulating of the FGFR4 an adenoviral approach was 
implemented. For this purpose a dominant negative construct of the FGFR4 called K5 
(see chapter 3.3.1.1) was introduced into an adenovirus. The K5 construct was derived 
from the FGFR4-sequence by substituting the kinase domain with a cyano-fluorescence 
protein (CFP). Consequently, the K5 construct is a 78kDa dominant negative FGFR4 
protein. GFP expressing virus and an unrelated noncoding virus (Cox as) were used as 
control. Because of its strong expression GFP virus was used with 1MOI (Multiplicity 
of Infection) whereas the K5 and Cox as virus were infected with 10MOI. 
 
4.5.2.1  mRNA expression 
Cells were infected with the adenovirus 24h before harvesting the RNA. Expression of 
the K5 construct was measured by assessing FGFR4 expression using TaqMan 
quantitative real-time PCR. TaqMan probe binds between exon 8-9 which is next to the 
transmembrane domain (located at exon 9-10) (Kostrzewa and Muller 1998), and 
consequently detects also the K5 construct.  
FGFR4 expression was up-regulated in all three cell lines which presents a high 
expression of the K5 construct after 24h in all cell lines. In SW480 the expression of 
FGFR4 was 3-fold, in HCT116 4-14-fold and in HT29 2-fold higher than in the GFP-
control.  
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Figure 90: K5 mRNA expression of K5-adenovirally infected CRC cell lines: real-time PCR  
K5 expression is shown by up-regulated FGFR4 expression detected by using FGFR4 TaqMan kit and 
quantitative real-time PCR. Results are presented as percentage of control virus and are pooled from two 
approaches for SW480 and HCT116. 
 
Additionally, standard PCR was performed with GFP-Primers which also detected the 
CFP in the K5 construct. 
In all three cell lines the K5 expression could be detected using a standard GFP-PCR 
protocol. GAPDH was used as a positive PCR control and loading control. No GFP-
band should be present in cells infected by Cox as. The expression of the K5 was even 
higher than the expression of the GFP infected cells. In the HT29 cells no GFP-band 
could be detected in cells infected by the GFP virus.  
 
 
Figure 91: K5 mRNA expression of K5-adenovirally infected CRC cell lines: standard PCR  
Pictures present gels of PCR-products from all three CRC cell lines infected with K5-, GFP- and the 
unrelated noncoding virus Cox as. K5 and GFP were detected using GFP-primers which also bind to the 
CFP domain of the K5-constuct. GAPDH was used as a PCR-control. 
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4.5.2.2 Protein expression 
Total protein lysates of SW480, HCT116 and HT29 cells infected with K5, GFP and 
Cox as virus were harvested after 24h and western blot was performed.  
The unmodified FGFR4 protein has a size of 88kDa but phosphorylated and 
glycosylated the protein reaches a size of ~110kDa. The expression of the K5 construct 
was evaluated by using a FGFR4-antibody which binds the N-terminal domain of the 
protein. The K5-band was expected at 80-90kDa because of an original size of 78kDa of 
the unglycosylated protein. Unfortunately, no signal verifying the K5 expression could 
be detected for the CRC cell lines when infected with 10MOI.  
Figure 92 shows the result of a western blot of HCT116 cells infected with K5 at 1, 10 
and 50MOI. Protein lysates were harvested 48h after infection. Only in cells infected 
with K5 at 50MOI a signal for the K5-protein could be detected. This could not be 
shown for SW480 or HT29 cells.  
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Figure 92: Expression of the K5-protein 
HCT116 cells were infected with the dominant negative FGFR4 adenovirus K5 and GFP at various 
MOIs. Protein lysates were harvested after 48h and western blot was performed. The K5-protein was 
expected to have a molecular weight of 78kDa when unglycosylated, the signal was detected at 90-95kDa 
with an N-terminal FGFR4 antibody. 
 
4.5.2.3  Viability 
To evaluate the impact of the dominant negative FGFR4 adenovirus on the viability 
cells were infected in a plate with K5 and the control virus. 24h later cells were seeded 
into a 24-well plate. For each group at least 4-6 wells were prepared. Viability was 
measured after 24h and after five days by using a neutral red assay. Viability was 
calculated by normalizing on values measured after 24h and the control. The assay was 
repeated at least three times. 
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Viability was significantly decreased in all of the three cell lines when treated with the 
dominant negative FGFR4 adenovirus (p-values: SW480: 0,034; HCT116: 0,083; 
HT29: 0,0129) compared to the control. 
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Figure 93: Cell viability of CRC cell lines infected with K5 adenovirus 
Viability was measured by neutral red assay on day 1 and 5. Results are presented as percentage of 
control and normalized to day 1. Results are pooled from three different approaches each at least four 
values. #, ## and ### = significantly decreased as compared to control at p≤0,05, 0,01 and 0,001 
respectively. 
 
4.5.2.4  Colony Formation 
Cells were infected in a plate with the K5 and the control virus. 24h later colony 
formation assay was performed as described in chapter 3.1.5. For each group six wells 
were evaluated and the assay was repeated at least three times for each cell line. 
Colony formation was down-regulated in cells infected with the K5 adenovirus 
compared to the control in SW480 and in HCT116 significantly (p-values: SW480: 
<0,0001; HCT116: 0,0063) but not in the HT29 cell line. 
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Figure 94: Colony formation of CRC cell lines infected with K5 adenovirus 
Colony formation of SW480, HCT116 and HT29 infected with K5 adenovirus is presented as percentage 
of control. Results are pooled from three different approaches each at least six values. .#, ## and ### = 
significantly decreased as compared to control at p≤0,05, 0,01 and 0,001 respectively. 
 
4.5.2.5  Migration 
Like for colony formation and viability cells were infected in a plate with the K5 and 
the control virus 24h before seeding into the transwell filters. Migration was assessed 
using filter migration assays described in chapter 3.1.6. For each group three wells were 
evaluated. Experiment was repeated at least three times for each cell line.  
Migration was significantly reduced in SW480 cells infected by K5 adenovirus 
(p<0,0001). In HCT116 cells results differed considerably from experiment to 
experiment. Also in the HT29 cells the variation of the results was remarkably high. In 
HT29 cells infected by K5 adenovirus there is a tendency for down-regulated migration 
when compared to the control. 
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Figure 95: Migration of CRC cell lines infected with K5 adenovirus 
Cell migration of SW480, HCT116 and HT29 infected with K5 adenovirus was assessed by filter 
migration assay. Results are presented as percentage of control and pooled from three different 
approaches each at least three values. #, ## and ### = significantly decreased as compared to control at 
p≤0,05, 0,01 and 0,001 respectively. 
 
4.5.2.6  Anchorage independent growth 
To evaluate the influence of the K5 adenovirus on malignant growth, soft agar assay 
was performed as described in chapter 3.1.7. For this purpose, cells were infected with 
the K5 and the control virus in a plate 24h prior to seeding them into the soft agar 
matrix. Colonies were counted after 2-3 weeks. For each group two wells were 
evaluated. 
Infection with the K5 adenovirus significantly reduced malignant growth in all three 
cell lines (p<0,0001) compared to the control. 
 Results 
 
166 
###
###
###
K5-adenovirus: anchorage independent growth
SW
48
0
HC
T1
16
HT
29
0
20
40
60
80
100
%
 o
f c
on
tr
ol
 
Figure 96: Anchorage independent growth of CRC cell lines infected with K5 adenovirus 
Malignant anchorage independent cell growth of SW480, HCT116 and HT29 infected with K5 
adenovirus was assessed by soft agar assay. Results are pooled and presented as percentage of control 
from one approach with ten values for HT29 and at least two approaches (each 10 values) for SW480 and 
HCT116. .#, ## and ### = significantly decreased as compared to control at p≤0,05, 0,01 and 0,001 
respectively. 
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4.5.3  Tet-inducible down-regulation of FGFR4  
After using the K5 construct in transient approaches with adenoviral vectors it was our 
aim to transfect the K5 vector into cell lines and let them stably express the construct. 
Due to its growth inhibiting effects it was not possible to get stable clones expressing 
the K5 construct. For this reason it was decided to clone the K5 construct into an 
inducible tet-off system. Hence, the construct is only expressed when induced in the 
context of an experiment and it should be easier to obtain stable transfectants because 
they do not constitutively express the growth inhibiting K5 gene. As for control a GFP 
construct was also cloned into the tet-off-system. 
 
4.5.3.1  Cloning of a tet-inducible dominant negative FGFR4 construct 
4.5.3.1.1 Excision of K5 and GFP 
First the dominant negative FGFR4 construct K5 and a GFP were excised from their 
plasmids. To cut out the K5 fragment three endonucleases were used (BcuI, EcoRV and 
NheI) which results in three pieces. The K5 gene contains 2194bp and the remaining 
plasmid contains 2284bp which was also cut into two fragments of 1822bp and 462bp 
size. For GFP excision a restriction digest with BamHI and HpaI was carried out to 
produce a 856bp GFP gene. Before using a preparative digest of 100µl conditions were 
tested with a smaller reaction mix (10µl). Samples were loaded on a 1% agarose-gel and 
quality of the restriction digest was monitored (data not shown). The preparative digest 
was separated under the same conditions, the correct band was cut out and the DNA 
was isolated. Amount of DNA was measured.  
 Results 
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Figure 97: Excision of K5 and GFP  
The upper panel shows the 856bp GFP-fragment and the 3873bp plasmid-fragment. BamHI and HpaI 
were used to cut out the GFP fragment.  
The lower panel shows the 2194bp K5-fragment cut by NheI, EcoRV and BcuI endonuclease. The 
remaining plasmid was also cut into two fragments which contained 1822bp and 462bp. Bands are 
detected on 1% agarose-gel. 
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4.5.3.1.2 Transformation of pTet-off and pTRE-tight into Jm109 bacteria strain  
The pTet-off vector and the pTRE-tight vector were inserted into bacteria (Jm109 
strain) according to the protocol described in chapter 3.3.5. Vector DNA was isolated 
from a 100ml bacteria culture and verified by a control restriction digest. pTet-off was 
cut with BamH1 and pTRE-tight with XhoI endonucleases. Fragments were separated 
on a 1% agarose-gel. 
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Figure 98: Control restriction digest of pTet-off and pTRE-tight 
pTet-off was cut with BamH1 and results in two fragments with 4,5kbp and 2,6kbp size whereas pTRE-
tight was cut with XhoI into a 2kbp and a 0,6kbp fragment. Restriction digests were separated on a 1% 
agarose-gel. 
 
4.5.3.1.3 Preparative digest of pTRE-tight for cloning 
Preparative digest pTRE-tight for GFP insert was performed with BamH1 and EcoRV. 
For the K5 insert NheI and EcoRV endonucleases were used. DNA was treated with a 
calf intestinal alkaline phosphatase (CIAP) to avoid the recircularization and relegation 
of the plasmid and then separated on a 1% agarose-gel. The correct band was cut out 
and DNA was isolated. 
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Figure 99: Preparative digest of pTRE-tight for cloning 
The pTRE-tight vector was cut for the GFP insert with BamHI and EcoRV and for the K5 insert with 
NheI and EcoRV. The opened plasmid contains a size of ~2,6kbp for both inserts. Bands were separated 
on a 1% agarose-gel.  
 
4.5.3.1.4 Ligation, transformation into XL1Blue bacteria strain and verification 
Insert and plasmid were mixed together in defined ratios and incubated with a ligase 
overnight. A negative control was performed with the vector and insert but no ligase 
and another with the vector but without the insert. On the next day XL1Blue bacteria 
were transformed with ligated plasmids and negative controls. Additionally, a positive 
control (uncut plasmid) was also brought into the bacteria. Bacteria were plated on an 
ampicillin-containing agar-plate and incubated over night. After 24h five colonies of 
each plate for the GFP-pTRE-tight and the K5-pTRE-tight constructs were picked and 
DNA was isolated for control restriction digests with BamHI & HpaI, and DraI. For 
each group one cloned plasmid was selected after the control restriction digests and 
larger amounts of DNA were prepared. 
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Figure 100: Control restriction digests of pTRE-tight-GFP and pTRE-tight-K5 
The two cloned plasmids pTRE-tight-GFP and pTRE-tight-K5 were verified by two control digests with 
BamHI & HpaI (left panel) and DraI (right panel). Fragments were separated on a 1% agarose-gel. 
 
4.5.3.2  Transfection of tet-inducible system into CRC cell lines 
For transduction with the tet-off-system two cell lines were chosen: SW480 and 
HCT116. SW480 expresses FGFR4 in very low amounts whereas in HCT116 high 
expression levels of FGFR4 were found (see chapter 4.2). 
 
4.5.3.2.1 Expression and function of the tet-off-system in cell model 
HCT116 cell line was used to test the function of the tet-off-system in a transient cell-
transfection model.  
First the expression of the pTet-off-vector was assessed by western blotting using a 
TetR-monoclonal antibody which binds the full-length Tet-repressor protein (TetR). 
Therefore 1*106 cells were seeded into small plates and pTet-off-vector was transfected 
via lipofection. Protein lysates were harvested after 24, 48, and 72 hours. pTet-off was 
expressed very strongly at early time points in this experiment but the expression 
declined after 72 hours. 
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Figure 101: Protein expression of TetR in a transient cell model  
HCT116 cell line was transfected with pTet-off vector and transient expression of TetR-protein was 
assessed after 24, 48, and 72hours. β-actin was used as a loading control. ut…untransfected cells 
 
The function of the tet-off system was tested in presence and absence of Doxycycline. 
Again one million cells were seeded into 6-well-plates per well and transfected with: 
• pTet-off and pTRE-tight-GFP (two separate approaches) 
• pTRE-tight-GFP: negative control 
• pcDNA-GFP: positive control 
Doxycycline was added at a concentration of 100ng/ml to one of the pTet-off/pTRE-
tight-GFP group. After three days expression of GFP was evaluated by FACS analysis. 
Each tested group was evaluated as duplicates. 
A pcDNA-GFP-vector was used as a positive transfection-control. 60% of the cells 
transfected with the pcDNA-GFP-vector were found positive with strong expression 
intensity (mean-value). Only about 19% of the pTet-off/pTRE-tight-GFP transfected 
cells were positive and the mean of GFP fluorescence-intensity was 2/3 of the positive 
control. At least 5-10% of the pTRE-tight-GFP transfected cells, which did not receive 
the pTet-off control element and should not express GFP, were also positive. Their 
expression-intensity was very low however. The same could be seen with pTet-
off/pTRE-tight-GFP expressing cells treated with Doxycycline where 5% of the cells 
were positive again with very low mean fluorescence intensity.  
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Figure 102: Function of tet-off-system in a transient cell model 
HCT116 were tranfected with pcDNA-GFP (positive control), pTRE-tight-GFP (negative control), and 
pTet-off and pTRE-tight-GFP +/- Doxycycline-treatment. GFP-expression was evaluated by FACS 
analysis. On the left panel percentage of GFP-positive cells is presented whereas on the right panel the 
expression-intensity of GFP was analyzed. 
 
4.5.3.2.2 Establishment of pTet-off expressing stable cells 
To establish pTet-off stable cells lipofection of pTet-off-vector and selection was 
performed according to the protocol described in chapters 3.1.13 and 3.1.14. After 2-3 
weeks clones were transiently transfected with the GFP-response plasmid pTRE-tight-
GFP and efficiency was evaluated by FACS analysis. 22% of HCT116 stably 
expressing pTet-off and 8,4% of SW480 stably expressing pTet-off were GFP positive 
after transient pTRE-tight-GFP transfection.  
To increase the number of positive pTet-off-stable cells both stable cell lines were 
seeded at a density of 3*106 cells per plate and transiently transfected with the pTRE-
tight-GFP-plasmid. 48 hours later GFP-positive cells were sorted out and seeded into a 
new plate, transfected and sorted for a second time. Sorted cells were split up into two 
groups: one group permanently treated with Doxycycline and one group without 
Doxycycline. pTet-off expression of double sorted cells was examined by transient 
transfection of pTRE-tight-GFP-plasmid and FACS analysis.  
 Results 
 
174 
After the second sort nearly 100% of the cells stably expressed the pTet-off vector. 
Again, SW480 and HCT116 cells transfected only with pTRE-tight-GFP were taken as 
a negative control to determine the leakiness of the tet-off-system. Although in SW480 
48% and in HCT116 30% of the pTRE-tight-GFP transfected cells were positive, the 
expression intensity was very low. Furthermore, the ability to switch off the signal was 
determined. pTet-off-stable cells constantly treated with Doxycycline were found to be 
positive concerning GFP-expression in 28% of SW480 and 40% of HCT116. 
Nevertheless, the mean-value was again negligibly low. A very low amount (6% in 
SW480, 1,5% in HCT116) of the double sorted pTet-off stable cells showed positive 
expression of GFP without transfecting the response plasmid. This is the consequence 
of the double-sorting-process where each time cells needed to be transfected with the 
GFP-response plasmid. With passaging most cells lost the transiently transfected pTRE-
tight-GFP-vector but a very small proportion still retained it. 
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Figure 103: Stable expression of pTet-off in SW480 and HCT116 
After sorting two times for transient pTet-off/pTRE-tight-GFP positive cells transient transfection with 
pTRE-tight-GFP was carried out and cells were analyzed by FACS to evaluate the pTet-off expression. 
Additionally, one group of pTet-off positive cells was treated constantly with Doxycycline to switch off 
the interaction with pTRE-tight-plasmid. On the left side percentage of positive cells is presented, on the 
right side the GFP fluorescence intensity represented by the mean value is given. The upper panel shows 
the results for SW480, the lower for HCT116 cell line. 
 
4.5.3.2.3 Establishment of pTet-off/pTRE-tight-K5 and -GFP stable cells 
Because the pTRE-tight-plasmid contains no selection marker for eukaryotes a 
linearized puromycin-resistence-gene was co-transfected. 1/5 of the transfected DNA-
amount was presented by the puromycin-resistence-gene. 4*105 pTet-off stable cells 
constantly treated with Doxycyclin were seeded into 6-well-plates and transfected with 
pTRE-tight-K5 or pTRE-tight-GFP together with puromycin-resistence-gene by 
lipofection. After 24h cells were transferred into plates and selection with 0,6µg/ml 
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puromycin for SW480 and 0,4µg/ml puromycin for HCT116 was started 24h later. 
Transfection and selection was performed in the presence of Doxycycline. 
Transfection with pTRE-tight-K5 and pTRE-tight-GFP was carried out two times.  
Mixed clone pools of SW480 stably expressing pTRE-tight-K5 were established. For 
HCT116 seven pTRE-tight-K5 stably expressing clones were selected by observation of 
the CFP fluorescence of the pTRE-tight-K5 under the microscope and isolated. 
All pTet-off/pTRE-tight-K5 positive clones (HCT116) and mixed clone pools (SW480) 
were split into 6-well-plates and incubated with and without Doxycycline. After 72h 
pTRE-tight-K5 expression was assessed by FACS analysis.  
For HCT116 pTet-off/pTRE-tight-K5 the highest expression was 3% positive cells in 
the absence of Doxycycline and 1,3% under Doxycycline treatment. SW480 pTet-
off/pTRE-tight-K5 had an expression of 8,6% and in presence of Doxycycline 0,8%. 
These two cell populations were used for the following experiments. 
For pTet-off/pTRE-tight-GFP positive clones could be picked under the UV-microscope 
for HCT and SW480 cells. They were also split and raised with and without 
Doxycycline and GFP expression was analyzed by FACS after a few days.  
Based on the on/off ratio of their GFP-expression appropriate pTet-off/pTRE-tight-GFP 
stable positive clones were chosen. The HCT pTet-off/pTRE-tight-GFP stable clone 
expresses 76% GFP without Doxycycline and in presence of Doxycycline the signal is 
down-regulated to 25% expression. For SW480 pTet-off/pTRE-tight-GFP stable clones 
72% GFP expression is reached in the absence of Doxycycline and 39% in the presence 
of Doxycyline. 
 
4.5.3.2.4 Expression of GFP and K5 in pTet-off/pTRE-tight stable cells 
RNA-expression of pTRE-tight-K5 and –GFP was assessed with and without 
Doxycycline treatment. Cells were seeded at equal densities and RNA was harvested. 
mRNA expression was measured by quantitative real-time PCR with GFP primer in the 
presence of SYBR-green. 
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Expression of K5 as well as switching off the expression of K5 and GFP by adding 
Doxycycline could be demonstrated. Results were normalized to GAPDH. Expression 
of GFP was very high in HCT116 cells whereas K5 expression was quite low. In 
SW480 the difference between GFP and K5 expression was not as clear compared to 
HCT116.  
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Figure 104: mRNA expression of GFP/K5 in pTet-off/pTRE-tight-K5 and –GFP stable cells 
mRNA expression of GFP and K5 was assessed by SYBR-Green real-time PCR. Expression was 
measured in the absence and presence of Doxycycline. Untransfected cell lines were used for negative 
control. Results are normalized to GAPDH expression. 
 
4.5.3.3 Influence of Doxycycline dependent K5 expression on cell biology 
4.5.3.3.1 Viability 
To analyze the impact of Doxycycline-dependent expression of K5 on cell viability 
1*104 cells per well were seeded into a 24-well plate with and without the presence of 
Doxycycline. Five days later a neutral red assay was performed. At least four wells per 
group were evaluated. Assay was repeated three times. 
Cells expressing the pTRE-tight-K5 construct showed decreased viability (significant in 
HCT116: p=0,0009). The viability of pTRE-tight-K5 expressing cells was reduced by 
26% in HCT116 cells and by only 9% in SW480.  
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Comparison of viability of cells with or without Doxycycline showed no differences 
induced by the antibiotic in any of the groups.  
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Figure 105: Viability of pTRE-tight-K5 and –GFP expressing cells +/- Doxycycline 
On the left panel viability of HCT116 and SW480 stably expressing the tet-off-K5 construct without 
treatment with Doxycycline is presented as percentage of tet-off-GFP expressing control. On the right 
panel differences in viability concerning presence of Doxycycline in the tet-off-K5 and -GFP expressing 
cell lines are shown. Results are pooled from three different approaches and presented as percentage of 
the corresponding cells with treatment of Doxycycline. ### = significantly decreased as compared to 
control at p≤0,001. 
 
4.5.3.3.2 Cell cycle: FACS analysis 
Investigating the impact of the K5 construct on cell cycle pTet-off/pTRE-tight-K5 and –
GFP stably expressing cells were analyzed by cell cycle FACS with and without 
Doxycycline.  
No Doxycycline-induced differences could be seen. 
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Figure 106: Cell cycle of pTRE-tight-K5 and –GFP expressing cells +/- Doxycycline  
Cells were treated with and without Doxycycline and after three days cell cycle FACS was performed. On 
the left panel results are given for HCT116 tet-off stables on the right panel for SW480 tet-off stables. 
 
4.5.3.3.3 Apoptosis: JC1-FACS 
Our working hypothesis assumed that cells expressing the pTRE-tight-K5 vector had a 
higher incidence for apoptosis. Consequently apoptotic cells were analyzed by FACS 
using the mitochondrial tracer JC-1 three days after plating. In SW480 the stable 
expression of the pTRE-tight-K5 vector in the cells did not cause elevated apoptosis as 
compared to the controls with Doxycycline. In HCT116 cells expressing the pTRE-
tight-K5 apoptosis rate seemed to be even higher when treated with Doxycycline. 
Surprisingly pTRE-tight-GFP expressing cells without Doxycycline had an elevated 
apoptosis incidence compared to cells treated with Doxycycline. 
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Figure 107: Apoptosis of pTRE-tight-K5 and –GFP expressing cells +/- Doxycycline  
All groups are presented with and without treatment of Doxycycline. After three days JC-1 FACS was 
performed. Results are presented as percentage of apoptosis. 
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4.5.3.3.4 Cell migration 
The effects of pTRE-tight-K5 expression on the cells’ ability to migrate were assessed 
by filter migration assay. Cells were treated with and without Doxycycline five days 
before seeding into the filter-membranes. The assay was carried out two times in 
triplicates for each group. 
Migration seemed to be reduced in the HCT116 pTRE-tight-K5 expressing cells 
whereas in SW480 cells the K5 expression elevated the ability to migrate.  
Regarding the differences in presence or absence of Doxycycline in HCT116 pTet-
off/pTRE-tight-K5 stable cells could migrate better in the absence of Doxycycline 
whereas in the control group pTet-off/pTRE-tight-GFP migration was inhibited by 
removing Doxycycline. In SW480 cell lines the case was different. pTet-off/pTRE-
tight-K5 expressing cells were slightly inhibited in migration by switching on the 
expression of pTRE-tight-K5 whereas the control group pTet-off/pTRE-tight-GFP 
migrated better in the absence of Doxycycline.  
None of these migration results could be proven as statistically significant. 
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Figure 108: Migration of pTRE-tight-K5 and –GFP expressing cells +/- Doxycycline 
In the left panel migration of pTRE-tight-K5 expressing stable cells is compared to the control pTRE-
tight-GFP. Results are presented as percentage of pTRE-tight-GFP expressing cells. In the right panel 
migration of pTRE-tight-K5 and –GFP expressing cells is shown in absence of Doxycycline and results 
are presented as percentage of Doxycycline treated cells. Results were pooled from two different 
experiments with three values each. 
 
 Results 
 
181 
4.5.3.3.5 Colony formation 
No significant difference could be found in the pTRE-tight-K5 expressing groups. In 
HCT116 pTet-off/pTRE-tight-K5 stable cells the ability to build single colonies was 
slightly reduced whereas in SW480 stable cells it was not altered compared to the 
control pTRE-tight-GFP. 
Switching on the expression of pTRE-tight by removing Doxycycline resulted in slight 
up-regulation of colony formation in HCT116 cells which failed statistical significance. 
In SW480 no effect was detected. 
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Figure 109: Colony formation of pTRE-tight-K5 and –GFP expressing cells +/- Doxycycline  
In the left panel colony formation of cells stably expressing the pTet-off and pTRE-tight-K5 constructs is 
shown as percentage of their corresponding control (pTet-off and pTRE-tight-GFP expressing cells). In 
the right panel the effect of removing Doxycycline on colony formation is presented for cells stably 
expressing pTet-off/pTRE-tight-K5 and –GFP. Results are shown as percentage of pTet-off/pTRE-tight-
K5 and –GFP stably expressing cells under treatment of Doxycycline. Results were pooled from two 
different approaches each six values. 
 
4.5.3.3.6 Anchorage independent growth 
The impact of pTRE-tight-K5 expression on anchorage independent growth was 
assessed using soft agar assay. Results were evaluated using triplicates and the assay 
was executed two times. 
Surprisingly, anchorage independent growth was significantly up-regulated in cells 
stably expressing the pTRE-tight-K5 construct (HCT116: p<0,0001; SW480: 
p=0,0009). No significant changes due to the presence or absence of Doxycycline could 
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be reported. HCT116 stably expressing pTet-off/pTRE-tight-K5 showed more colonies 
when not treated with Doxycycline whereas pTet-off/pTRE-tight-GFP expressing 
HCT116 had a reduced anchorage independent growth without Doxycycline compared 
to cells treated with Doxycycline. The same was true for SW480 cells stably expressing 
pTet-off/pTRE-tight-GFP. 
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Figure 110: Malignant growth of pTRE-tight-K5 and –GFP expressing cells +/- Doxycycline  
The left panel shows anchorage independent growth of pTet-off/pTRE-tight-K5 stably expressing cells 
compared to their control pTet-off/pTRE-tight-GFP expressing cells. In the right panel the effects of 
Doxycycline on anchorage independent growth for pTet-off/pTRE-tight-K5 and –GFP expressing cells 
are demonstrated. Results are presented as percentage of pTet-off/pTRE-tight-K5 and –GFP stably 
expressing cells under treatment of Doxycycline. Results are pooled from two approaches each 10 values. 
*** = significantly increased as compared to control at p≤0,001. 
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5 Discussion 
As a member of the FGFR family the FGFR4 is involved in the regulation of cell 
proliferation, differentiation and survival but also in tumor development. Its oncogenic 
role has so far been described in various cancer types like prostate cancer, breast cancer 
or rhabdomyosarcoma. In particular the FGFR4 G388R polymorphism was analyzed for 
different cancers and correlated with increased tumor risk, progression and 
aggressiveness and decreased survival of the patients. The mechanisms underlying the 
FGFR4 G388R polymorphism and its effects on cancer patients are not well elucidated 
so far. One hypothesis is that the polymorphism leads to increased receptor stability and 
sustained phosphorylation identifying the FGFR4Arg as a pro-oncogen (Wang et al. 
2008). However, in colorectal cancer the impact of FGFR4 and the G388R 
polymorphism has only been insufficiently described until now. In this project we 
analyzed the role of FGFR4 and the G388R polymorphism in the biggest CRC patient 
cohort so far. In addition we have used three different CRC cell line models to 
characterize the impact of the polymorphism on cell behavior in terms of growth, 
migration and adhesion in vitro and in vivo. Furthermore, we tried to discover the 
influence of the FGFR4Arg on cell signaling events. By different approaches for FGFR4 
inhibition and down-regulation we aimed to demonstrate the impact of FGFR4 on CRC. 
 
5.1 Summary of our results 
The results of this project illustrate the importance of FGFR4 and the G388R 
polymorphism in human CRC. (1) We found a significant up-regulation of the FGFR4 
expression in human CRC tissue compared to normal mucosa tissue. 2-fold FGFR4 
over-expression or higher compared to normal mucosa was found in 25% of the 
carcinoma tissue. (2) The presence of the FGFR4Arg allele was correlated with higher 
tumor stage highlighting the impact of the G388R polymorphism on CRC progression. 
(3) In cell models the FGFR4Arg was found associated with cell migration in vitro and 
with metastasis in vivo. This supports the hypothesis that the allele causes increased 
tumor aggressiveness. Over-expression of FGFR4Gly revealed an increased cell 
attachment, colony outgrowth and malignant growth. (4) We could also demonstrate 
reduced cell viability, proliferation, colony formation, migration and anchorage 
independent growth induced by FGFR4 inhibition or down-regulation in vitro.  
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(5) With regard to cell signaling both FGFR4 variants stimulated the phosphorylation of 
GSK and localized FRS to the cell membrane and increased S6 and on protein level 
whereas a down-regulation of PLCγ phosphorylation in FGFR4 over-expressing cells 
was detected. Localization of the PLCγ protein at the cell membrane was elevated in 
FGFR4Gly compared to control and FGFR4Arg. In FGFR4Arg expressing cells Src protein 
level was elevated compared to control and FGFR4Gly. 
 
5.2 Role of the FGFR4 G388R polymorphism in human CRC 
5.2.1 Expression of FGFR4 in CRC tissue 
Up-regulation of FGFR4 expression has already been reported in various cancer types 
like prostate cancer (Sahadevan et al. 2007; Wang et al. 2008), rhabdomyosarcoma 
(Taylor et al. 2009), breast and gynecological cancers (Jaakkola et al. 1993), head and 
neck squamous cell carcinoma (Streit et al. 2004) as well as gastric cancer (Ye et al. 
2011). FGFR4 over-expression was correlated with higher tumor grade and stage in 
prostate cancer and rhabdomyosarcoma (Sahadevan et al. 2007; Taylor et al. 2009) but 
also with higher lymph node involvement in breast and gastric cancer (Jaakkola et al. 
1993; Ye et al. 2011) compared to tumors which express low amounts of FGFR4. High 
expression of FGFR4 was associated with poor clinical outcome and survival (Streit et 
al. 2004; Taylor et al. 2009; Ye et al. 2011). 
In this study 81 tissue pairs consisting of colon carcinoma tissue and a sample of normal 
mucosa tissue were analyzed. Screening the tissue pairs on mRNA expression of 
FGFR4 revealed a 2-fold up-regulation of FGFR4 expression in 25% of the tumor 
specimen. No correlation between FGFR4 expression profile and histopathological 
parameters were seen.  
 
5.2.2 Correlation between FGFR4 allele and expression  
In our study population 45% of the cases were Gly-homozygous and 6% Arg-
homozygous which did not differ from the general population. In head and neck 
squamous cell carcinoma higher FGFR4 expression in Arg-carriers has been reported 
(Streit et al. 2004). The same was also observed in breast cancer cell lines (Bange et al. 
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2002). In the lung expression of FGFR4 was not related to the genotype however 
(Spinola 2005). Similarly, in our study FGFR4 expression level and genotype were not 
related in human CRC tissue. The association was observed in 11 CRC cell lines 
however: HT29, Colo201, LT97 and Caco2 that carry FGFR4Arg alleles consistently 
expressed higher levels of FGFR4 than Gly-homozygous cell lines.  
 
5.2.3 FGFR4 G388R polymorphism and CRC initiation and development  
To date most of the studies concerning FGFR4 G388R polymorphism and cancer risk 
could not find any correlation for example in breast cancer (Bange et al. 2002; Naidu et 
al. 2009; Spinola et al. 2005), prostate cancer (FitzGerald et al. 2009), soft tissue 
sarcoma (Morimoto et al. 2003) and head and neck squamous cell carcinoma (Streit et 
al. 2004; Tanuma et al. 2010). However, Ma and colleagues found an increased risk for 
prostate cancer as well as for benign hyperplasia in Arg/Arg carriers compared to Gly-
homozygous people (Ma et al. 2008).  
To assess the connection between the FGFR4 G388R polymorphism and the initiation 
and development of CRC we used the biggest cohort studied so far in this context. 3471 
participants in an early detection study in eastern Austria divided into a control group 
free of tumors in the gut, a low-risk adenoma, a high-risk adenoma and a carcinoma 
group. In the control group 48,4% had a Gly-homozygous, 43,4% a heterozygous and 
8,1% a Arg-homozygous genotype. Regarding the carcinoma patients the percentage of 
Arg-homozygotes increased to 12,6% whereas the percentage of heterozygotes 
decreased to 39,1%. Surprisingly in the group of high risk adenoma patients only 5,5% 
had an Arg-homozygous genotype and the highest percentage of Gly-homozygotes. The 
low-risk adenoma group had a genotype distribution comparable to the control. This 
indicates that FGFR4Arg conferred a more rapid progression of high-risk adenomas to 
carcinomas. However, statistical analysis revealed that the difference was not 
significant (p=0,350). For this reason an even larger study population would be 
necessary. 
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5.2.4 FGFR4 G388R polymorphism and histopathological parameters  
An association between Arg-carriers and lymph node involvement has so far been 
described for several kinds of cancer. For example Bange et al. showed a positive trend 
(which failed significance) between Arg-allele and axillary lymph node involvement in 
breast cancer (Bange et al. 2002). Naidu and colleagues found a significant correlation 
between Arg-allele and lymph node involvement by analyzing a bigger cohort of breast 
cancer patients than Bange et al. (Naidu et al. 2009). It has been reported that in lung 
adenocarcinoma the hazard ratio for being stage II or more was higher for Arg-carriers 
(Falvella et al. 2009). An earlier study also shows that lung adenocarcinoma patients 
who carried the Arg-allele were younger at cancer onset. In addition the genotype was 
associated with an advanced clinical stage as well as nodal status and shorter overall 
survival. The Arg-allele in this study was significantly more present in higher stages 
when compared to stage I (Spinola 2005). Additionally, in prostate cancer the presence 
of the Arg-allele could be related to lymph node metastasis but also to a significant 
prostate-specific antigen (PSA) recurrence and consequently with occurrence of 
aggressive disease (Wang et al. 2004). 
 
However, there are also various studies that did not find an association of Arg-allele 
with nodal status, tumor stage or any other histopathological parameters for instance in 
breast cancer (Becker et al. 2003; Jezequel et al. 2004; Spinola et al. 2005; Thussbas et 
al. 2006), lung cancer (Matakidou et al. 2007), soft tissue and osteosarcoma (Morimoto 
et al. 2003), head and neck squamous cell carcinoma (Streit et al. 2004; Tanuma et al. 
2010) and bladder cancer (Yang et al. 2006). 
 
To analyze the importance of FGFR4 G388R polymorphism in human CRC the 
allelotype was associated with tumor size, stage, grade and lymph node metastasis. For 
this purpose we analyzed 136 carcinoma patients and divided them into Arg-carriers 
and Gly-homozygotes. No difference concerning tumor size and tumor grade and 
allelotype were detected. Although the correlation between lymph node metastasis and 
allelotype missed statistical significance we can see a trend of Arg-allele associated 
with lymph node metastasis. Nevertheless, we found a significant correlation between 
allelotype and tumor staging. The Arg-allele was significantly more present in higher 
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stages (II, III and IV) compared to stage I. These data totally agrees with the findings 
from Spinola and colleagues in lung adenocarcinoma. The relevance of Arg-allele and 
tumor stage becomes even more dramatic when the patients cohort is divided into two 
groups. 55 of the CRC patients were part of a screening program for early diagnosis of 
colon carcinoma. In contrast to the other 81 tissue samples which were collected from 
advanced cases most of the 55 CRC patients were in an early tumor stage and revealed a 
higher number of stage I and II tumors. Excluding these 55 CRC patients from our 
analysis resulted in a significant increase (p=0,0381) of lymph node metastasis in Arg-
carriers compared to Gly-homozygotes. 63% (22/35) of the Arg-carriers suffered from 
lymph node metastasis whereas in the group of Gly-homozygotes only 38% (12/32) 
developed metastasis. Furthermore, there was no stage I tissue sample in this subgroup 
expressing the Arg-allele. 
 
5.2.5 FGFR4 G388R polymorphism and survival  
Most of the studies so far found a correlation between the Arg-allele and a short 
disease-free or overall survival in various cancer types. Poorer survival for Arg-allele 
carriers above all in node-positive patients has been described for lung adenocarcinoma 
(Falvella et al. 2009; Sasaki et al. 2008; Spinola 2005), breast cancer (Bange et al. 2002; 
Thussbas et al. 2006), head and neck squamous cell carcinoma (Dacostaandrade et al. 
2007; Streit et al. 2004; Tanuma et al. 2010), prostate cancer (FitzGerald et al. 2009), 
soft tissue sarcoma (Morimoto et al. 2003), and melanoma (Streit et al. 2006). 
Additionally, in breast cancer it was also reported that Arg-carriers had less benefit 
from adjuvant systemic therapy and chemotherapy than Gly-carriers (Thussbas et al. 
2006). Only one study associated the Gly-homozygous patients with poor recurrence-
free survival (in bladder cancer) so far (Yang et al. 2006). 
Data relating the G388R polymorphism in FGFR4 to overall survival and patient 
recurrence could not be evaluated in this study because of lack of information 
concerning patient outcome but will be analyzed as soon as data is available.  
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5.3 FGFR4 G388R polymorphism in vivo and in vitro: cell culture 
model 
To analyze the FGFR4 G388R polymorphism in cell culture three different CRC cell 
lines (SW480, HCT116 and HT29) with different allelotypes and FGFR4 expression 
levels were transfected with FGFR4Arg, FGFR4Gly and a control vector and selected for 
stable expression. On the mRNA-level a 4-fold over-expression of both FGFR4 
allelotypes in SW480 was achieved whereas in HCT116 and HT29 the FGFR4 over-
expression was lower and the Arg-variant was better expressed than the Gly-variant. 
Due to the transfection of the FGFR4Arg the Arg/Gly ratio in SW480 shifted from 0:1 to 
8:1 and in HCT116 from 0:1 to 1:3. In HT29, which is heterozygote but preferentially 
expresses the Arg-allele, the Arg/Gly ratio shifted from 1:0 to 1:3 when transfected with 
the FGFR4Gly allele. 
More FGFR4Arg than FGFR4Gly was present on the cell membrane in all three 
transfected cell lines. This could indicate a higher stability of the FGFR4Arg protein 
which was already reported for prostate cancer. Wang and colleagues described an 
increased stability and sustained phosphorylation of the FGFR4 due to the G388R 
polymorphism whereas the Gly-variant needs to be stabilized by a second protein called 
HIP1 (Wang et al. 2008).  
 
5.3.1 FGFR4 G388R polymorphism and cell growth 
Concerning viability and proliferation no difference was observed in all three cell line 
models compared to the control. Only in very low density cultures there was a 
significant increase in proliferation for HT29 and HCT116 but also in SW480 which 
just missed significance. Viability assays were evaluated five days after seeding so that 
the cell density might have been too high and no effect of FGFR4 could be observed. 
Consequently, growth curves of FGFR4 over-expressing cell lines were evaluated in a 
follow-up study, which showed a significant stimulatory effect of FGFR4 on growth of 
SW480 cells.  
Nevertheless, for anchorage independent growth in soft agar, that permits three 
dimensional growth, an increase of colony formation in FGFR4 over-expressing cells 
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was observed for both FGFR4 alleles while FGFR4Gly being the stronger inducer. 
FGFR4Arg even decreased growth in soft agar significantly in HCT116.  
 
5.3.2 FGFR4 G388R polymorphism and cell migration and cell adhesion 
Decreased cell adhesion and consequently increased cell migration are important 
determinants for metastasis. It has been published that the FGFR4 allelotype clearly 
affects cell migration. For example in non-tumorigenic prostatic epithelial cell line 
PNT1A stably expressing FGFR4, migration was stimulated by the Arg-allele (Wang et 
al. 2004). There are reports about the Gly-variant decreasing cell motility in breast 
cancer cell lines (Bange et al. 2002; Stadler et al. 2006). In contrast to these reports in 
our study both FGFR4 alleles significantly increased cell migration in SW480 and 
HCT116. Both wild type cell lines are Gly-homozygous and in both cell lines the 
transfected Arg-allele stimulated migration even more than the transfected Gly-variant. 
However, in a FGFR4Arg expression background of HT29 the expression of the Gly-
allele decreased migration whereas the transfection of FGFR4Arg over-expression vector 
had no impact on migration compared to control. These findings demonstrate an impact 
of FGFR4 on migration and a stronger pro-migratory effect induced by the Arg-allele 
compared to the Gly-allele.  
 
A functional interaction between FGFR and the cell surface protein neural cell adhesion 
molecules (NCAM) has been described both in the nervous system and in non-neuronal 
cells. Frequently, FGFR1 and FGFR2 are involved in this association. For example 
FGFR1 is stabilized and recycled rather than degraded when associated with NCAM 
(Francavilla et al. 2009). FGFR4 is also reported to associate strongly with NCAM and 
forming a FGFR4/NCAM/N-cadherin adhesive complex (Ezzat et al. 2004). 
Cell attachment and colony outgrowth in all three cell lines were significantly induced 
by the FGFR4Gly over-expressing cells compared to control. The FGFR4Arg over-
expressing cells did not alter colony formation at all. These findings indicate a 
correlation between FGFR4Gly and cell adhesion. A correlation between FGFR4 G388R 
polymorphism and NCAM will be analyzed in a continuative project. 
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5.3.3 FGFR4 G388R polymorphism in SCID mouse xenografts 
Consistent with our in vitro findings, SW480-FGFR4Gly xenografts in SCID mice 
formed tumors earlier and grew into bigger tumors than FGFR4Arg and control. This was 
also confirmed by Ki67 staining that was significantly increased in FGFR4Gly tumors. 
Surprisingly, incidence of mitosis was highest in the control group and apoptosis was 
significantly elevated in both the FGFR4Arg and FGFR4Gly groups which does not fit the 
observations described above. This can be explained by the fact that tumors were 
isolated after reaching maximal size. Consequently, mitosis and apoptosis rate may not 
be representative for the period of tumor growth. 
While FGFR4Gly had a greater impact on local tumor growth, FGFR4Arg stimulated the 
formation of micro-metastasis. Tumors growing under the skin metastasize to the lungs 
where they formed more and larger colonies from FGFR4Arg-xenografts than from 
FGFR4Gly or control mice. To confirm these findings a metastasis model in vivo was 
used by injecting SW480 FGFR4 over-expressing cells and control cells into the tail 
vein of the mice. Unfortunately, this metastasis model was not quite as successful as 
expected because only one mouse developed metastasis. We are currently working on 
another in vivo metastasis model which is more suitable for our FGFR4 cell models.  
 
5.3.4 FGFR4 G388R polymorphism and epithelial mesenchymal transition 
FGFR4Arg affects tumor cells concerning migration and development of metastasis but 
also leads to smaller cell morphology. FGFR4Gly in contrast increases cell adhesion and 
local tumor growth. These results led to the hypothesis that FGFR4Arg may induce an 
epithelial mesenchymal transition (EMT). EMT is a process where polarized epithelial 
cells acquire a mesenchymal migratory morphology. This is of great importance in the 
embryonic development during gastrulation but is also involved in wound healing, 
tissue repair and tissue fibrosis. If EMT takes place in carcinoma cells they acquire 
migratory properties which lead to metastasis and tumor invasion (Thiery 2002). FGF-
signaling has already been connected to EMT - for example during embryonic 
development where FGF-signaling is important for mesoderm induction and 
gastrulation movements (Hardy et al. 2011). In the context of tumor development the 
loss of E-cadherin is correlated with the loss of epithelial phenotype and therefore with 
tumorigenicity. In bladder carcinoma the loss of E-cadherin is associated with a low 
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expression of FGFR2IIIb. FGFR2IIIb is present in all normal epithelia and important to 
maintain the epithelial phenotype. Also FGF2 which binds preferentially to the IIIc 
isoforms and is highly expressed in tumors and wounds is associated with the induction 
of EMT (Shirakihara et al. 2011). The involvement of FGFR2IIIb/IIIc in EMT has been 
well investigated. Whether other FGFRs play a role in EMT processes is not clear so 
far, especially for FGFR4 which lacks the IIIb/IIIc splice variant.  
Analyzing the three FGFR4 over-expressing cell models revealed a clear decrease of E-
cadherin in the SW480 cells on transcript and on protein level. This did not happen in 
HCT116 and HT29 transfectants. Additionally, nuclear β-catenin was elevated in the 
SW480 transfectants whereas in HCT116 and HT29 it was significantly down-
regulated. Based on these findings we cannot conclude that FGFR4 expression and 
allelotype are involved in the induction of EMT. Although in SW480 there might be an 
impact of FGFR4 leading to a mesenchymal phenotype of the cells it also must be 
mentioned that SW480 is an undifferentiated cell line and expresses low levels of E-
cadherin. This leaves the question open whether the impact of FGFR4 is only seen when 
E-cadherin is already down-regulated. The influence of FGFR4 on EMT will be the 
topic of a subsequent project. 
 
5.3.5 FGFR4 dependent cell signaling 
A point mutation analogous to the G388R polymorphism of FGFR4 has been described 
in the transmembrane domain of FGFR3 at position 380. Like the G388R 
polymorphism in FGFR4 a glycine is substituted by an arginine and leads to familial 
achondroplasia. On the cellular level it results in ligand independent activation of the 
receptor. In this special case the kinase activation seems to be due to a ligand 
independent stabilization of the receptor dimers (Webster and Donoghue 1996). 
Bange and colleagues report that substituting a hydrophobic amino acid like glycine by 
a charged amino acid like arginine increases the tyrosine kinase activity. However, they 
could not find an enhanced tyrosine activity in FGFR4Arg transfected breast cancer cell 
line MDA-MB231 after FGF stimulation. They consequently assume that the activation 
property of Arg is only subtly changed (Bange et al. 2002). But also in a non-
tumorigenic prostate epithelial cell line over-expressing FGFR4Gly and FGFR4Arg no 
activation of the tyrosine kinase phosphorylation also in response to FGF2 was found 
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(Wang et al. 2004). Cell lines obtained from hepatomas and stably over-expressing 
FGFR4 showed an increased ERK phosphorylation in response to FGF1 and compared 
to control cells (Huang et al. 2009).  
To answer the question whether FGFR4 over-expression activates downstream 
signaling pathways we used the SW480 transfectants because they mainly express the 
transfected allele. Analyzing phosphorylation of direct FGFR targets like FRS and 
PLCγ at the cell membrane and also as total protein revealed differences between 
FGFR4 over-expressing cells and control. FRS expression and activation was not 
affected in FGFR4 over-expressing cells in the total protein fraction. When localized at 
the cell membrane phosphorylation was increased by both FGFR4Gly and FGFR4Arg 
although FGFR4Arg recruited less FRS to the receptor. Downstream of FRS ERK 
phosphorylation was not affected by FGFR4 over-expression. Nevertheless, GSK3β 
phosphorylation was increased by FGFR4 over-expressing cells. As described in 
chapter 1.7.1.6 GSK3β connects FGF-signaling pathway to Wnt-signaling pathway. 
Phosphorylation of GSK3β results in a down-regulation of its activity which leads to the 
repression of E-cadherin and translocation of β-catenin into the nucleus (Katoh 2006a). 
However, in our case increased phosphorylation of GSK3β could be the cause for the 
down-regulation of E-cadherin and the translocated β-catenin (described above in 
chapter 5.3.4).  
Phosphorylation of S6-kinase is involved in the regulation of cell proliferation and 
tumor growth, protein translation, cell survival as well as cytoskeletal arrangements 
(Fenton and Gout 2011). FGFR4 over-expressing SW480 showed an increased S6 
protein level as well as increased protein phosphorylation. In our case S6 was analyzed 
as a pathway indicator. Together with the activation of GSK3β S6 phosphorylation 
indicates a pathway activation via PI3K leading to activation of cell survival.  
PLCγ over-expression is correlated with a variety of cancers, colorectal cancer among 
them, and its signaling is involved in cell growth and survival as well as cell motility 
(Suh et al. 2008; Tan et al. 2007). PLCγ was elevated on total protein level in both 
FGFR4 over-expressing cell lines. Recruitment to the cell membrane was higher 
compared to control in FGFR4Gly but not in FGFR4Arg cells, suggesting a role in the 
enhanced local tumor growth of SW480Gly cells. Phosphorylation of the PLCγ localized 
at the cell membrane was decreased however. Especially FGFR4Arg revealed hardly any 
PLCγ phosphorylation at all. As several studies have described a connection of PLCγ to 
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cell adhesion and spreading (Choi et al. 2007; Tvorogov et al. 2005) the decreased 
phosphorylation may be related to decreased cell attachment and consequently 
increased cell motility of FGFR4Arg over-expressing cells.  
In tumor cells PLCγ also interacts with Src kinase which could serve as adaptor protein 
between FGFR and PLCγ (Suh et al. 2008; Tvorogov et al. 2005). Src is also recruited 
by phosphorylated FGFR to FRS and is important for activation and termination of 
FGFR signaling (Sandilands et al. 2007). Src prevents the association of Cbl to FRS 
which consequently blocks the ubiquitination of FGFR and its degradation and 
promotes receptor recycling (Francavilla et al. 2009). Although we found no alterations 
of Src phosphorylation by FGFR4 over-expression Src protein level was increased in 
FGFR4Arg over-expressing cells. A higher protein level of Src in FGFR4Arg expressing 
CRC cells could contribute to increased receptor stability which has been also described 
for prostate cancer (Wang et al. 2008). Furthermore, Src plays a crucial role in many 
cellular processes like invasion, migration, proliferation, angiogenesis and apoptosis. 
Increased expression of Src is found in 80% of CRC specimens and also associated with 
increased metastasis and poor clinical prognosis in all stages of colon cancer. Like 
FGFR4Arg, a high expression of Src is also associated with enhanced cell motility (Lieu 
and Kopetz 2010). Consequently, the more aggressive phenotype of FGFR4Arg over-
expressing SW480 may be strongly related to an increase in Src protein expression 
levels.  
 
5.4 FGFR4 knock down via siRNA 
In prostate cancer FGFR4 down-regulation by siRNA inhibited proliferation and 
invasion of prostate cancer regardless of allelotype (Sahadevan et al. 2007). In our study 
cell viability was significantly reduced in all three cell lines caused by siRNA2. DNA 
synthesis was significantly inhibited in low density cell cultures by siRNA2 in HCT116 
and HT29. In high density cell cultures proliferation of SW480 and HT29 cell lines 
were significantly diminished by both siRNAs.  
Cell migration and colony formation were both inhibited by siRNA2 in HCT116 and 
HT29 but not in SW480 which expresses very low levels of FGFR4 in SW480 so that a 
knock down in this cell line does not much impact on protein level.  
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We could not see any impact of siRNA knock down on anchorage independent growth. 
This may be due to the quite long incubation period (2-3 weeks): knock down with 
siRNA is transient and not sustained long enough to prevent growth throughout this 
period. Surprisingly, in SW480 we saw a clear inhibition of anchorage independent 
growth when transfected with siRNA2. 
In the breast cancer cell line BT-474 which expresses high levels of FGFR4 a siRNA 
mediated knock down of FGFR4 resulted in an reduction of ERK phosphorylation 
(Roidl et al. 2009). Investigation of down-stream signaling effects of FGFR4 knock 
down revealed ambiguous results like up-regulation of pERK in SW480 and HT29 as 
well as up-regulation of pS6 in HT29 but down-regulation in SW480 compared to a 
scrambled control. Further analyzes are required to reveal more information on 
signaling alterations due to FGFR4 knock down. 
 
5.5 Tool development for stable and inducible FGFR4 inhibition 
FGFR4 knock down by siRNA resulted in an inhibition of cell viability, cell migration 
and colony formation. To analyze the impact of FGFR4 inhibition on local tumor 
growth in vivo siRNA mediated knock down is not an appropriate tool. Due to its 
transience the siRNA mediated knock down is not stable enough for a period longer 
than a few days. During tumor growth and cell division the siRNA is diluted out and 
FGFR4 expression is not altered anymore. For that reason we tried to develop more 
stable tools for FGFR4 down-regulation. 
 
5.5.1 Introduction of a dominant negative FGFR4 construct 
In the course of former projects dominant negative constructs for FGFR1, FGFR3 and 
FGFR4 were generated. The dominant negative FGFR4 (K5) construct consists of the 
extracellular domain and the transmembrane domain of the FGFR4 but its intracellular 
kinase domain is substituted by a CFP reporter tag. The K5 acts as a decoy receptor and 
traps FGFR4 ligands but without transmitting a signal. Local tumor growth of SW480 
cells transduced with dominant negative FGFR 3 and K5 adenoviral constructs were 
assessed for a former project on FGFR3IIIc. Whereas local tumor growth was decreased 
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about 40% (Sonvilla et al. 2010) by the dominant negative FGFR3 construct the K5 
construct inhibited the outgrowth of tumors completely (unpublished). 
 
5.5.1.1 Influence of dominant negative FGFR4 adenovirus on cell growth, 
migration and adhesion 
To analyze the mechanisms behind the strong inhibitory effects of the K5 in vitro we 
used an adenovirus expressing the K5 and transduced the three cell lines SW480, 
HCT116 and HT29. Although the expression of the K5 construct was detected on the 
RNA level evaluating the K5 protein was more complicated. High MOIs were necessary 
for detection of fluorescent cells. Both the CFP tag and the K5 protein could also be 
verified by western blotting.  
 
Viability and 3-dimensional growth in an agar matrix was significantly down-regulated 
by the K5 in all three cell lines. These findings are consistent with the in vivo results 
from our former project. In SW480 also migration and colony formation were 
significantly reduced whereas in HCT116 only colony formation was significantly 
inhibited by the K5 construct. HT29 did not show any impact on colony formation when 
transduced by the K5 and migration was reduced but failed statistical significance.  
 
Although FGFR4 inhibition by siRNA showed only little impact on the low FGFR4 
expressing cell line SW480, the effects caused by the K5 adenovirus resulted in a strong 
inhibition of viability, anchorage independent growth, colony formation, migration and 
local tumor growth. One explanation could be the ligand spectrum which is affected by 
a dominant negative decoy FGFR4 receptor. SW480 expresses large amounts of FGF18 
which also binds to the FGFR4 and which was found to play a pro-tumorigenic role in 
colorectal cancer. Decreasing the FGF18 signaling cascade in SW480 results for 
instance in reduced colony formation (Sonvilla et al. 2008). Trapping ligands like 
FGF18 affects not only FGFR4 but also other FGFRs – mostly FGFR3-IIIc (Sonvilla et 
al. 2010). The precise effects of the K5 construct on FGF-signaling need to be explored 
in a consecutive project. 
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5.5.1.2 Establishment of an inducible tet-off system for dominant negative FGFR4 
construct 
In addition to the K5 adenovirus we tried to transfect three CRC cell lines with the K5 
plasmid and select stable clones. Probably due to the growth-inhibiting effects of the K5 
on the cell lines no stably expressing K5 clones could be selected. Therefore, we 
decided to use a tet-off system and clone the K5 construct into a Doxycycline inducible 
vector. A GFP-gene was used as control for in vitro approaches and for testing the 
function of the inducible gene expression system. Consecutive transfection of pTet-off 
vector and pTre-tight-GFP vector resulted in 72-76% GFP positive SW480 and 
HCT116 cells which under treatment of doxycycline were decreased to 25-39% GFP 
expressing cells. Presence of Doxycycline not only reduced the percentage but also the 
intensity of fluorescence of the remaining GFP-positive cells. In addition, transfection 
of the pTRE-tight-GFP vector without the pTet-off expressing transactivator protein 
still leads to the expression of the GFP protein in 48% of SW480 and 30% of HCT116. 
In summary, the tet-off system worked basically well in our hands but still was too 
leaky for our purpose. Due to the strong growth-inhibitory effect of the K5 construct we 
assume that pTRE-tight-K5 expressing cells died right after transfection. Consequently, 
we could not select cells with an appropriate expression of the K5 construct. Therefore, 
pTet-off/pTRE-tight-K5 clones, which were selected, showed no impact on cell 
biological properties like viability, migration, or cell adhesion.  
 
5.6 Conclusion  
Based on the results of this study we identified FGFR4 as an oncogene and relevant 
target for therapy in colorectal cancer. Specifically we could demonstrate oncogenic 
potential for both polymorphic forms of FGFR4. Concluding from our data FGFR4 
G388R is involved in tumor aggressiveness in CRC mediated by changes in cell 
behavior affecting growth, migration and cell adhesion. Therefore, we suggest the 
FGFR4 G388R SNP to be regarded as a genetic modifier in colorectal cancer and to 
play a predictive role in tumor prognosis. The characterization of genetic modifiers as 
markers predicting increased risk for metastasis development would permit 
identification of patient groups who will profit from adjuvant treatment. The FGFR4 
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G388R SNP may be part of a marker set for prognostic testing and classification into 
“higher” and “lower” risk patients (Drafahl et al. 2010).  
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6 Abstract 
The interest in fibroblast growth factors (FGFs) and their receptors (FGFRs) in cancer 
research constantly increased over the last decade because of the crucial role they play 
in cell proliferation, differentiation, and migration. During tumorigenesis their 
expression and activity is frequently deregulated. Especially FGFR4 with its genetic 
polymorphism affecting the transmembrane domain of the receptor (G388R) is involved 
in a wide variety of malignancies. The R388 (FGFR4Arg) form is associated with 
increased tumor risk, progression, aggressiveness and decreased survival in various 
cancer types. In colorectal cancer (CRC) the role of FGFR4 is not well described to 
date. Therefore, it was the aim of the study to elucidate the impact of FGFR4 and 
especially the G388R polymorphism on CRC.  
Our data show an up-regulation of FGFR4 mRNA expression in 25% of CRC tissue 
specimen. Moreover, FGFR4Arg carriers had an increased risk for higher tumor stage at 
diagnosis and metastatic lesions than FGFR4-G388 (FGFR4Gly) homozygous patients 
suggesting a role for the FGFR4Arg allele in invasion and metastasis. In vitro data, using 
three different CRC cell lines with differing FGFR4 endogenous expression and 
genotype, displayed stimulated cell migration but decreased clonogenicity for FGFR4Arg 
whereas over-expression of FGFR4Gly had a stimulatory effect on clonogenicity and 
anchorage independent growth. In vivo FGFR4Gly enhanced local tumor growth, while 
FGFR4Arg stimulated metastasis from subcutaneous xenotransplants to the lung. FGFR4 
siRNA mediated knock down and a dominant-negative adenoviral construct expressing 
dominant negative FGFR4 caused down-regulation of cell viability, migration and 
colony formation CRC cell lines. On the cellular level phosphorylation of FRS2α was 
increased by FGFR4 over-expression leading to activation of cell survival pathways 
independent of the genotype.  
Based on the results of this study both allelic forms of FGFR4 have to be regarded as 
oncogenes and relevant targets for therapy in CRC. While FGFR4Arg over-expression 
was correlated with higher tumor aggressiveness in vivo, mediated by up-regulation of 
cell migration, over-expression of FGFR4Gly stimulated malignant cell growth in vitro 
and enhanced local tumor growth in vivo.  
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7 Zusammenfassung 
In den letzten zehn Jahren haben die Fibroblasten Wachstumsfaktoren (FGF) und deren 
Rezeptoren (FGFR) in der Krebsforschung immer mehr an Bedeutung gewonnen, nicht 
zuletzt auf Grund ihrer besonderen Rolle für zelluläres Wachstum, Differenzierung und 
Migration. Sie sind während der Krebsentstehung häufig von Mutationen betroffen. Vor 
allem FGFR4, welcher zudem einen Polymorphismus in der transmembranen Domäne 
des Rezeptors (G388R) aufweist, ist an verschiedensten Krebserkrankungen beteiligt. 
Die R388 (FGFR4Arg) Form wird häufig mit erhöhtem Tumorrisiko, schnellerem 
Krankheitsverlauf und schlechteren Überlebenschancen in Verbindung gebracht. Da die 
Rolle des FGFR4 im Dickdarmkrebs bisher nicht ausreichend geklärt war, sollte in 
dieser Arbeit der Einfluss des FGFR4 und dessen G388R Polymorphismus auf das 
Kolorektalkarzinom erforscht werden. 
Unsere Daten belegen eine erhöhte Expression der FGFR4 mRNA in 25% der 
untersuchten humanen Dickdarmkarzinomgewebe. Zudem weisen Patienten mit einem 
oder zwei FGFR4Arg Allelen ein höheres Tumor-Staging mit vermehrter 
Wahrscheinlichkeit zur Metastasierung auf. Folglich wird das FGFR4Arg Allel mit 
erhöhter Tumor Invasion und Metastasierung in Zusammenhang gebracht, was sich in 
Zellkulturmodellen bestätigte. In drei verschiedenen Kolonkarzinom-Zelllinienmodellen 
stimulierte FGFR4Arg die Migration und hemmte gleichzeitig Zelladhäsion und 
Koloniebildung. Im Gegensatz dazu stimulierte FGFR4Gly sowohl das Wachstum von 
Kolonien aus dünnen Kulturen als auch das 3-dimensionale, anheftungs-unabhängige 
Wachstum in einer Agarmatrix. Auch im Tiermodell konnte FGFR4Gly mit schnellerem 
Tumorwachstum assoziiert werden, während FGFR4Arg Tumormetastasierung von 
subkutanen Transplantaten in die Lunge beschleunigte. Hemmung des FGFR4 über 
siRNA oder ein adenovirales dominant-negatives Konstrukt führten beide zu 
verminderter Viabilität, Migration und Koloniebildung der Kolonkarzinom-Zelllinen. 
Unabhängig vom Polymorphismus stimulierte eine erhöhte Expression von FGFR4 
Überlebens-Signalwege über die Aktivierung von FRS2α.  
Die Ergebnisse dieser Arbeit identifizieren beide allelische Formen des FGFR4 als 
Onkogene, welchen in der klinischen Krebstherapie unbedingt Beachtung geschenkt 
werden sollte. Eine erhöhte Expression von FGFR4Arg stimuliert Zellmigration und 
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erhöht somit die Tumor-Aggressivität in vivo, während die erhöhte Expression von 
FGFR4Gly malignes Zellwachstum in vitro und in vivo fördert.  
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